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General introduction and 





Clostridium difficile is an enteropathogenic anaerobic Gram-positive spore forming 
rod, which can cause a wide variety of  symptoms. Clostridium difficile infection (CDI) 
is recognized as the leading cause of  infectious nosocomial diarrhoea. In the last 
decade the incidence and severity of  CDI has increased and currently C. difficile is 
also frequently recognized as an important cause of  community-acquired diarrhoea 
in humans. Finally, C. difficile may be present in the intestinal tract of  asymptomatic 
and diarrhoeal (farm) animals.
Clostridiaceae
A major part of  the human gut microbiome consists of  Firmicutes (1). The 
phylum Firmicutes was traditionally classified to include all Gram-positive bacteria, 
but recently it was re-classified as a bacterial core-group with low-G+C genomic 
DNA content (2). Many Firmicutes are able to form (endo)spores, which are highly 
resistant to disinfectants and extreme environmental conditions (2). The phylum 
of  Firmicutes can be roughly divided into two main classes; the Bacilli, which are 
aerobic, and the Clostridiaceae, which are obligate anaerobic (3).
The genus Clostridium belongs to the class of  Clostridiaceae which consists 
of  approximately 100 species (4). Clostridium spp. are ubiquitously found in the 
environment, soil, water and in the human and mammalian gastro intestinal tract as 
part of  the commensal microbial flora (5). The genus Clostridium comprises several 
well characterized important human pathogens such as: Clostridium tetani, Clostridium 
botulinum, Clostridium perfringens, Clostridium sordellii and Clostridium difficile (2,4,6). All 
diseases caused by Clostridium spp. are mediated by the secretion and action of  the 
secreted (exo)toxins (2,4,6,7).
Clinical disease and epidemiology
Almost eighty years ago (1935), Clostridium difficile was first described by Hall and 
O’Toole as Bacillus difficilis (8,9). Clostridium difficile was isolated from faeces of  new-
born infants and described as an actively motile, heavy bodied Gram-positive rod 
with elongated subterminal or nearly terminal non-bulging spores (8). Injection 
of  whole or filtrated cultures in guinea pigs and rabbits resulted in rapid death 
(8). Survival of  the animals injected with boiled and filtrated cultures led to the 
conclusion that C. difficile was able to produce a soluble heat labile toxin (8).
More insights in the pathogenicity of  C. difficile were obtained by investigations 
in germfree mice and rats (10). In addition, a prospective study by Tedesco et al, 
evaluating 200 patients, subsequently reported that clindamycin administration 




colitis (PMC) (10%) (11). In retrospect this was the first study to describe C. 
difficile as a nosocomial human pathogen (11). In 1977, Larson and Price isolated 
a clostridial toxin from faeces of  patients with antibiotic-associated colitis and 
PMC (12). Subsequently, Bartlett and colleagues reported that the causative agent 
of  antibiotic-associated PMC was indeed a toxin producing C. difficile (13). The 
lack of  sensitive and reliable detection and identification methods has delayed the 
recognition of  C. difficile as an important nosocomial pathogen for a long time 
(14). However, nowadays C. difficile is recognized as the most frequent cause of  
infectious nosocomial diarrhoea worldwide (9,15,16).
Several reports indicate that up to 3% of  healthy individuals and up to almost 
40% of  hospitalized patients are colonized with toxinogenic C. difficile strains (17-
19). Healthy individuals are usually protected by their normal colonic microflora 
(17). However, disturbance of  the colonic microflora by for instance antibiotic 
usage leads to loss of  the colonization resistance, enabling C. difficile to colonize, 
overgrow and cause disease (17). Besides antibiotic usage, other risk factors for 
CDI are advanced age (>60 years), underlying diseases and infection pressure (20). 
During infection C. difficile can produce three toxins which affect the integrity of  
the colon epithelium by destruction of  the tight junctions, disrupt the cytoskeleton 
and lead to the formation of  protrusions (21-24).
The typical clinical features of  CDI range from mild diarrhoea to fulminant 
colitis, which can be life-threatening (25-27). Endoscopic examination of  patients 
suffering from CDI may reveal minor abnormalities to extensive pseudomembranes 
(25). The formation of  these pseudomembranes is caused by deep haemorrhagic 
ulcerations of  the colon epithelium and a massive host inflammatory response (28). 
Symptoms of  pseudomembranous colitis are cramping, fever, hypo-albuminemia, 
leukocytosis, nausea and general malaise besides the typical lesions observed by 
endoscopy (25,26). Eventually, pseudomembranous colitis may evolve into a 
syndrome called toxic megacolon, the most serious form of  disease caused by 
CDI (29). Toxic megacolon is a toxic dilatation of  the colon causing paralysis of  
the peristaltic movement and systemic cytotoxicity (29) accompanied by sepsis and 
organ dysfunction and resulting in high (33%) mortality rates (29,30).
In the last decade the epidemiology of  CDI has changed radically. North-
America was the first to report numerous hospital outbreaks with an increased 
incidence of  CDI cases with a more severe course of  the disease (27,31,32). 
Later on reports of  outbreaks in Europe followed (33-35). These epidemics were 
primarily due to C. difficile PCR Ribotype (RT) 027, also known as North America 
Pulse-field type (NAP) 1 and Restriction Endonuclease Analysis (REA) type 
B1 (027/NAP1/B1) strain. Clostridium difficile RT 027 strains were referred to as 




rates, more severe course of  the disease and increased mortality rates (19,27,36-39). 
Certain other C. difficile types (e.g. RT017 and 078) have also been reported to be 
associated with outbreaks and a more severe course of  disease in a hospital setting 
(34,39-44). Besides the increase of  CDI incidence rates in a health care setting, 
an increased incidence rate in a community setting was reported (45-47). In some 
studies C. difficile RT 078 was more frequently associated with community acquired 
CDI than other ribotypes and affected a younger population than for instance C. 
difficile RT 027 strains (48,49). The course of  C. difficile RT 078 associated disease 
can be as severe as observed for the hypervirulent C. difficile RT 027 strain (48) 
and the incidence of  C. difficile RT 078 has increased in the Netherlands and other 
European countries (34,50). Interestingly recent studies have demonstrated that 
C. difficile RT 078 is the predominant type in cattle and pigs, suggesting a zoonotic 
potential (51-54).
Diagnostic and Typing methods
Diagnosis of  CDI
The emergence of  C. difficile strains as an important nosocomial human pathogen 
has stimulated the development of  better diagnostic, detection and typing methods. 
The diagnosis of  CDI is primarily based on clinical symptoms in combination with 
laboratory assays (55). Culturing C. difficile and the detection of  the toxin(s) with a 
cytotoxicity assay is regarded as the gold standard for diagnosis of  CDI (28,55,56). 
However, in many diagnostic laboratories culturing and cell cytotoxicity assays 
are not performed routinely, as they are labour intensive and costly (55,57,58). 
Most diagnostic laboratories depend on rapid and easy-to perform enzyme 
immuno assays (EIAs) that are generally designed to detect C. difficile Toxins A 
and/or B (55,57). Unfortunately, EIAs have limited specificity and/or sensitivity 
in an endemic situation (55). The limitations of  EIAs have tempted clinicians into 
testing multiple samples per patient and to develop two-step algorithms for CDI 
diagnosis (55,59). However, for prevention and management of  CDI rapid and 
more accurate assays are essential.
Quantitative real-time PCRs (qPCRs) are potential rapid assays with better 
performances than EIAs (56,60-62). Additionally, molecular tests such as qPCR 
have high sensitivities and specificities, comparable to the cell cytotoxicity assays 
for diagnosis of  CDI (56,60,63-66). Both commercial and in-house developed 
qPCRs for the detection of  C. difficile are primarily based on the detection of  the 
toxin B and/or toxin A genes (56,60,63-66). In some cases the detection of  the 
toxin genes is combined with the detection of  point mutations in the tcdC gene, or 




The disadvantage of  molecular tests compared to conventional phenotypic tests 
such as the cytotoxicity assay is the lack of  discrimination between asymptomatic 
and symptomatic carriership. Despite the improved performances (sensitivity 
and specificity), molecular tests have in general low positive predictive values and 
therefore cannot be applied as stand-alone test (64). However, due to the high 
negative predictive values molecular tests, such as qPCRs, are valuable as first 
screening method in a two-step testing algorithm for diagnosis of  CDI (56,60).
Typing of  Clostridium difficile strains
Typing methods have been developed to study the epidemiology of  C. difficile for 
several reasons; for detection and investigation of  outbreaks, to recognize new 
emerging strains, to investigate local and global transmission routes, and to study 
the phylogeny (67,68). One of  the most crucial properties of  a typing method is 
the capability to differentiate between strains (67-69). Other important features are 
reproducibility and ease of  use (69,70). Typing methods can be differentiated into 
two groups: phenotypic assays and genome based assays. Phenotypic assays are 
based on gene expression products, whereas genotyping methods are based on the 
DNA content of  the strain (67,69,70).
Until the 1980s, phenotypic assays were standard to determine relatedness of  
strains (28,69). The simple and rapid serotyping assay was the most commonly used 
phenotypic assay (69,71). Eventually the assay was able to discriminate 23 different 
serotypes (69). Several of  these (A, G, K, S1 and S4) were associated with (severe) 
CDI and PMC caused by CDI (72). Other serotypes (D and Cd-5) were suggested 
to be associated with asymptomatic carriership (72). Other typing methods were 
the Radio PAGE (25 types) and immunoblotting assay (26 types) (69). Eventually, 
the phenotypic typing methods were abandoned due to low reproducibility and 
a low discriminatory power for epidemiological studies with a larger -than local- 
scope (69).
The emergence of  the important global epidemic C. difficile RT 027 strain has 
stimulated the development of  genotyping methods. Molecular typing methods 
rely on purified DNA of  a single cultured C. difficile clone. Often these techniques 
are performed in national reference centres, since culturing of  C. difficile is not 
routinely performed in most diagnostic labs (69). Molecular methods are generally 
more reproducible and sensitive compared to the phenotypic assays used in the 
1980s (69). The most common genotyping methods to include PCR ribotyping, 
Multi Locus Variable number of  tandem repeat Analysis (MLVA), Multi Locus 
Sequence Typing (MLST) and single nucleotide polymorphisms (SNP) typing (60).
PCR ribotyping is the most frequently used molecular typing method in Europe 




intergenic spacer region between 16S and 23S ribosomal DNA, as well as rDNA 
copy numbers (73-75). In comparison to other DNA based typing assays PCR 
ribotyping is superior in discriminatory power, (inter laboratory) reproducibility 
and its low hands on time (67,70). Although PCR ribotyping is the preferred typing 
method for monitoring outbreaks, it is not able to differentiate between strains in 
an outbreak situation (70).
MLVA is a highly discriminatory (sub)typing method to discriminate between 
strains within one Ribotype to identify outbreak transmission routes (60,68,70,76). 
MLVA is based on the amplification of  short tandem repeats that vary in size and 
are spread throughout the genome (77). Marsh et al., were the first to describe an 
automated analysis of  the number of  tandem repeats per locus followed by van 
den Berg et al., (78,79). The two independently developed MLVA typing methods 
contained four out of  seven identical loci (78,79). Based on MLVA results, a 
minimum spanning tree can be constructed to determine genetic relationships 
among strains. Genetic relationships are based on the number of  Summed Tandem 
Repeat Differences (STRD) (41,78). Despite the lack of  variability of  two loci in 
RT027, MLVA has been reported to be the most discriminatory subtyping method 
to investigate outbreaks with the epidemic C. difficile RT 027 strain (79,80).
The availability of  multiple genome sequences has made whole genome 
sequencing (WGS) accessible as a typing method (77,81-83). Recently, major 
advances have been made with WGS-based typing of  C. difficile strains (81,84). 
WGS is able to reveal the natural history, phylogeny and global spread of  epidemic 
strains (81,82,84). In addition, WGS is a reliable sequencing method that can 
distinguish strains at a single nucleotide level (81,84). The identification of  single 
nucleotide polymorphisms (SNPs) across sequenced genomes has the potential 
to improve the discriminatory power over the more traditional MLVA genotyping 
method (81,85). Although MLVA and WGS analyse different aspects of  the C. 
difficile genome, a recent publication on the performance of  both techniques resulted 
in similar discriminatory power in an outbreak situation (85). WGS is also capable 
of  detecting mixed infections, which offers prospects of  screening for mixed 
infections in transmission studies (86). To date, the costs of  WGS are still relatively 
high compared to other typing methods (67,86). However, the ability of  WGS to 
extrapolate PCR ribotyping, MLST, sequences of  toxin and resistance genes and 
other additional data, combined with standardized computational pipelines, could 
balance the cost benefit towards WGS in the future (38,67,77,81-83).
Mobile elements
WGS as a typing method is based on the non-repetitive core genome (82,84,87). 




mosaic genome which consists of  a large proportion (11%) of  mobile elements 
(77,88). These mobile elements from phage, plasmid or transposon origin constitute 
the so called accessory genome (83,89). Mobile DNA elements can be transferred 
between C. difficile strains and may be passed on to other bacteria (77,90). Many C. 
difficile conjugative transposons (CTn) contain genes or other functions that could 
potentially contribute to the fitness and or virulence of  strains harbouring them 
(76,77,90-92).
Conjugative transposons are defined as “specific DNA elements that can 
integrate into one or more sites in one or more genomes” (93). In general, CTns 
consist of  a core region (conjugation and regulation module), a recombination 
module and a module with accessory gene(s) (91,93,94). After excision from the 
genome, intermediates are formed that can be transferred through conjugation into 
a recipient strain, where they can integrate via specific target site recombination 
(91,93,94). The accessory module can be diverse, and the genes primarily present 
encode determinants for antibiotic resistance or metabolic functions (76,91,93-98), 
often accompanied by dedicated transcriptional regulators (94).
The genomic sequence of  C. difficile strain 630 revealed the presence of  
six putative CTns in addition to the extensively investigated Tn5397 element 
(76,77,95,99). The putative CTns are named based on their locations in the 630 
genome (77). Four of  the identified transposons are closely related to Tn916 (77). 
The Tn916-like family of  conjugative transposons generally encode tetracycline 
resistance determinants and is broadly found in Firmicutes (94). The other CTns 
present in C. difficile strain 630 are more closely related to Tn1549, a conjugative 
transposon responsible for vancomycin resistance (77,100). Transposons in other 
(non 630) C. difficile strains encode resistance to chloramphenicol, spectinomycin, 
streptomycin and erythromycin (81,96).
It is easy to envisage how the presence of  antibiotic resistance determinants could 
increase the fitness of  strains, but the contribution of  other genes in the accessory 
genome to virulence remains largely unexplored. A recent study suggested that the 
accessory genome could be involved in the increased virulence and mortality of  a 
sub-group of  Clostridium difficile RT 015 strains (39). Furthermore, some virulence 
associated genes, including the C. difficile pathogenicity locus (PaLoc) have been 
suggested to be of  phage origin (101-103). Moreover, it has been demonstrated 





Clostridium difficile virulence factors
Clostridium difficile toxins
The symptoms of  CDI are mainly caused by the two main virulence factors, 
Toxin A (TcdA) and Toxin B (TcdB) (23,105-107). All naturally disease causing 
(toxinogenic) C. difficile strains produce Toxin B, and most of  the strains also Toxin 
A (23,34,108,109). No naturally occurring Toxin B negative strains have been 
reported to date. Toxin A (308 kDa) and Toxin B (270 kDa) belong to the family 
of  large clostridial cytotoxins (21,24). The members of  this family are single chain 
toxins consisting of  at least four domains (Figure 1): a receptor binding domain 
(110,111), a cysteine protease domain, a translocation domain (112,113) and a 
glycosyltransferase domain (21,23,24).
Figure 1: Schematic view of  the domain structure of  clostridial toxins. The catalytic 
domain is located at the N-terminus and the CROP region, which serves as receptor binding 
domain, is situated at the C-terminus. In between the N- and C-terminus the translocation 
domain (hydrophobic region) and the cysteine protease domain are located (113). Jank, 
T and Aktories K., Structure and mode of  action of  clostridial glycosylating toxins: the 





The receptor binding domain is located at the C-terminus and covers almost one 
third of  the toxin, in the case of  Toxin A (23,24). The C-terminus is characterized 
by repetitive peptide elements that are called combined repetitive oligopeptides 
(CROPS) (23,24,111). The crystal structure of  the CROPs of  Toxin A shows a 
solenoid like structure (110). Solenoid structures are widely present on bacterial 
surfaces and play a role in protein-protein or protein-carbohydrate interactions. 
The crystal structure of  the CROP region in complex with a carbohydrate 
demonstrated a specific interaction (114). However, the carbohydrates used in the 
crystal structure are absent in sensitive cells and in human tissue (113,115) and 
other (human) glycan structures need to be tested for their role in toxin binding.
Despite a similar structure of  the C-terminus of  Toxin B, experimental data 
suggest that binding of  Toxin A and B is mediated by different types of  receptors 
(113,116). Interestingly, it has recently been shown that toxins can enter eukaryotic 
cells via a CROP independent mechanism (117). Although the biological relevance 
of  this observation is not yet clear, it is suggestive of  an alternative binding 
motif  within the toxin (117).Binding of  the toxin to the eukaryotic cell receptor 
results in receptor-mediated endocytosis (21,24). Internalization of  the toxins 
occurs through the clathrin mediated pathway (118,119). After the clathrin coated 
vesicle is fused to an endosome (118), the low pH in the endosome results in a 
conformational change of  the toxin characterized by an increased exposure of  the 
hydrophobic region (21,24,115). This, in turn, allows translocation of  the catalytic 
domain and the cysteine protease domain into the cytosol (115). Cytosolic inositol 
hexaphosphate (InsP6) can subsequently induce the autocleavage activity of  the 
cysteine protease domain, resulting in the release of  the catalytic domain in the 
cytosol (21,24,115). Interestingly, it has recently been shown that cytotoxicity of  
Toxin B can be independent of  catalytic domain cleavage (120). The catalytic 
domain is a glycosyltransferase which inactivates Rho GTPases (Rho, Rac and 
Cdc42) in the cytosol by glycosylation (21,24,115,121). This results in the inhibition 
of  multiple effectors that ultimately results in apoptosis of  the targeted cell 
(21,23,24,113). A subsequent inflammatory response and further degradation of  
the intestinal epithelial cell layer eventually leads to the development of  the clinical 
symptoms of  CDI (23,24,122).
Transcriptional regulation of  the Pathogenicity Locus 
The genes encoding the major clostridial toxins, tcdA and tcdB, are located on a 
19-kb genomic region called the Pathogenicity Locus (PaLoc) (23,24). In between 
the toxin genes the tcdE gene is situated, which encodes a holin-like protein 
(101,123,124). TcdE is a membrane associated protein (23,101) but its involvement 
in the release of  the toxins is disputed (123,124). Besides the toxin genes and tcdE, 




The tcdR gene encodes the alternative RNA polymerase sigma (σ) factor, TcdR 
that positively regulates toxin production. It mediates binding of  RNA polymerase 
core enzyme to the tcdA, tcdB and tcdR promoter regions (125-127). TcdR belongs 
to the sub-family of  extra cytoplasmic factor (ECF) σ70 factors (125). In other 
bacteria, members of  this family have also been demonstrated to positively regulate 
potent toxins, such as the tetanus neurotoxin of  Clostridium tetani (128). TcdC has 
been reported to act like an anti-sigma factor for toxin production by destabilizing 
the TcdR-RNA polymerase core enzyme complex in a way that is not yet fully 
understood (126). Besides the PaLoc encoded regulators, toxin levels are also 
directly influenced by the nutritional regulators CodY and CcpA, and the sigma 
factors σH and σD (129-134).
In strain VPI10463, the exponential growth phase of  C. difficile is associated 
with a high transcription level of  the tcdC gene and low transcription levels of  
tcdR and the toxin genes, whereas the stationary growth phase is associated with a 
low transcription level of  the tcdC gene and high transcription levels of  tcdR and 
the toxin genes (135). The synthesis and secretion of  the toxins is increased upon 
entry into the stationary growth phase (135-138). The decreasing transcription of  
tcdC correlates with diminishing TcdC protein levels in stationary growth phase 
(135,138,139). Interestingly, mutations in the tcdC gene in the hypervirulent strains 
RT 027 (Δ117) and RT 078 (C184T) have been linked to increased virulence (43,140). 
These mutations result in the absence of  a functional TcdC caused by a frame shift 
mutation (∆117 bp) or a premature stopcodon (C184T) in tcdC which is linked to 
an increased toxin production (19,140). Together, the reported inverse correlation 
between the transcription of  tcdC and the toxin genes and the expression patterns 
of  the corresponding proteins (TcdC, TcdA and TcdB), have led to the prevailing 
model that TcdC is an important repressor of  toxin expression (125,126,135,139). 
However, recently some doubts have been raised about the importance of  TcdC in 
the regulation of  toxin expression. (137,138).
Some strains that are associated with an increased mortality and morbidity (e.g. 
RT 027 and RT 078) also produce a third toxin, called the binary toxin since it 
consists of  two polypeptides encoded by the cdtA and cdtB genes (27,43). The 
binary toxin genes are located on a 6.2 kb region called the Cdt locus, or CdtLoc 
(141). A gene (cdtR) encoding for a regulatory protein is located alongside the 
binary toxin genes on the CdtLoc (141). It has been suggested that binary toxin 
may contribute to disease in hamsters (106) and in-vitro assays have demonstrated 
that the binary toxin affects adhesion of  C. difficile to cells through induction of  




Non-toxin virulence factors of  Clostridium difficile
Clostridium difficile sporulation
Clostridium difficile is transmitted through the faecal-oral route. Spores are believed 
to form the primary vehicle for infection and sporulation is recognized as a crucial 
factor in the transmission route and as a persistence factor for C. difficile (143). 
Ingested spores germinate in the small bowel upon exposure to bile acids (144). 
The newly formed vegetative cells start to produce toxins and can cause disease 
(144).
The primary purpose for sporulation is survival of  the bacteria under harsh 
environmental conditions for prolonged periods of  time. Spores have a high 
tolerance against disinfectants and resistance towards antimicrobial compounds 
and therefore are able to persist on (hospital) surfaces and in the environment 
(145,146). The ability to form spores is a key factor to infect a new host, as they are 
able to survive the oxygenated environment outside the host as well as the harsh 
conditions in the host. Moreover, they confer the ability to persist whereas the 
commensal flora is eliminated by an antibiotic treatment (144,147).
The regulation of  spore formation in C. difficile is still poorly characterized 
compared to the extensively studied spore forming Bacillus subtilis (148). Though 
the pathways downstream of  the master regulator for sporulation, Spo0A, seem 
to a large extent conserved between B. subtilis and Clostridia, this is less so for the 
pathways upstream Spo0A activation (149-152). As expected, spo0A is required 
for sporulation in C. difficile (153). The sporulation pathway in Bacillus subtilis is 
induced under conditions of  nutrition-starvation (148). Under these conditions 
phosphorylation of  the master regulator Spo0A occurs (150,154). Phosphorylated 
Spo0A (Spo0A-P) is an essential activator of  the sporulation signalling cascade in 
Bacilli which ultimately leads to the formation mature spores (149,150). Importantly, 
in other organisms Spo0A regulates many other processes than sporulation, such 
as stress responses, biofilm formation, competence for genetic transformation, and 
DNA replication but also the synthesis of  virulence factors (155-164).
Clostridium difficile factors affecting colonization 
Spores and toxins are established virulence factors that contribute to transmission, 
infection and development of  disease (23,122,143,144). But an essential first step 
in establishment of  C. difficile in the colon is adhesion to the mucosal surfaces and 
subsequent colonization of  the host (Figure 2) (144). Relatively little is known 
about adhesion and colonization factors of  C. difficile. The surface layer of C. difficile 
contains a whole arsenal of  proteins that could potentially be involved in adhesion 




play a role in adhesion to cells or colonization of  the host. Among these proteins 
are fibronectin-binding protein A (165), Cwp84 (166), flagellar proteins (167) 
CD1581 (168), and several S-layer proteins (169).
Figure 2: Visualisation (SEM picture) of  an adhered vegetative C. difficile (arrows) to host 
colon epithelium (This picture was kindly provided by A.M. Buckley).
Mechanisms of  stress survival
During its life cycle C. difficile encounters stressful environments, like antibacterial 
substances and proteins, elevated temperatures, extreme pH and osmotic stress. 
These extracellular stresses can result in the accumulation of  (partially) unfolded 
proteins, especially in the bacterial envelope, which are non-functional or form 
poisonous aggregates (170). They may also affect the integrity of  the bacterial cell 
envelope, compromising cell viability. Thus, sensing and responding to extracellular 
stresses is important for survival of  the bacteria. Adaptation to these host-induced 
stresses can play a vital role in the virulence of  bacteria and the establishment of  
an infection.
Regulated intramembrane proteolysis (RIP) is one of  the mechanisms that 




The RIP mechanism activates regulatory pathways by releasing the sequestered 
sigma factors from their cognate anti-sigma factors as the result of  envelope stress 
(171,172). In Bacillus subtilis, extracellular stresses are sensed by an site-1 protease, 
PrsW (172). Upon stress, PrsW undergoes conformational changes which allow 
cleavage of  an anti-sigma factor at the C-terminus (172). The cleaved anti-sigma 
factor is recognized and further processed by extracytoplasmic proteases and a site-
2 protease, RasP (171,172). The remaining part of  the anti-sigma factor is further 
degraded in the cytoplasm by proteases like ClpX, leading to release of  the sigma 
factor (171,172). The sigma factor then interacts with RNA polymerase to activate 
transcription of  stress related genes (171,172).
Another well described mechanism to sense and respond to stress are two-
component systems. Two component systems are composed of  a sensor kinase 
and a response regulator (173,174). Monitoring envelope stress by the sensor 
kinase results in phosphorylation of  the response regulator (174). This in turn 
leads to activation of  stress related target genes (173,174). In Bacillus subtilis a two 
Figure 3: Schematic view of  the RIP pathway in Bacillus subtilis. The stress induced PrsW 
degrades the C-terminus of  the anti-sigma factor (RsiW) resulting in further processing of  
RsiW by extracytoplasmic proteases and RasP. The partially degraded anti-sigma factor is 
released into the cytoplasmic and further degraded by cytoplasmic proteases like Clp. The 
released sigma factor interacts with RNA polymerase which results in activation of  stress 
related genes (171). Heinrich, J and Wiegert T. Regulated intramembrane proteolysis in the 
control of  extracytoplasmic function sigma factors. Res. Microbiol.160:696-703 Copyright 




component system consisting of  a sensor kinase (CssS) and a response regulator 
(CssR) plays a role in the detection of  extracytoplasmic misfolded proteins (174). 
It does so primarily through the activation of  expression of  two homologous 
proteins of  the High temperature requirement A (HtrA) family (174).
Bacillus subtilis HtrA and HtrB are associated with the cytoplasmic membrane 
and are composed of  membrane spanning domain, a trypsin-like serine protease 
domain and one PDZ domain (174-178). Both proteins have fairly broad substrate 
specificity. PDZ domains are highly flexible domains and are involved in substrate 
recognition and/or the regulation of  protease activity (177,179). Bacterial HtrA-
like proteins are important for controlling protein quality and homeostasis by 
combining proteolytic and chaperone activities (175,176,179). Membrane anchored 
HtrA-like proteases are active as trimers and soluble HtrA-like proteases form 
larger active oligomers (176,179).
Outline of  this thesis
This thesis covers a broad range of  research topics varying from an applied 
approach to more fundamental experiments. Chapter 1 is the current chapter 
where we provide a general overview.
Applied research 
In Chapter 2 we describe the evaluation of  a modified in-house developed 
molecular assay with improved performance for diagnosis of  CDI. In addition we 
evaluated two other in-house developed qPCRs, of  which one detects the presence 
of  both toxin genes and the other detects the frame shift mutation in the tcdC 
gene. We evaluated the qPCRs by comparing them to a commercially available 
molecular assay and to the gold standards. In Chapter 3, the relatedness between 
human and porcine C. difficile RT 078 strains is investigated using a modified and 
optimized MLVA. Moreover, we also investigate the susceptibility to tetracycline 
and determined the genetic origin of  tetracycline resistance to further support 
the high relatedness between human and porcine RT 078 strains. In Chapter 4 
we identified a 100kb insert in a porcine RT 078 strain through whole genome 
sequencing and characterized this mobile element further.
Fundamental research 
Chapter 5 reports that C. difficile Spo0A recognizes and binds to similar sequences 
as the well characterized B. subtilis Spo0A. The in-vitro binding assays suggest that 
tcdB may be a direct target of  Spo0A. Therefore, we also characterized the toxin 
production of  an isogenic Spo0A mutant strain. In Chapter 6 we generated an 




In Chapter 7 we propose an alternative role for the putative anti-sigma factor TcdC. 
Chapter 8 describes the identification and characterization of  a C. difficile HtrA-like 
protease. The effect on the transcriptome and in-vivo virulence was determined by 
comparing the generated isogenic HtrA mutant to wild type. 
Discussion
Chapter 9 provides the general discussion, including the main conclusions of  this 
thesis and future perspectives. Chapter 10 provides an overview of  the content of  
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In the past decade, incidence of  Clostridium difficile infections (CDI) with more severe 
course has increased in Europe and Northern America. Assays that are capable to 
rapidly diagnose CDI are essential. Two real-time PCRs (LUMC and LvI) targeting 
C. difficile toxin genes (tcdB; tcdA and tcdB, respectively), were compared with the 
BD GeneOhm PCR (targeting the tcdB gene), using cytotoxigenic culture as gold 
standard. In addition, a real-time PCR targeting the tcdC frame shift mutation 
at position 117 (Δ117 PCR) was evaluated for detecting toxigenic C. difficile and 
the presence of  PCR Ribotype (RT) 027 in stool samples. In total, 526 diarrheal 
samples were prospectively collected and included in the study. Compared with 
cytotoxigenic culture, sensitivity, specificity, positive predicted value (PPV) and 
negative predicted value (NPV) were: for PCR LUMC 96.0%, 88.0%, 66.0% and 
98.9%, for PCR LvI 100.0%, 89.4%, 69.7% and 100.0%, for PCR Δ117 98.0%, 
90.7%, 71.9% and 99.5% and for PCR BD GeneOhm 88.3%, 96.9%, 86.5% 
and 97.4%. Compared to faeces samples cultured positive for C. difficile RT 027, 
sensitivity, specificity, PPV and NPV values of  the Δ117 PCR were: 95.2%, 96.2%, 
87.0% and 98.7%. We conclude that all real-time PCRs can be applied as a first 
screening test in an algorithm for diagnosing CDI. However, the low PPVs hinder 
the use of  the assays as a stand-alone test. Furthermore, the Δ117 PCR may provide 
valuable information for minimising the spread of  the epidemic C. difficile RT 027.




Clostridium difficile is a major cause of  nosocomial diarrhea and pseudomembranous 
colitis (1). Incidence of  Clostridium difficile infection (CDI) has increased in the 
past decade, which is associated with the emergence of  the hypervirulent PCR 
Ribotype (RT) 027 (2,3). The C. difficile enterotoxin A (TcdA) and cytotoxin B 
(TcdB) are considered as major virulence factors, whereas the binary toxin might 
play a role in virulence through the formation of  microtubule-based protrusions 
thereby increasing the adherence of  the bacteria (4-6). CDI can also be caused 
by strains that produce only TcdB (7), but strains producing TcdA only have not 
been described. Assays for the rapid diagnosis of  CDI are important to prevent 
the spread of  C. difficile, in particular for hypervirulent strains like the RT 027. 
Conventional diagnostic methods for CDI, such as cytotoxigenic culture (CYTGC) 
are time-consuming and not available at all routine diagnostic laboratories, whereas 
the performance of  rapid enzyme immuno-assays to detect toxins in faeces is 
insufficient (4,5,11). Previously, we developed a real-time PCR that detects the 
presence of  the tcdB gene (8). In this study we have improved the performance of  
this PCR and compared it with the commercially available BD GeneOhm PCR, 
and another in-house developed real-time PCR assay that detects the presence of  
the tcdA and tcdB gene (9). In addition, we evaluated a real-time PCR that targets 
the tcdC gene frame shift mutation at position 117 which can act as a marker for the 
RT 027/NAP1 strain (10,11).
Materials and methods
Cytotoxicity assay (CYT) and cytotoxigenic culture (CYTGC)
In total, 526 routine diagnostic diarrheal samples were submitted to the Department 
of  Microbiology at Leeds Teaching Hospitals and tested prospectively by the CYT 
and CYTGC assays as previously described (12). Briefly, all stool samples (less 
then 48h old) were stored at 2 to 5°C. Twenty μL of  diluted fecal sample (1:5 in 
PBS) was filtered and added to a monolayer of  both C. sordelli-antitoxin protected 
(Prolab Diagnostics, United Kingdom) and unprotected Vero cells. A sample was 
considered toxin-positive when cell rounding was observed after 24 or 48 hours of  
incubation. In addition, cultured C. difficile isolates from faeces samples that were 
found negative by the CYT assay, were investigated for toxin production using the 
CYTGC assay (12). Isolates were inoculated into brain heart infusion broth (BHI). 
After 48 hours of  incubation culture supernatants were added to a monolayer of  
protected and unprotected Vero cells. Cultured C. difficile isolates that were positive 





Culture of  isolates was performed as previously described (12). In short, following 
alcohol shock, samples were cultured on Braziers CCEY agar (Bioconnections, 
Wetherby, United Kingdom) supplemented with 5 mg/l lysozyme (Sigma, United 
Kingdom) and without egg yolk supplement. Incubation was done in an anaerobic 
workstation (Don Whitley, United Kingdom) for at least 48 hours. Grey-brown 
colonies with the characteristic horse manure odor were identified as C. difficile. 
Whenever the identification of  an isolate was questionable the Microgen C. difficile 
latex agglutination kit (Microgen Bioproducts Ltd., Camberley, United Kingdom) 
was used to confirm the identity.
DNA extraction
Fecal samples were stored at 4°C for 1 week and then frozen at -20°C. Specimen 
preparation and DNA extraction for the BD GeneOhm Cdiff  assay was performed 
according to the manufacturers’ protocol. For the other real-time PCRs, fecal 
samples were pre-treated with stool transport and recovery (STAR) buffer (Roche, 
Penzberg, Germany) according to the manufacturers’ protocol. For the LUMC 
real-time PCR, DNA was extracted on the MagNA Pure (Roche) using LC DNA 
Isolation Kit III (Roche, Penzberg, Germany) according to the manufacturers’ 
protocol. In short, 100 μL supernatant of  STAR buffer and chloroform pre-treated 
fecal sample was added to lysisbuffer (130 μL) and Prot K (20 μL). This mixture 
was heated at 65°C for 10 min followed by 95°C for 10 min, after which it was 
centrifuged for 1min at 1000 x g. 200 μL supernatant was used for automated DNA 
extraction. DNA was eluted in 100 μL elution buffer. The Phocine Herpes Virus 
(PhHV), which served as internal control, was added to the lysis buffer. For the 
LvI real-time PCR, DNA was extracted on the NucliSENS easyMAG (Biomérieux, 
Boxtel, The Netherlands) according to the specific A protocol (Biomérieux, Boxtel, 
The Netherlands). In short, 150 μL of  STAR buffer and chloroform pre-treated 
faeces suspension was added to 2 mL lysis buffer (NucliSENS; Biomérieux, Boxtel, 
The Netherlands). After incubation for 10 min at room temperature, the total 
suspension was transferred to the sample vessel including 140 μL magnetic silica 
beads and used for automated DNA extraction. DNA was eluted in 110 μL elution 
buffer. The internal control Phocine Herpes Virus (PhHV) was added to the lysis 
buffer.
Real-time PCR
Amplification of  part of  the tcdB gene by the BD GeneOhm Cdiff  PCR was 
performed on a Smartcycler (Cepheid, United Kingdom) according to the 
manufacturers’ protocol. Primers and probes that were used for the LUMC real-
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time PCR and the LvI PCR are described in Table 1. Amplification of  the tcdB 
gene by the LUMC real-time PCR was performed on a CFX detection system 
(Biorad, Veenendaal, The Netherlands) as previously described (8) with some 
optimizations. The PCR amplification was performed in a 50 μL final volume, 
containing 25 μL Hotstar mastermix (Qiagen, Venlo, The Netherlands), forward 
and reverse primers at 80 nM each, 3.5 mM MgCl2, 100 nM tcdB probe and 10 μL 
DNA. The PhHV primers described by Niesters (13) were used with a modified 
probe. Amplification protocol included an enzyme activation step for 15 min at 
95°C, followed by 50 cycles of  amplification; 94°C for 30 sec, 50°C for 30 sec and 
72°C for 30 sec. The LvI real-time PCR was designed to target both tcdA and tcdB 
gene. Amplification of  these genes was performed as a multiplex PCR on an AB 
7500 PCR system (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). 





Nucleotide sequence (5’ 3’)
LUMC TcdB 398CLDs GAAAGTCCAAGTTTACGCTCAAT
399CLDas GCTGCACCTAAACTTACACCA
551CLD-tq-FAM FAM-ACAGATGCAGCCAAAGTTGTTGAATT-BHQ1
LvI TcdA CD-tcdA-F TTG TAT GGA TAG GTG GAG AAG TCA GT
CD-tcdA-R AAT ATT ATA TTC TGC ATT AAT ATC AGC CCA T
CD-tcdA-MGB1 FAM-ATA TTG CTC TTG AAT ACA TAA A-NFQ-MGB
CD-tcdA-MGB2 FAM-TAT TGT TCT TGA ATA CAT AAA AC-NFQ-MGB
TcdB CD-tcdB-F1 GAA ACA GGA TGG ACA CCA GGT T
CD-tcdB-F2 AAG AGG ATG GAC GCC AGG TT
CD-tcdB-R1 ACG GTC TAA CAG TTT TGT GCC A
CD-tcdB-R2 CTG CCC TTC ATA ATG ATC TCT TAT ACG
CD-tcdB-MGB FAM-AAG AAG CTT AGA AAA TG-NFQ-MGB
∆117 PCR TcdC CD-tcdC-F GCA CAA AGG RTA TTG CTC TAC TGG
CD-tcdC-R1 AGC TGG TGA GGA TAT ATT GCC AA
CD-tcdC-R2 CAA GAT GGT GAG GAT ATA TTG CCA
CD-tcdCwt-MGB FAM-AAA CAC RCC HAA AAT AA-NFQ-MGB
CD-tcdCmut-MGB VIC-AAA CAC RCC AAA ATA A-NFQ-MGB
All PhHV 295PhHVs GGGCGAATCACAGATTGAATC
296PhHVas GCGGTTCCAAACGTACCAA
531PhHV-tq-CY5 CY5-TTTTTATGTGTCCGCCACCATCTGGATC-BHQ2* 
NED-CGC CAC CAT CTG GAT-NFQ-MGB ** 
BHQ = Black hole quencher; NFQ = Non fluorescent quencher; MGB = Minor groove 




Each PCR reaction was performed in a 25 μL final volume, containing 1x TaqMan 
Universal PCR Master Mix (Applied Biosystems, Nieuwerkerk a/d IJssel, The 
Netherlands), forward and reverse primers at 300 nM each, TaqMan MGB probes 
at 100 nM each, 2.5 μg bovine serum albumin (Roche), and 5 μL DNA extract. For 
PhHV, the primers described by Niesters (13) were used, whereas the probe was 
modified to a MGB-probe. Amplification protocol included 2 min at 50°C, 10 min 
at 95°C followed by 40 cycles of  amplification; 94°C for 15 sec, 60°C for 1 min.
The Δ117 real-time PCR was designed to target the tcdC gene frame shift 
mutation at position 117. This assay utilizes two Taqman MGB probes, a wildtype 
(WT) probe and a mutant (MUT Δ117) probe respectively, that both can hybridize 
with part of  the tcdC gene sequence flanking the 1 bp deletion at position 117. 
Isolates that do not carry the 1 bp deletion, will give a stronger signal with the WT 
probe, while 027/NAP1 isolates will do so with the MUT Δ117 probe. Hence, the 
ΔCt (Ct WT – Ct MUT Δ117) for 027/NAP1 strains will be positive, whereas the 
ΔCt for other C. difficile ribotypes will be negative, which enables discrimination. 
The primer/probe set was used in the same multiplex setup as the LvI PCR assay 
described above, with the primers at 300 nM and the MGB probes (5’-FAM and 
5’-VIC, 3’-NFQMGB) (Applied Biosystems) at 100 nM. Reactions were run on an 
ABI 7500 with the same amplification protocol as for the LvI PCR.
PCR ribotyping
PCR ribotyping was performed at the Department of  Microbiology at Leeds 
Teaching Hospitals following the protocol from the C. difficile Ribotyping Network 
for England (CDRNE) laboratory (12).
Data analysis
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) were determined by comparing the real-time PCRs with the CYTGC gold 
standard; using statistical software PASW 17.0.2. Differences in the sensitivity and 
specificity between the real-time PCRs were determined by using the McNemar’s 
Test for correlated proportions. Samples with a Ct-value higher then 40 were 
considered as negative. In addition, samples with an internal control Ct-value that 
deviated more than 3 Ct-values compared to the internal control Ct-value of  the 
negative control were considered inhibited and discarded from the analyses for the 
LUMC PCR. For the LVI PCR, samples were considered inhibited and discarded 
from analysis when the Ct value for the internal control exceeded 34.91 cycles (i.e., 
the mean Ct value for uninhibited specimens ± 2 standard deviations). The number 
of  inhibited samples for the Δ117 PCR was equally determined as for the LVI 
PCR. Furthermore, the Δ117 PCR was compared with PCR ribotyping of  CYTGC 
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positive isolates. The BD GeneOhm Cdiff  PCR tests were interpreted according 
to the manufacturers’ protocol. The software on the Smart cycler (Cepheid, UK) 
recorded the results of  the PCR assay as positive, negative or unresolved.
Results
Comparing the real-time PCRs with the gold standard CYTGC
In total, we evaluated 526 diarrheal samples, of  which 101 samples (19.2%) were 
positive in the CYTGC assay. Of  101 positive samples, 13 were derived from CYT-
assay negative samples. For the evaluation of  the LUMC PCR 10 samples (1.9%) 
were excluded from the analysis due to inhibition during the amplification step, 
whereas 16 samples (3.1%) and 15 samples (2.9%) were inhibited and excluded 
from the analysis of  the LvI PCR and Δ117 PCR, respectively. Five samples (1%) 
were recorded as unresolved by the BD GeneOhm PCR assay and excluded from 
the analysis. Sensitivity, specificity, PPV and NPV for all PCR methods against 
CYTGC are shown in Table 2. All stool samples that tested positive for C. difficile 
by the CYTGC assay were also detected by the LvI PCR. Comparable sensitivity 
was achieved by the LUMC PCR (96%) and Δ117 PCR (98%), while the sensitivity 
of  the commercial BD GeneOhm PCR was lower (88.3%). The difference in 
sensitivity between the BD GeneOhm PCR and the three in-house developed 
PCRs was significant with p-values of  0.00, 0.01 and 0.04 for the LvI PCR, the 
∆117 PCR and the LUMC PCR, respectively. In contrast, the BD GeneOhm PCR 
showed higher specificity (96.9%) compared to the LvI PCR (89.4%), the Δ117 
PCR(90.7%) and the LUMC PCR (88.0%). The difference in specificity between 
the BD GeneOhm PCR and all three in house developed PCRs was significant with 
a p-value off  0.00. Compared to CYTGC, all PCRs had similar NPV ranging from 
97.4 to 100%. The BD GeneOhm PCR had the highest PPV (86.5%) compared to 
the LvI PCR (69.7%), the Δ117 PCR (71.9%) and the LUMC PCR (66.0%).
Discrepancy analysis
Analysis of  false positive results showed an overlap of  the numbers of  false positives 
detected by the different PCR methods (Figure 1A). In total, 13 false positive 
results (14% of  total amount of  positives) were found by the BD GeneOhm PCR 
compared to CYTGC. Of  these false positives, 54% (n = 7) was also detected as 
such by all other PCR methods. Compared to CYTGC, the most false positives 
(34%) were detected by the LUMC PCR, whereas the LvI PCR and the Δ117 PCR 











































LUMC PCR 526 10 + 97 50 96.0 88.0 66.0 98.9
- 4 365 (90.3-98.5) (84.5-90.7)
LvI PCR
522b 16 + 99 43 100.0 89.4 69.7 100.0
- 0 364 (96.3-100) (86.1-92.1)
∆117 PCRa
522b 15 + 97 38 98.0 90.7 71.9 99.5
- 2 370 (92.9-99.4) (87.5-93.1)
BD GeneOhm 512c N/A + 83 13 88.3 96.9 86.5 97.4
- 11 405 (80.3-93.3) (94.8-98.2)
For each PCR method the number of  samples included and inhibited is shown. Sensitivity, 
specificity, negative predictive value (NPV) and positive predictive value (PPV) of  the PCR 
methods are given as percentages, and the corresponding 95% confidence interval (95% 
CI) is shown in parentheses.a. The lowest Ct value belonging to either the tcdC wildtype or 
mutant probe was used for the evaluation of  the ∆117 PCR as a screening assay. b 4 samples 
were not present in the collection. c data for 14 samples were not available.
Figure 1: (A) False positive results and (B) false negative results detected by real-time 
PCRs with overlapping samples. All false positive and false negative results from each PCR 
method compared to the CYTGC assay were analyzed for resemblances. Resemblances in 
false positive and false negative results were ordered by PCR method. No false negative 
results were found by the LvI real-time PCR.
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Fourteen percent of  the false positives detected by the LUMC PCR were also 
detected as such by all other PCR methods, whereas for the LvI PCR and the 
Δ117 PCR 16% and 19% of  the false positives had a similar test outcome by all 
other PCR methods. Figure 1B shows the number of  false negative results detected 
by the real-time PCRs. No false negative results were found by the LvI real-time 
PCR with the CYTGC as standard. Compared to CYTGC, 11 false negative results 
(2.6% of  the total amount of  negatives) were detected by the BD GeneOhm PCR, 
whereas the LUMC PCR and the ∆117 PCR had 1.1% and 0.5% false negative 
samples, respectively. None of  the false negative samples were detected as such by 
all three PCR methods; only overlapping results between two PCR methods were 
found.
Comparing the Δ117 PCR with PCR ribotyped CYTGC positive samples
Of  the 99 CYTGC positive samples, a total of  21 samples were typed as RT 027 by 
PCR-Ribotyping (Table 3). The ∆117 PCR was able to confirm 20 of  these samples 
(95%) by detection of  the 1 bp deletion at position 117 in the tcdC gene, with a ∆Ct 
(Ct WT – Ct MUT ∆117) = + 2.9 cycles difference on average. Compared with 
CYTGC positive, RT 027 samples, sensitivity, specificity, PPV and NPV values 
were for this assay: 95.2%, 96.2%, 87.0% and 98.7%. The Δ117 PCR detected 3 
samples carrying the ∆117 mutation, which were ribotyped as RT 005, RT 106 and 
an unknown RT, not RT 027.
Table 3: Comparison of  the LvI Δ117 PCR with PCR ribotyping.
Assay Samples includeda Result





























+ 20 3b 95.2 96.2 87.0 98.7
- 1 73
All CYTGC positive samples (N=99) were analyzed by the ∆117 PCR. Sensitivity, specificity, 
negative predictive value (NPV) and positive predictive value (PPV) of  the PCR method 
are given as percentages.a Only CYTGC positive samples were included.b Three CYTGC 






Rapid and accurate diagnosis of  CDI is essential for patient management and 
prevention of  nosocomial transmission. A main issue in diagnosing CDI is that 
most conventional tests do not have sufficient performance for applying it as a 
standalone test. Molecular tests are increasingly applied for diagnosing CDI and 
are also mentioned in a recent published guideline as potentially rapid assays with 
better performances (4). This study was performed to compare the diagnostic 
value of  three in-house developed real-time PCRs and a commercially available BD 
GeneOhm Cdiff  assay, using the appropriate gold standard on 526 prospectively 
collected stool samples. The sensitivity of  the in-house developed PCRs was better 
than the BD GeneOhm test, in contrast to the specificity. Subsequently, NPVs 
were similar whereas the PPV was the highest for the BD GeneOhm test (86.5%). 
Peterson et al. (14) evaluated a real-time PCR that targeted the tcdB gene of  C. 
difficile and reported a sensitivity of  93.3% and a specificity of  97.4% This is in line 
with what has been reported by Sloan et al. (15) on the performance of  a real-time 
PCR, which was directed against the tcdC gene. They reported a sensitivity of  86% 
and specificity of  97%. The sensitivity and specificity reported by both studies 
are comparable to what has been found in this study for the BD GeneOhm Cdiff  
PCR. 
Our study had a prevalence of  toxigenic C. difficile positive samples of  
approximately 20%, repeated samples from positive patients were excluded. The 
prevalence was high, due to a selection of  faeces samples with high suspicion 
of  CDI. The PPV is dependent on the prevalence of  the disease in the tested 
population. Several studies report that in the hospital 5%-10% of  the antibiotic-
associated diarrhea samples contain C. difficile (16-18). In the community the 
prevalence of  CDI is close to 2% (19,20). Therefore, we calculated PPVs for all 
PCR methods at prevalence’s of  2%, 5% and 10%. The calculated PPVs at 10% 
and 5% prevalence decreased to 76% and 60% for the BD GeneOhm PCR, 51% 
and 33% for the LvI PCR, 54% and 36% for the ∆117 PCR and 47% and 30% for 
the LUMC PCR. At 2% prevalence PPVs are 37% (BD GeneOhm), 16% (LvI), 
18% (∆117) and 14% (LUMC). 
The performance of  the LUMC real-time PCR reported in this evaluation 
was better than reported previously by van den Berg et al. (8). This difference 
can be explained by the difference in prevalence of  CDI positive samples used in 
this study (20%) and the previous study (6%). Furthermore, we optimized PCR 
conditions (PCR-mix, modified probe), and reached a detection limit of  103 CFU/
gram stool samples (data not shown) which is improved compared to 105 CFU/
gram as reported by van den Berg et al. (14).
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When the false positive PCR results were analyzed, 54% of  the false positives 
detected by the BD GeneOhm PCR were also detected as such by the other PCRs. 
This suggests that 54% of  the false positives contained C. difficile specific tcdB 
DNA, since the samples were detected by three PCRs targeting the tcdB gene using 
different primer sets. In addition, these samples were also found positive by the 
∆117 PCR using the tcdC gene as a target. It can not be excluded that the cultures 
were false negative due to previous antibiotical treatment but discrepancies with 
CYTGC assay still remain present. We consider this finding as an important lack 
of  the currently available gold standard and think that future clinical studies are 
necessary to interpret the findings more precisely.
In comparison to CYTGC positive samples with C. difficile RT 027, the ∆117 
PCR targeting the tcdC gene ∆117 1 bp deletion has a high concordance of  95.2%. 
This high concordance makes the utility of  the ∆117 PCR for direct detection of  
the epidemic strain promising, although further research is needed to determine 
if  other C. difficile RTs contain the tcdC point mutation at position 117 and, 
consequently, are detected by this PCR. Furthermore, the performance of  this 
PCR for detection of  toxigenic C. difficile indicates that this assay has the potential 
to diagnose CDI, without pre-screening for the toxin genes A and B. The tcdC gene 
has been recognized as a putative negative regulator of  tcdA and tcdB and thereby 
is indicative of  the presence of  the pathogenicity locus (21). 
A difference between the three in-house developed real-time PCRs was 
the percentage of  inhibited samples. In total, 3.1% (n = 16), and 2.9% (n=15) 
of  all samples (n = 522) tested by the LvI PCR and ∆117 PCR were inhibited 
respectively, whereas 1.9% (n = 10) of  all samples (526) tested by the LUMC PCR 
were inhibited. The PCRs used different DNA extraction methods and different 
platforms which might contribute to the observed differences.
Most rapid diagnostic tests do not have sufficient performance for applying 
it as a standalone test. Recently, Planche et al. (17) defined that a test is applicable 
as a standalone test when a sensitivity of  at least 90% and a specificity of  at least 
97% is reached. The three in-house developed PCRs lack specificity, whereas the 
BD GeneOhm PCR lacks sensitivity resulting in too low PPVs of  all PCRs ranging 
from 66% to 86.5% at 20% CDI-prevalence. These PPVs decrease substantially 
when calculating PPVs for CDI-prevalence’s that are more common for a clinical 
setting (10%) or observed in the community (2%). None of  our evaluated real-
time PCR methods fulfilled the criteria defined by Planche et al. (17). Therefore, 
it was concluded that they cannot be applied as a standalone test. This finding is 
in line with what has been found for toxin detection assays and other molecular 
based assays by other studies (12,16,17). However, due to their high NPVs all four 




in a two-step algorithm. In this algorithm the PCR assay is followed by a second 
confirmation step to confirm the first positive test result.
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One hundred and two human and 56 porcine Clostridium difficile PCR Ribotype 
(RT) 078 strains from four European countries were investigated by an optimized 
Multiple Locus Variable number tandem repeat Analysis (MLVA) and for 
tetracycline susceptibility. Eighty-five percent of  all isolates were genetically 
related, irrespective of  human or porcine origin. Human strains were significantly 
more resistant to tetracycline than porcine strains. All tetracycline resistant strains 
contained the Tn916-like transposon, harboring the tet(M) gene. We conclude 
that strains from human and porcine origin are genetically related, irrespective of  
country of  origin. Further studies are needed to clarify the genetic relatedness of  
C. difficile RT 078 strains, including whether this is a consequence of  less natural 
variability in this ribotype versus other ribotypes.




Recently, we reported that Clostridium difficile PCR Ribotype (RT) 078 is an increasing 
cause of  Clostridium difficile Infections (CDI) in humans in the Netherlands with 
similar disease severity as the hypervirulent RT 027 (1). Also the incidence of  CDI 
in England caused by RT 078 has increased (2). In addition, recent studies have 
demonstrated that RT 078 is the predominant type in cattle and pigs (3,4). In the 
Netherlands, we have noticed an overlap in the occurrence of  human CDI cases 
caused by RT 078 and the distribution of  pig farms in the eastern part of  the 
country (1). This suggests a possible link between human and porcine RT 078 
strains.
To investigate the relatedness between human and porcine RT 078 strains, we 
applied a Multiple locus variable number tandem repeat analysis (MLVA) developed 
for C. difficile on a collection of RT 078 isolates (1,5,6). This MLVA has been proven 
to be more discriminatory than other genotyping methods (7,8). Since it has been 
suggested that the wide dissemination of  Staphylococcus aureus ST398 in pigs and 
humans is associated with the frequent usage of  tetracycline in pig farms, we also 
investigated the susceptibility to tetracycline and the genetic origin of  tetracycline 
resistance (9-11).
Clostridium difficile strains
A total of  102 human and 56 porcine RT 078 strains were available for this 
study. Table 1 depicts the location of  isolation and the year of  isolation of  each 
strain. All human RT 078 strains were recovered from diarrhoeal patients. The 
“Leeds collection” (n=67) consisted of  44 strains originating from an outbreak in 
Northern Ireland, 20 strains from other parts of  the UK and 3 strains originating 
from Ireland. The “Leiden collection” consisted of  34 strains of  endemic cases 
in the year 2006-2007. The 56 porcine strains were collected from 11 Dutch pig 
farms in the years 2006, 2007 and 2009. All pig farms had persistent problems 
of  neonatal diarrhoea. Forty-seven (84%) isolates were recovered from diarrhoeal 
piglets.
Modification of  MLVA
MLVA was adjusted for RT 078 due to the lack of  specific PCR products for loci 
A6Cd, B7Cd, C6Cd and G8Cd. Sequence analysis of  7 human and 8 porcine RT 078 
strains revealed multiple mismatches in the primer annealing sites for loci B7Cd, 
C6Cd and G8Cd and the absence of  locus A6cd. We adjusted the magnesium chloride 
concentration (4 mM) and annealing temperatures for loci B7Cd, G8Cd (47°C) and 




PCRs for the other loci and the analysis of  the MLVA data were performed with the 
previously described conditions (5). The calculated Variable Number of  Tandem 
Repeats (VNTR) of  the adjusted MLVA was in complete concordance with the 
manually measured VNTR. The absence of  locus A6Cd could theoretically result 
in less discriminative power of  the MLVA. Therefore, we reanalyzed the MLVA 
on previously typed RT 027 (n=57) and 017 (n=71) strains (5,6). This reanalysis 
based on 6 loci resulted in equal numbers of  Genetically related Clusters (GCs) and 
Clonal Complexes (CCs). Subsequently, we concluded that the optimized MLVA 
for RT 078, based on 6 loci is capable to discriminate between strains from various 
countries and origins.
Tetracycline susceptibility
All strains were tested for their susceptibility to tetracycline. The breakpoint for 
tetracycline was defined as MIC ≥ 8 mg/l (12). Seventy-five of  the 102 human and 
15 of  the 56 porcine strains were resistant to tetracycline. Tetracycline resistance 
was not found among randomly selected isolates of  the 2 most common human 
types 001 (n=10) and 014 (n=10). There were significantly more human strains 
resistant to tetracycline compared to porcine strains (p<0.005 measured by Chi-
squared method). This difference could be explained by the fact that we included 
44 outbreak strains. Thirty-eight (86%) of  the outbreaks strains were resistant to 
tetracycline versus 15 (65%) resistant strains originating from other parts of  the 
UK and Ireland.
The origin of  tetracycline resistance was investigated by detection of  mobile 
elements Tn5397-like and Tn916-like transposons as previously described (13). All 
tetracycline resistant strains contained the Tn916-like transposon, harboring the 
tet(M) gene. Filtermating experiments demonstrated the transfer of  the Tn916-
like transposon from a donor strain to a recipient strain. We did not detect either 
of  the transposons in tetracycline susceptible strains. This observation suggests a 
high degree of  relatedness of  human and porcine isolates and is in agreement with 
recently published findings (13). Although, we cannot exclude horizontal transfer 
of  the Tn916-like transposon since this transposon is widely distributed in Gram-
positive bacteria and additional data are required from tetracycline resistant non-078 
RTs (14-16). Recent publications show that tetracycline resistance is predominantly 
present in RTs 012, 017, 046 and 078 (12,17,18). A screening of  randomly selected 
strains of  these types demonstrated that tetracycline resistance in RT 012 and 
046 is encoded by the Tn5397-like transposon, whereas the origin of  tetracycline 
resistance in RT 017 and 078 is encoded by the Tn916-like transposon.
Relatedness of  human and animal Clostridium difficile PCR Ribotype 078
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Application of  optimized MLVA
Table 1 depicts the results of  the MLVA of  each strain per locus. A minimal 
spanning tree (MST) was constructed to determine the genetic relationships among 
strains as previously described (Figure 1) (1). In total, 116 strains belonged to one 
of  the GCs, defined as a Summed Tandem Repeat difference (STRD) ≤ 10. The 
largest GC (green cluster) contained 103 strains, encompassing 47 porcine strains, 
41 Leeds collection strains and 15 Leiden collection strains. Fifty-five strains were 
Figure 1: Minimum spanning tree analysis of  158 C. difficile RT 078 isolates by MLVA: Each 
circle represents either a unique isolate or more isolates that have identical MLVA types. 
The numbers between the circles represent the summed tandem repeat difference (STRD) 
between MLVA Types. Thick lines represent single locus variants, thin lines represent 
double locus variants and the interrupted lines represent triple locus variance between 
MLVA types. Clonal clusters are defined by a STRD ≤ 2 and genetically related clusters are 
defined by a STRD ≤ 10. Porcine (n=56) isolates susceptible are printed in red italic bold 
font, human isolates susceptible to tetracycline from the Leeds collection are printed in red 
italic underlined font and human isolates from the Leiden collection susceptible to tetracycline 
are printed in red italic normal font. Isolates resistant to tetracycline from the Leeds collection 
are printed in black underlined font. Porcine isolates resistant to tetracycline are printed in 
bold font and human isolates from the Leiden collection are printed in normal font. The 
numbers represent isolates from different geographical locations: The Leeds collection: 
Northern Ireland 1-44, Yorkshire and Humber 45-53, South West England 54-57, North 
West England 58-62, East England 63-64, Ireland 65-67. The Leiden collection: Noord 
Holland 68-76, Zuid Holland 77-79, Utrecht 80-87, Gelderland 88-91, Brabant 92-93, 
Groningen 94-95, Friesland 96, Flevoland 97, Limburg 98, Overijssel 99-101 and Belgium 




susceptible and 48 strains were resistant to tetracycline. The yellow GC contained 
only strains which originated in the Netherlands, encompassing both tetracycline 
susceptible and resistant strains. The blue GC contained only porcine strains 
susceptible to tetracycline which originated from one pig farm. The last GC (purple) 
contained only tetracycline resistant strains from the Leiden collection. Sixteen of  
the 23 recognized CCs (defined as a STRD ≤2) belonged to the largest GC, whereas 
the other 7 CCs were either single or double locus variants of  the largest GC. Five 
CCs contained only porcine strains and 13 CCs contained only human strains, 
of  which 8 CCs derived from the Leeds collection and 5 CCs derived from the 
Leiden collection. The remaining 5 CCs contained both porcine and human strains, 
irrespective of  origin of  country. Two CCs contained human strains isolated in 
different locations from a specific region. Nine of  the 23 CCs contained outbreak 
strains and strains from distinct settings. Interestingly, 12 CCs contained only 
strains resistant to tetracycline and 8 CCs contained both tetracycline susceptible 
and resistant strains. The remaining 3 CCs contained only tetracycline susceptible 
strains. In total, 4 MLVA profiles could be recognized that contained both human 
and porcine strains. Overall, the MST could not differentiate between geographical 
origin or tetracycline phenotype, irrespective of  human or porcine origin.
Table 1: Depicts of  each strain the results of  the optimized MLVA for each of  the 7 loci 
(A6Cd, B7Cd, C6Cd, G8Cd E7Cd, F3Cd and H9Cd).
MST 
no.
location of  isola-
tion (anonymised)
year of  
isolation A6Cd B7Cd C6Cd E7Cd F3Cd G8Cd H9Cd
001 A 2008 n/a 19 28 8 4 4 2
002 B 2008 n/a 18 26 8 4 4 2
003 E 2008 n/a 24 34 8 4 4 2
004 E 2008 n/a 13 18 6 4 4 2
005 B 2008 n/a 15 33 8 4 3 2
006 H 2008 n/a 26 27 12 4 4 2
007 GP 2008 n/a 17 49 7 4 1 2
008 I 2008 n/a 16 32 8 4 4 2
009 J 2008 n/a 22 30 8 4 6 2
010 A 2008 n/a 16 26 5 4 6 2
011 M 2008 n/a 25 25 8 4 4 2
012 T 2008 n/a 18 29 5 4 0 2
013 U 2008 n/a 21 39 5 4 6 2
014 GP 2008 n/a 21 38 8 4 3 2
015 W 2008 n/a 21 38 8 4 3 2





location of  isola-
tion (anonymised)
year of  
isolation A6Cd B7Cd C6Cd E7Cd F3Cd G8Cd H9Cd
016 X not supplied n/a 19 39 5 4 4 2
017 GP 2008 n/a 21 34 8 4 5 2
018 M 2008 n/a 37 36 8 4 4 2
019 AA not supplied n/a 6 42 6 4 5 2
020 T not supplied n/a 21 32 8 4 3 2
021 E 2008 n/a 19 24 5 4 4 2
022 GP 2008 n/a 19 32 8 4 3 2
023 AD 2008 n/a 19 32 8 4 3 2
024 E 2008 n/a 19 38 5 4 5 2
025 E 2008 n/a 37 36 8 4 4 2
026 GP 2008 n/a 37 36 8 4 4 2
027 GP 2008 n/a 37 36 8 4 4 2
028 M 2008 n/a 19 38 5 4 5 2
029 AA not supplied n/a 21 39 5 4 6 2
030 AH 2008 n/a 35 43 5 4 5 2
031 M 2008 n/a 19 37 5 4 4 2
032 M 2008 n/a 6 43 6 4 5 2
033 GP 2008 n/a 21 41 5 4 6 2
034 AI 2008 n/a 24 33 8 4 4 2
035 AJ 2008 n/a 21 43 5 4 5 2
036 E 2008 n/a 24 33 8 4 4 2
037 AJ 2008 n/a 21 43 5 4 3 2
038 AI 2008 n/a 21 39 8 4 3 2
039 AK 2008 n/a 19 24 5 4 4 2
040 AI 2008 n/a 24 33 8 4 4 2
041 AK 2008 n/a 20 45 5 4 0 2
042 M 2008 n/a 17 33 8 4 4 2
043 M 2008 n/a 24 33 8 4 4 2
044 M 2008 n/a 37 36 8 4 4 2
045 K 2008 n/a 15 23 8 4 5 2
046 D not supplied n/a 18 26 8 4 4 2
047 G 2008 n/a 19 32 8 4 8 2
048 G 2008 n/a 28 34 8 4 4 2
049 C 2007 n/a 20 33 8 4 3 2
050 G 2008 n/a 19 24 5 4 4 2
051 AB 2007 n/a 6 43 6 4 5 2






location of  isola-
tion (anonymised)
year of  
isolation A6Cd B7Cd C6Cd E7Cd F3Cd G8Cd H9Cd
053 D 2007 n/a 6 42 6 4 5 2
054 F 2008 n/a 19 39 5 4 5 2
055 Y 2007 n/a 29 32 8 4 0 2
056 Y 2007 n/a 37 36 8 4 4 2
057 AF 2008 n/a 19 38 5 4 5 2
058 L 2007 n/a 15 32 8 4 8 2
059 V 2007 n/a 21 34 8 4 3 2
060 Z 2007 n/a 20 37 5 4 4 2
061 AE 1953 n/a 21 38 8 4 3 2
062 AL not supplied n/a 24 26 8 4 4 2
063 O 2007 n/a 17 43 5 4 4 2
064 S 2008 n/a 21 34 8 4 3 2
065 P not supplied n/a 35 38 8 4 3 2
066 Q 2008 n/a 21 38 8 4 3 2
067 R 2008 n/a 21 38 8 4 3 2
068 AL 2006 n/a 26 38 12 2 4 8
069 AM 2007 n/a 26 33 10 2 4 9
070 AM 2007 n/a 26 33 11 2 4 9
071 AL 2007 n/a 29 40 9 2 4 8
072 AN 2007 n/a 24 41 9 2 4 8
073 AO 2007 n/a 25 35 13 2 4 8
074 AP 2007 n/a 20 20 12 2 4 8
075 AZ 2006 n/a 26 34 11 2 4 8
076 AZ 2006 n/a 21 34 12 2 4 9
077 AV 2007 n/a 21 37 12 2 4 8
078 BB 2007 n/a 31 35 11 2 4 8
080 AQ 2006 n/a 23 30 9 2 4 8
081 BE 2006 n/a 20 41 12 2 4 8
082 BF 2006 n/a 22 31 10 2 4 8
083 BG 2006 n/a 24 31 11 2 4 8
084 BE 2007 n/a 31 36 7 2 4 8
085 BG 2006 n/a 27 31 10 2 4 8
086 BG 2006 n/a 23 33 9 2 4 8
087 BG 2006 n/a 23 33 9 2 4 8
088 AR 2006 n/a 23 30 11 2 4 8
089 AU 2007 n/a 25 39 12 2 4 8
090 BA 2006 n/a 23 25 11 2 4 8





location of  isola-
tion (anonymised)
year of  
isolation A6Cd B7Cd C6Cd E7Cd F3Cd G8Cd H9Cd
091 BJ 2006 n/a 26 32 10 2 4 8
092 AT 2007 n/a 18 52 11 2 4 8
093 BI 2006 n/a 27 34 12 2 4 8
094 AY 2007 n/a 29 40 9 2 4 8
095 AX 2007 n/a 29 40 9 2 4 8
096 AW 2007 n/a 26 43 13 2 4 8
097 BC 2006 n/a 19 28 10 2 4 8
098 BD 2007 n/a 18 32 9 2 4 8
099 BP 2006 n/a 23 41 12 2 4 8
100 BK 2007 n/a 18 33 10 2 4 8
101 BK 2007 n/a 18 33 10 2 4 8
102 AS 2005 n/a 18 33 9 2 4 8
103 BL 2006 n/a 21 37 9 2 4 8
104 BL 2006 n/a 21 37 9 2 4 8
105 BM 2007 n/a 23 36 11 2 4 8
106 BN 2007 n/a 19 32 9 2 4 8
107 BN 2007 n/a 19 32 9 2 4 8
108 BN 2007 n/a 13 25 9 2 4 8
109 BN 2007 n/a 18 34 4 2 4 8
110 BN 2007 n/a 13 32 9 2 4 8
111 BN 2007 n/a 18 33 9 2 4 8
112 BN 2007 n/a 18 34 4 2 4 8
113 BO 2007 n/a 21 37 9 2 4 8
114 BR 2009 n/a 8 43 8 4 4 2
115 BR 2009 n/a 28 43 8 4 4 2
116 BS 2009 n/a 25 33 8 4 6 2
117 BS 2009 n/a 21 32 8 4 3 2
118 BS 2009 n/a 25 32 8 4 3 2
119 BS 2009 n/a 25 32 8 4 3 2
121 BS 2009 n/a 23 31 8 4 3 2
122 BS 2009 n/a 23 32 8 4 3 2
123 BS 2009 n/a 24 30 8 4 3 2
124 BS 2009 n/a 23 32 8 4 3 2
125 BT 2009 n/a 20 45 8 4 4 2
126 BT 2009 n/a 20 44 8 4 4 2
127 BT 2009 n/a 16 38 8 4 4 2






location of  isola-
tion (anonymised)
year of  
isolation A6Cd B7Cd C6Cd E7Cd F3Cd G8Cd H9Cd
129 BU 2009 n/a 21 34 8 4 4 2
130 BU 2009 n/a 18 37 8 4 4 2
131 BU 2009 n/a 15 35 8 4 4 2
132 BU 2009 n/a 16 35 8 4 4 2
133 BU 2009 n/a 16 35 8 4 4 2
134 BV 2009 n/a 16 39 8 4 3 2
135 BV 2009 n/a 15 38 8 4 3 2
136 BV 2009 n/a 16 36 8 4 4 2
137 BV 2009 n/a 28 38 8 4 5 2
138 BV 2009 n/a 21 38 8 4 3 2
139 BV 2009 n/a 21 38 8 4 5 2
140 BV 2009 n/a 21 38 8 4 5 2
141 BV 2009 n/a 15 38 8 4 4 2
142 BV 2009 n/a 15 35 8 4 3 2
143 BV 2009 n/a 16 38 8 4 5 2
144 BW 2009 n/a 16 36 8 4 4 2
145 BW 2009 n/a 17 33 8 4 4 2
146 BW 2009 n/a 21 38 8 4 4 2
147 BW 2009 n/a 20 37 8 4 4 2
148 BW 2009 n/a 17 34 8 4 4 2
149 BW 2009 n/a 23 34 8 4 4 2
150 BW 2009 n/a 11 35 8 4 4 2
151 BX 2009 n/a 8 35 8 4 1 2
152 BX 2009 n/a 18 33 8 4 6 2
153 BX 2009 n/a 18 33 8 4 4 2
154 BX 2009 n/a 18 32 8 4 4 2
155 BX 2009 n/a 20 33 8 4 3 2
156 BX 2009 n/a 18 33 8 4 3 2
157 BX 2009 n/a 8 35 8 4 6 2
158 BX 2009 n/a 12 34 8 4 3 2
All strains have a MST number which corresponds to the number used in the MST (Figure 
1); geographical location: Northern Ireland 1-44, Yorkshire and Humber 45-53, South West 
England 54-57, North West England 58-62, East England 63-64, Ireland 65-67. Noord 
Holland 68-76, Zuid Holland 77-79, Utrecht 80-87, Gelderland 88-91, Brabant 92-93, 
Groningen 94-95, Friesland 96, Flevoland 97, Limburg 98, Overijssel 99-101 and Belgium 
102. Porcine strains 103-158. For each strain an anonymised location (institute or pigfarm) 
of  isolation, year of  isolation and the MLVA results for each locus is described.




The suggested high relatedness between human and porcine RT 078 strains is in 
concordance with earlier publications based on MLVA, whole-genome analysis 
and Multi-Locus Sequence typing (19-22). The relatedness between human and 
porcine RT 078 strains in this study could be an indication of  a common source as 
suggested in previous publications (1,19,20). However, the geographical locations 
of  some related isolates are very distinct and can not logically be explained by 
any direct epidemiological link. A possible common source of  RT 078 could be 
further supported by the observation that all tetracycline resistant strains contain 
the mobile element Tn916-like transposon which has also been described for 
tetracycline resistant enterococci from human and porcine origin (13). Interspecies 
transmission or transmission through meat is suggested as sources of  infection but 
these are not yet established (23-25). However, data of  a direct epidemiological 
link between human and porcine strains in this study is lacking. We also need to 
consider that the high relatedness between human and porcine RT 078 strains 
could be the consequence of  less natural variability in RT 078 than in other types. 
A limitation of  this study is the inclusion of  porcine strains from only one country, 
while human strains derived from 4 European countries. Further studies are needed 
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Clostridium difficile is the main cause of  antibiotic associated diarrhea. In the past 
decade, the number of  C. difficile patients has increased dramatically, coinciding 
with the emergence of  two PCR Ribotypes, 027 and 078. PCR Ribotype 078 is also 
frequently found during C. difficile outbreaks in pigfarms. Previously, the genome 
of  the PCR Ribotype 078 strain M120, a human isolate, was described to contain a 
unique insert of  100 kilobases.
Analysis of  this insert revealed over 90 open reading frames, encoding proteins 
originating from transposons, phages and plasmids. The insert was shown to be a 
transposon (Tn6164), as evidenced by the presence of  an excised and circularised 
molecule, containing the ligated 5’and 3’ends of  the insert. Transfer of  the element 
could not be shown through filter-mating experiments. Whole genome sequencing 
of  PCR Ribotype 078 strain 31618, isolated from a diarrheic piglet, showed that 
Tn6164 was not present in this strain. To test the prevalence of  Tn6164, a collection 
of  231 Clostridium difficile PCR Ribotype 078 isolates from human (n = 173) and 
porcine (n = 58) origin was tested for the presence of  this element by PCR. The 
transposon was present in 9 human, tetracycline resistant isolates, originating from 
various countries in Europe, and none of  the pig strains. Nine other strains, also 
tetracycline resistant human isolates, contained half  of  the transposon, suggesting 
multiple insertion steps yielding the full Tn6164. Other PCR ribotypes (n = 66) 
were all negative for the presence of  the transposon. Multi locus variable tandem 
repeat analysis revealed genetic relatedness among transposon containing isolates. 
Although the element contained several potential antibiotic resistance genes, it did 
not yield a readily distinguishable phenotype.
Tn6164 is a newly described transposon, occurring sporadically in C. difficile 
PCR Ribotype 078 strains. Although no transfer of  the element could be shown, 
we hypothesize that the element could serve as a reservoir of  antibiotic resistance 
genes for other bacteria. Further research is needed to investigate the transfer 
capabilities of  the element and to substantiate the possible role of  Tn6164 as a 
source of  antibiotic resistance genes for other gut pathogens.




Over the past decade, Clostridium difficile has emerged as an important gut pathogen, 
causing hospital- and community-acquired diarrhea. The number of  patients and 
the severity of  disease have increased dramatically, due to the emergence of  two 
hypervirulent PCR ribotypes (RT), 027 (1) and 078 (2,3). Traditionally, RT 027 
has been linked to nosocomial outbreaks. In contrast, RT 078 has been detected 
frequently in farming animals, especially pigs (2,4), and is found more during 
community acquired infection. The increase in C. difficile infections (CDI) of  
humans has boosted interest in C. difficile biology, diagnostics and pathogenesis.
In the past few years, multiple genome sequences of  several RTs have been 
determined (5-8). The analyses of  the genomes, aided by comparative genomics of  
DNA-DNA microarrays (9,10) has shown that the genomes of  C. difficile are highly 
variable with inserts of  mobile DNA from phage, plasmid or transposon origin. 
These mobile DNA elements are actively moving within C. difficile genomes and are 
frequently passed on to neighboring bacteria, harboring mosaic genomes (7,11). It 
is unclear what role the mobile elements play in the virulence of  C. difficile. Some 
virulence linked genes, for example the holin-like tcdE, have a phage origin (12). In 
fact, it has been suggested that the whole Pathogenicity Locus (PaLoc), encoding 
the major C. difficile virulence factors TcdA and TcdB, is of  phage origin (13,14). 
Recently, phages have been shown to upregulate toxin production in C. difficile, 
thereby increasing the virulence (15). C. difficile transposons have been shown to 
contain antibiotic resistance genes (5,7,16,17), and therefore acquiring such an 
element could increase the virulence and/or colonization potential of  a particular 
strain.
Mobile elements play an important role in the diversification of  bacterial 
genomes. One important group of  mobile genetic elements is the Tn916 family 
of  conjugative transposons (also known as integrative and conjugative elements 
(ICEs)) (18). These conjugative transposons usually code for tetracycline resistance 
and are found primarily in the Firmicutes. Numerous transposons have been described 
to be present in C. difficile genomes (5,7,11,17,19). Several elements closely related 
to Tn916 are present in diverse C. difficile strains, including Tn5397 which confers 
tetracycline resistance (20,21). Other transposons have been described to confer 
resistance to chlooramphenicol and erythromycin (5).
Recently, the first full length genome of  a RT 078 strain was published (5). This 
M120 strain has been isolated from an Irish diarrheic patient. It was shown that RT 
078 is highly divergent from RTs 027, 001, 017 and 012. In addition, this RT 078 
strain was described to contain a unique 100 kb insert that showed 80% similarity 




paper we show that the 100 kb insert is a mobile element that is only sporadically 
present in RT 078 strains. Furthermore, we show that the 100 kb consists of  at 
least two independent mobile elements that were fused during evolution.
Material and Methods
Bacterial isolates and culture conditions
RT 078 C. difficile strain 31618 was obtained from a pig farm in the eastern part 
of  the Netherlands where neonatal diarrhea was present. Culturing of  the feces 
yielded C. difficile, as determined by an in-house PCR for the presence of  the 
gluD gene encoding the glutamate dehydrogenase specific for C. difficile (39). PCR 
Ribotype was determined as previously described (40).
The other RT 078 strains used in this study were obtained from a previously 
described RT 078 strain collection (16), consisting of  strains isolated from humans 
and pigs, supplemented with human RT 078 strains from the European Clostridium 
difficile Infection Survey (ECDIS) study in 2010 (32). In addition, recently isolated 
RT 078 strains from Dutch diarrheic piglets (2007–2010) and human (2006–2010) 
strains collected by the Dutch C. difficile Reference Laboratory (CDRL) were used. 
The 58 Pig strains were collected on 27 pig farms in the Netherlands.
RT 126 strains used in this study originate from the ECDIS study, isolated in 
2010, from several countries in Europe (32). PCR Ribotype reference strains (n = 
68) were obtained from the CDRL. The nontoxinogenic strain CD37 (41,42) was 
used as a recipient in filter mating experiments as this has previously been shown 
to be a good recipient for mobile genetic elements from other C. difficile strains (11). 
C. difficile strain M120 was kindly provided by Dr. Trevor Lawley (Sanger Institute). 
Standard culturing of  C. difficile isolates was carried out on blood agar plates at 37 
°C and anaerobic conditions.
DNA Sequencing, reference assembly and annotation
DNA was isolated from one colony of  the 31618 strain by standard techniques 
(43). The isolate was sequenced using the Illumina platform (Solexa) at the Leiden 
Genome Technology Center (LGTC) at the LUMC, using the manufacturers’ 
protocols. Single end reads were generated and submitted to the NCBI sequence read 
archive (http://www.ncbi.nlm.nih.gov/sra) under accession number SRX030155. 
A reference assembly of  the reads was carried out against strain C. difficile RT 078 
strain M120 (GenBank accession no. FN665653), using CLC genomics workbench 
(CLCbio, Aarhus, Denmark). Number of  reads used was 5267302, of  which 
2968638 reads could be mapped to the M120 genome sequence. The unique 100 kb 
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insert present in M120 was readily identified with the CLC genomics workbench. 
The ORFs present in the insert were identified by CLC genomics workbench and 
annotation was carried out manually, using BLAST and SMART. ORFs identified 
as “protein of  unknown function” were further analyzed by profile-profile searches 
through HHpred (http://toolkit. tuebingen.mpg.de/hhpred).
Bioinformatic comparison of  the mixed origin of  Tn6164
The genome of  strain M120 was compared to the genomes of  C. difficile 630 
(Genbank accession no. AM180355), Thermoanaerobacter sp. (GenBank accession no. 
CP002210), S. pneumonia (Genbank accession no. CP002121) and C. fetus (Genbank 
accession no. FN594949) using the Artemis Comparison Tool (44).
Circularization of  the transposon
In order to investigate if  the putative element could excise itself  from the genome, 
PCR analysis was performed to amplify the joint region of  a circular molecule using 
primers at the ends of  the element, facing outward (primers 14 and 15 in Table 
1). PCR amplifications were carried out using the NEB Taq Polymerase kit (New 
England Biolabs, Herts, UK) according to the manufacturer’s instructions with 
10 mM dNTPs (NEB). The primers that were used are listed in Table 1 (Sigma-
Genosys, UK). 
Filter-matings assays
Filter-matings were carried out as described previously (45). C. difficile strains 
M120 and CD37 were cultured on Brain heart infusion (BHI) (Oxoid Ltd.) agar 
supplemented with 5% Horse blood (E&O laboratories). C. difficile strain CD37 was 
used as recipient. Transconjugants were selected for on BHI plates supplemented 
with 25 μg/mL rifampicin (Sigma Aldrich) and 10 μg/mL tetracycline (Sigma 
Aldrich). Transconjugants were examined using PCR with primer pair Lok1/Lok3 
to confirm identity of  the recipient strain and primer pairs Tn6164 accessory region 
Fw + Rev and Tn916 Fw + Rev to confirm the transfer of  Tn6164 or Tn6190.
Inverse PCR
C. difficile genomic DNA was digested with PstI or EcoRI. After purification, the 
genomic DNA fragments were self-ligated to create circular DNAs. Subsequently, 
the DNA was precipitated and dissolved in H2O. PCR was carried out on the DNA, 
using primers 4-rev and 5-rev or 14 and 15 (annealing at 58°C, 35 cycles). PCR 
products were visualized by gel electrophoresis and sequences were determined 
through direct sequencing on the purified PCR amplicons or through cloning into 




primers T7 and M13reverse. Oligonucleotides used in this study are shown in Table 
1.
PCR
PCRs were carried out using Gotaq polymerase (Promega, Leiden, the Netherlands). 
Reactions contained 0.4 mM dNTPs, 0.4 uM oligonucleotides. Annealing 
temperature of  the PCR was set at 50°C and PCRs were standardized at 30 cycles.
Antibiotic resitance
The MIC for tetracycline was determined using E tests (BioMérieux, Boxtel, the 
Netherlands) on blood plates under anaerobic conditions at 37°C. Breakpoint for 
Table 1: Oligonucleotides used in this study.
Name Sequence (5’-  3’) Purpose
1 GAGATATGGTTATGAGATTAGG Presence/absence of  insert
2 CCCACCTTTATAGCATCATATAG Absence of  insert
3 CTAACCTATCAACTCAACCCC Presence of  insert  
4 AGGATAAGACCGCAGCAGAA Presence 5’half  of  insert
5 AAAAACGACGGTTTTCCTGTG Presence 5’half  of  insert
6 GGGCAAATAGAAAGTCAAAACG Presence 3’half  of  insert
7 AAGTGGTGTTTTCTTTGGAGGA Presence 3’half  of  insert
8 CCACAGGGATACCTTTCTCGTGC Presence of  tet(44) gene
9 TTCCATATCCTCGGGTTTTTGCAT Presence of  tet(44) gene
10 CAGGTGTTGAAATAGATATTGAG Detect 3’ end half  insert
11 CAGAAGTCGATCCTTTCTGGG Detect 3’ end half  insert
12 GGTGGCTGAACTCGTTAATC Detect 3’ end half  insert
13 CTCCACATGGCTCGAGTTG Detect 3’ end half  insert
14 GAGGAATTTAACAGAACAGTATTT Excision studies
15 TCTATCCTGCCTTCTCAACC Excision studies
16 CGAATCGCTGAAATGACTGA Excision studies
17 GCGAATGATTTCATGGAAGG Excision studies
18 CGACTGCATTACCAGTTCCA Excision studies
Lok1 (13) AAAATATACTGCACATCTGTATAC Transconjugant screening
Lok3 (13) TTTACCAGAAAAAGTAGCTTTAA Transconjugant screening
19 CAGCTGCAGTTTTTCCATGA Transconjugant screening
20 GCAGCTAACGGTGATGACAA Transconjugant screening
Tn916 Fw (30) GACGGAAGATACTTATACA Transconjugant screening
Tn916 Rev (30) GCCTTTGGATTCATTCCTGC Transconjugant screening
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tetracycline was 8 μg/mL. Spectinomycin resistance was determined by an agar 
dilution method of  C. difficile colonies on BHI agar plates, supplemented with 
increasing amounts of  spectinomycin. Streptomycin resistance was tested by disk 
diffusion method, using Sensi-Neotabs (Rosco, Denmark) (Streptomycin 500 ug 
disks) on blood plates under anaerobic conditions at 37°C.
Statistical analyses
Patients samples with the full 100 kb insert were compared to patients’ samples 
with a part of  the insert or no insert. The Chi-square test and t-test were used 
to calculate the p-value. Analyses were performed using the SPSS for Windows 
software package, version 17.0.
MLVA
Sixty eight strains were subjected to MLVA, of  which 39 were previously 
characterized (16). MLVA and construction of  the minimal spanning tree based on 
the MLVA results were carried out as described previously (16).
Results
Previously, an insert, unique for C. difficile, was described in the genome of  strain 
M120, a PCR Ribotype078 strain, isolated from an Irish diarrheic patient (5). We 
analyzed the open reading frames (ORFs) present in the insert to investigate their 
nature and origin (see Figure 1 and Table 2).
The 100 kb insert has a modular composition
Bioinformatic analysis revealed that the insert has a modular composition. The 
3’ end of  the insert (module E) is homologous to Tn1806 of  S. pneumoniae which 
confers erythromycin resistance. Although this element has not been shown to 
transfer via conjugation, transfer via transformation was shown (22). In C. 
difficile strain M120 this element appears to be the backbone into which several 
other elements have been inserted (see Figure 1 top panel). The first 7.3 kb on the 
5’ end of  the insert (module A) has only moderate homology (60–70% maximum 
sequence identity) to known sequences. Interestingly, this part of  the insert 
contains 2 putative modification DNA methylases and a putative endonuclease, 
possibly enabling a form of  molecular vaccination as described by Kobayashi 
et al. (23). During this process methylation protects the incoming element from 
host endonucleases and, following integration, will protect the host chromosome 
from endonucleases present on other mobile genetic elements. This sequence is 
followed by a complete prophage of  approximately 39.5 kb (module B), which 




Figure 1: Schematic view of  full Tn6164 (top panel) and half  the element (bottom panel) 
and its open reading frames, flanked by C. difficile regions. Various parts of  the insert are 
colored according to their homology. White, C. difficile; Red, Module A; Yellow, Module B; 
Purple, Module C; Orange, Module D; Blue, Module E; black, unknown. Location of  the 
oligonucleotides used for the data in Table 3 is indicated by arrowheads.
Figure 2: Circular representation of  the genome of  C. difficile strain M120. The two 
concentric circles represent the genome (outer circle) and the G + C content (inner circle; 
window size 10,000; Step size 200). Green represents values higher than average (29%), 
purple below average. In between the two circles, the presence of  the two transposable 
elements is indicated in red (Tn6164) and blue (Tn6190). Figure was created using DNA 
plotter (46)
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accession no. CP002210). The next 4.5 kb stretch (module C) is 99% identical 
to part of  the Enterococcus faecalis plasmid pEF418 containing, amongst others, a 
putative methyltransferase and a putative spectinomycin adenyltransferase (ant(9)
Ia) (24). It is also described to be part of  a pathogenicity island in Streptococcus suis 
(25). Finally, an insertion of  approximately 4.5 kb (module D) with 90% sequence 
identity to the transferable pathogenicity island of  Campylobacter fetus subsp fetus (26) 
is present within the sequence of  Tn1806. This sequence contains, amongst others, 
putative tet (44) and ant(6)-Ib genes, which could respectively confer tetracycline and 
streptomycin resistance.
The G + C content of  the entire insert (34%) was significantly higher than 
that of  the entire genome (29%), clearly indicating that the insert was of  foreign 
origin (Figure 2). In addition, within the insert the different modules could be 
distinguished by their G + C contents. The G + C content of  module A, B, C, D 
and E was 31%, 41%, 35%, 28% and 31%, respectively.
The 100 kb insert is a transposon
Based on the bioinformatic comparison of  the insert described above, the possible 
excision of  3 (independent) elements was predicted. Primers were designed (primers 
14–20, see Table 1) to amplify the circular intermediates of  the complete insert 
(primers 14 and 15), the putative Thermoanaerobacter sp. phage (module B, primers 
15 and 16) and the C. fetus pathogenicity island (module D, primers 17 and 18) of  
the element. PCR confirmed only the excision and circularisation of  the entire 
insert (results not shown). It is expected that the serine recombinase at the 3’ end 
of  the element is responsible for excision (see Table 2). Sequencing of  the circular 
intermediate was used to determine the precise ends of  the element, showing 
the element is flanked by a TG dinucleotide; serine recombinases prefer a 2 bp 
crossover site identical in the target site and joint of  the circular intermediate (27). 
In silico extraction of  this sequence from the genome confirms that the element is 
present in the homologous target site of  CTn2 in strain 630 (7). The precise size of  
the element is 106,711 bp and it runs from bp 418,525-525,236 (including the TG 
dinucleotide at both ends) in the M120 genomic sequence (GenBank accession no. 
FN665653). Upon our request, the transposon number Tn6164 was provided by 
the Transposon registry (28) (http://www.ucl.ac.uk/eastman/tn/index.php). To 
test the conjugative transfer of  the element, filter mating assays were performed, 
selecting for the possible tetracycline resistance by means of  the tet(44) gene. 
However, M120 contains also a copy of  tet(M) present on a conjugative transposon 
with 97% sequence identity to Tn916 (16), which we have designated Tn6190. This 
element has inserted intragenically in the homologue of  C. difficile strain 630 ORF 
CD2015. Tn6190 contains homologues to all Tn916 ORFs except orf12 which is 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































During filter mating experiments with M120 as a donor strain and CD37 as a 
recipient, all putative transconjugants were identified as the recipient strain. In total 
70 transconjugants were tested by PCR, using primers Lok1, Lok3 (13), 19, 20, 
Tn916 Fw, and Tn916 Rev (30). However, none contained Tn6164, all contained 
only Tn6190 (results not shown).
Tn6164 is sporadically present in PCR Ribotype078
Simultaneously with the publication of  the M120 sequence, we obtained Illumina 
sequence reads of  the C. difficile strain 31618, which was isolated from a diarrheic 
piglet from a pig farm in the Netherlands (16). Comparative genomic analysis 
of  31618 to M120 revealed an almost complete overlap of  the two genomes. 
However, reference assembly of  the 31618 reads to M120 showed that Tn6164 
was not present in 31618 (results not shown). This prompted us to investigate the 
prevalence of  Tn6164 in RT 078 strains. We designed a PCR to show presence 
(primers 1 and 3) or absence (primers 1 and 2) of  Tn6164 in RT 078 genomic 
DNA (see Figure 1 top panel). In addition, in view of  the heterogeneous origin of  
Tn6164 and to investigate the presence of  both the Thermoanaerobacter prophage 
and Streptococcus DNA (Modules B and E, respectively), we designed two more 
PCRs (primers 4–5 and 6–7). Finally, we designed a PCR to detect the presence 
of  the tet(44) gene present on Tn6164 (Module D, primers 8 and 9). Besides the 
sequenced 31618 strain, 173 human RT 078 strains and 58 porcine RT 078 strains 
(from 27 pig farms) were tested for the presence of  these elements.
A minority of  the isolates tested did contain a DNA insert at the indicated 
location in the genome; 18 of  the 231 isolates (7.8%) were positive in the 1–3 
PCR (Table 3). Remarkably, all 18 strains were tetracycline resistant human isolates. 
None of  the porcine strains contained an insert at the position tested. Strains 
positive in the 1–3 PCR were negative in the 1–2 PCR, and vice versa, showing 
complete complementarity of  the two PCRs in RT 078 strains.
Evidence for multiple insertions in Tn6164
All the strains that contained an insert (based on the 1–3 PCR) were further analyzed 
for the presence of  Module B and E present in Tn6164, using primer pairs 4–5 and 
6–7 (see Figure 1 top panel and Table 1). Only nine of  18 strains positive for PCR 
1–3 were positive for PCRs 4–5 and 6–7, suggesting the presence of  the complete 
element as described for M120. The other 9 strains were only positive for Module B 
(PCR 4–5), showing the existence of  alternative (shorter) elements (see Table 3), as 
predicted by the bioinformatic analysis. The strains that were positive for Module 
E (PCR 6–7) were also positive for Module D (PCR 8–9, see Table 3). In contrast, 
strains containing Module B, but not Module E, thus containing only half  the 
Analysis of  a Clostridium difficile PCR Ribotype 078 transposon
81
4
element, also lacked Module D. This indicates that the 3’end of  half  the element 
was situated upstream of  Module D. Of  the isolates that were only positive for the 
PCR 4–5, the exact 3’end of  the insert was determined by sequencing the PCR 
product obtained with primers 12 and 2 (see Figure 1 bottom panel), which yielded 
a 350 bp product. The border of  the 3’end was between the 3’ end of  Module C 
and the 5’end of  Module E. A similar sequence was found at the homologous site 
when the full element was present, but also at the 3’ end of  the full element, the 5’ 
end of  the element, the joint of  the circular intermediate and the predicted target 
site as based on the 630 sequence (see Table 4). This indicates that Tn6164 was 
created by two elements integrating in the same target site (next to each other) and 
fusing, with a second copy of  the target site still present between the two original 
elements within Tn6164.
Table 3: Detection of  specific regions of  Tn6164 in RT 078 strains.
Strain PCR 1-2* PCR1-3§ PCR 4-5# PCR 6-7¶ PCR 8-9† PCR 12-2‡
56/69 - + + - - +
26222 - + + - - +
26114 - + + - - +
26247 - + + - - +
26235 - + + - - +
6065935 - + + - n.t. n.t.
ES1203 - + + - - n.t.
7047337 - + + - n.t. n.t.
8088158 - + + - n.t. n.t.
50/19 - + + + + -
GR0106 - + + + + n.t.
DE1210 - + + + + n.t.
BG1209 - + + + + n.t.
NO1311 - + + + + n.t.
NO1307 - + + + + n.t.
IE1102 - + + + + n.t.
GR0301 - + + + + n.t.
10053737 - + + + n.t. n.t.
*PCR only positive when no insert is present, §PCR only positive when insert is present 
#PCR detects Module B, ¶PCR detects module E, †PCR detects module D. ‡ PCR only 
positive in strains containing half  of  the element. Location of  the oligonucleotides used is 




The sequences at the 3’ end of  the element in strains that contain half  the insert 
or the full insert are identical. These are related to the sequence at the 5’ end of  
the element and the middle section of  the full element and also to the joint of  the 
circular intermediate of  Tn6164 and the empty target site, compared to the empty 
target site of  CTn2 from strain 630. Sequence shown in underlined bold is the 
dinucleotide which is predicted to be recognised by the serine recombinase.
Absence of  Tn6164 sequences in other PCR ribotypes
Since RT 126 has been shown to be very closely related to RT 078, with an almost 
indistinguishable PCR Ribotype banding pattern, we also tested a small collection 
of  RT 126 strains with the 1–2 and 1–3 PCRs. In none of  the 10 RT 126 strains 
tested could we demonstrate the presence of  an insert at the site in which Tn6164 
was inserted in M120 (results not shown).
In addition, a collection of  66 other PCR ribotypes was tested as well. This 
collection consisted of  the 25 most frequently found PCR ribotypes in Europe, 
supplemented with the Leeds-Leiden collection (31). None of  the other PCR 
ribotypes, was positive for PCR 1–3, 4–5 or 6–7.
No antibiotic resistance phenotype linked to presence of  Tn6164
Since several putative antibiotic resistance genes were found to be present on the 
element (see Figure 1 and Table 2), strains containing full Tn6164, only half  of  
the element, or no element at all were tested for antibiotics resistance. Resistance 
to tetracycline, spectinomycin and streptomycin was tested using several methods 
(see materials and methods). Surprisingly, no correlation was found between the 
presence of  tet(44), ant(6)Ib or ant(9)Ia and resistance to tetracycline, spectinomycin 
or streptomycin (see Table 5).
Table 4: Sequences of  the joints between the genome and Tn6164 and the joint of  the 
circular form.
CGCATTGCG-AGACTATAG 3’ends of  half  insert
CGCATTGCG-AGACTATAG 3’ends of  full insert
CTCA-TGTGGAGTGCGTGG 5’end of  full insert
GCCA-TGTGGAGACTATAG middle section of  full element
CACA-TGCGTTGTCTTGTG Joint of  circular intermediate Tn6164
CACATTGTG-AGACTGTAG CTn2 target site in strain 630
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Table 5: Antibiotic sensitivity of  RT 078 strains with(out) Tn6164.
Genes present 
(transposon)





56/69 24 > 750 N.D.
26222 16 N.D. R
ant(9)Ia (Tn6164) 26114 32 N.D. R
tet(M) (Tn6190) 26247 16 > 750 R
26235 48 N.D. N.D.
06065935 8 N.D. R
50/19 48 >750 S
GR0106 12 >750 R
ant(9)Ia (Tn6164) DE1210 8 >750 R
ant(6) (Tn6164) BG1209 8 >750 R
tet(44) (Tn6164) NO1311 12 >750 R
tet(M) (Tn6190) NO1307 8 >750 R
IE1102 12 >750 R
GR0301 8 >750 R
10053737 N.D N.D R
tet(M) (Tn6190) 45/22 8 >750 N.D.
29/74 <8 >750 N.D.
31618 N.D. <250 N.D.
None 07053152 <8 N.D. R
R20291(027) N.D. <250 N.D.
R, resistant (no halo around diffusion disk); S, sensitive (15 mm halo).
Strains containing full Tn6164 are all genetically related
Since we could not find many isolates containing Tn6164, we reasoned that the 
element could be relatively recently acquired and that the isolates thus might be 
genetically closely related. Therefore, we applied MLVA (3,16) on all the isolates 
containing Tn6164, or only half  of  it, supplemented with a number of  isolates 
without the element, to investigate the genetic relatedness of  the strains. In Figure 
3, a minimal spanning tree of  all the isolates containing an element is shown, with 
control strains. Based on the MLVA, all the isolates containing full Tn6164 (n = 9) 
are genetically related (STRD < 10) and four of  them are in one clonal complex. 
Six isolates containing half  of  the element are also in this genetically related cluster, 




Figure 3: Minimum spanning tree of  all the RT 078 isolates that contained an insert (50 
or 100 kb), supplemented with strains not containing the element. Each circle represents 
either one unique isolate or more isolates that have identical MLVA types. Red circles 
indicate strains with full Tn6164 and blue circles indicate strains with half  the element. 
The numbers between the circles represent the summed tandem-repeat differences (STRD) 
between MLVA types. Underlined numbers represent porcine strains and normal numbers 
represent human isolates. Thick red lines represent single-locus variants; thin green lines 
represent double-locus variants and dotted blue lines represent triple locus variants between 
MLVA types. Clonal clusters are defined by an STRD of  <2 (pink area), and genetically 
related clusters are defined by an STRD of  <10 (green area).
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Suggestive link between the 100 kb insert and increased virulence
To investigate a possible increased virulence of  strains containing the element, 
clinical parameters of  patients with a C. difficile infection due to a strain that contained 
Tn6164 were compared to parameters of  patients that suffered from a strain that 
did not contain the full element. Patients with Tn6164 resembled patients without 
the element concerning demographic characteristics. Clinical characteristics were 
only known for patients from the ECDIS study (32) and patients registered in 
the CDRL (n = 84). Patients with and without the element suffered from severe 
diarrhea in similar proportions. Mortality due to CDI was more common in 
patients infected with C. difficile::Tn6164 (29% vs 3%). This suggests that Tn6164 
might convert PCR Ribotype078 strains to a more virulent strain. However, since 
the number of  patients infected with a Tn6164-positive strain, and for which the 
clinical data was available, was very low (n = 7), no multivariate analysis could 
be performed, which means that a bias cannot be ruled out. Further research is 
needed to confirm a possible link between increased virulence and the presence 
of  Tn6164.
Discussion
PCR Ribotype 078 has recently emerged as a hypervirulent C. difficile strain (2,3). 
Previously published MLVA studies have shown that all PCR Ribotype 078 strains 
are closely related (3), irrespective of  human or porcine origin (16), fostering the 
notion that PCR Ribotype 078 infection could be a zoonosis. Recently, the full 
genome sequence of  a C. difficile PCR Ribotype 078 strain was published (5). This 
M120 strain was shown to contain a unique insert of  approximately 100 kilobases. 
In this paper we show that this insert is a transposable element, Tn6164. It is not 
representative for all PCR Ribotype 078 strains. On the contrary, we found that the 
majority of  the PCR Ribotype 078 strains do not contain the element. Moreover, 
some strains contain only half  of  the element. So, three different kinds of  PCR 
Ribotype 078 can now be distinguished: Those with a full length element, those 
with half  the element, and those with no element at all. Tn6164 was exclusively 
found in tetracycline resistant PCR Ribotype 078 strains, isolated from humans. 
We tested a collection of  other PCR ribotypes, of  which none contained the 
element. Since we only tested 1 strain per PCR ribotype, we cannot rule out the 
possibility that Tn6164 is present in other PCR ribotypes. We covered the whole 
genomic spectrum of  C. difficile since we tested multiple samples of  each genetic 
clade previously identified (10,33-35). In addition, Tn6164 has not been found in 




Tn6164 contained a tet(44) gene, we could not demonstrate increased tetracycline 
resistance of  strains containing the element.
Previously, it has been shown that this gene, present on a homologues resistance 
island, is active in C. fetus (26). In C. difficile, the copresence of  the tet(44) gene 
on Tn6164 and the tet(M) gene on the Tn6190 in one bacterium does not result 
in an increased resistant phenotype. Also the spectinomycin and streptomycin 
resistance genes did not result in a phenotype, despite the presence of  two potential 
aminoglycoside resistance genes (ant(9)Ia) and ant(6)) on Tn6164 (see Figure 1 and 
Table 2). We do not know if  the resistance genes are expressed in M120. However, 
since we show the presence of  the circular intermediate transposon DNA, some 
activity of  transposon related genes is expected.
Since we have only found Tn6164 in strains also containing Tn6190, it is 
possible that Tn6164 transfer is dependent on Tn6190. Further research is needed 
to investigate the possibility of  Tn6190 dependent transfer of  Tn6164. In addition, 
remarkably, Tn6164 (the whole or half  the element) was significantly (p = 0.01) more 
found in strains isolated from humans than in strains isolated from pigs. Although 
the same strains circulate in humans and pigs (16), and also Tn6190 circulates in 
pig strains (16), we did not find any porcine strain that contained the element. 
We have no explanation for this difference. None of  the transconjugants tested 
showed the presence of  Tn6164, but all contained Tn6190. These results indicate 
that Tn6164 has a (much) lower transfer frequency than Tn6190. Nevertheless, 
a complete set of  proteins, required for transfer, is present on Tn6164. Loss of  
Tn6190 or introduction of  another selection marker in Tn6164 (11) could prove to 
be a strategy to further study the capability of  conjugative transfer of  this element.
Tn6164 has integrated intergenically between homologs of  the 630 ORFs 
CD0406 and CD0437, a tRNA methyltransferase and a hypothetical protein 
respectively. In strain 630, this target site is occupied by the conjugative transposon 
CTn2 (7,11). There is no significant homology between Tn6164 and CTn2. The 
empty target site is present in many sequenced strains of  C. difficile. However, no 
other mobile genetic elements have been reported to integrate at this site.
It was impossible to phenotypically distinguish strains containing Tn6164 from 
strains without the element. Although we have no transcriptional data available of  
the genes that are located on Tn6164 it is clear that it could provide an advantage 
under certain circumstances. In this respect it is interesting to note that the patients 
suffering from an element-containing strain are suggested to undergo a more 
severe illness than patients with a strain not containing Tn6164. However, because 
of  the low number of  strains containing the insert no multivariate analysis could 
be carried out. Therefore, we cannot rule out that these data are biased. Further 
research is needed to confirm this observation.
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Isolates containing the full element originated from all over Europe, including 
Ireland, England, Norway, Germany, Bulgaria, Greece and the Netherlands, whereas 
isolates containing half  the element were only found in the United Kingdom, 
Spain and the Netherlands. MLVA showed genetic relatedness between most of  
the strains, although no epidemiologic link between the strains from different 
countries could be found. It has recently been shown that RT 078 strains show a 
lot less heterogeneity in MLVA than for instance RT 027 or RT 017 (36-38). This 
could indicate a higher level of  relatedness, or it could mean that the mechanism 
behind the MLVA variability is different in RT 078 strains than in other RTs (16).
Altogether, we show the presence of  a 100 kb transposon in some C. difficile 
RT 078 strains. Although we could not show any evolutionary benefits of  the 
transposon, it could very well serve as a reservoir of  antibiotic resistance (26), for 
commensal bacteria in the human gut.
Conclusion
Tn6164 is a novel transposon of  approximately 100 kb, found sporadically in 
Clostridium difficile RT 078 strains, isolated from humans. Tn6164 has a modular 
composition and is the product of  multiple insertions of  separate elements from 
various origins, as evidenced by the existence of  strains containing only half  the 
element. Strains containing Tn6164 were all genetically related. We were not able to 
find a readily distinguishable phenotype for strains containing the element, although 
several potential antibiotic resistance genes were present on Tn6164. Tn6164 may 
act as a source of  antibiotic resistance genes in the human gut. Further research is 
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Clostridium difficile is a Gram positive, anaerobic bacterium that can form highly 
resistant endospores. The bacterium is the causative agent of  C. difficile infection 
(CDI), for which the symptoms can range from a mild diarrhea to potentially fatal 
pseudomembranous colitis and toxic megacolon.
Endospore formation in Firmicutes, including C. difficile, is governed by the key 
regulator for sporulation, Spo0A. In Bacillus subtilis, this transcription factor is also 
directly or indirectly involved in various other cellular processes.
Here, we report that C. difficile Spo0A shows a high degree of  similarity to the 
well characterized B. subtilis protein and recognizes a similar binding sequence. We 
find that the laboratory strain C. difficile 630Δerm contains an 18bp-duplication near 
the DNA-binding domain compared to its ancestral strain 630. In vitro binding 
assays using purified C-terminal DNA binding domain of  the C. difficile Spo0A 
protein demonstrate direct binding to DNA upstream of  spo0A and sigH, early 
sporulation genes and several other putative targets. In vitro binding assays suggest 
that the gene encoding the major clostridial toxin TcdB may be a direct target 
of  Spo0A, but supernatant derived from a spo0A negative strain was no less 
toxic towards Vero cells than that obtained from a wild type strain, in contrast to 
previous reports. 
These results identify for the first time direct (putative) targets of  the Spo0A 
protein in C. difficile and make a positive effect of  Spo0A on production of  the 
large clostridial toxins unlikely.




Sporulation is an adaptive strategy that enables bacteria to survive harsh 
environmental conditions for prolonged periods of  time, and is an integral part 
of  the transmission of  sporulating pathogens and their tolerance and resistance 
towards antimicrobial compounds.
Spo0A is the key regulator for sporulation (1,2). Most of  our knowledge 
about the protein is based on work in Bacilli. Spo0A is a response regulator that 
demonstrates phosphorylation dependent binding to DNA (3–5). Phosphorylation 
occurs through the concerted action of  several proteins that together form a 
so called phosphorelay (6). The signaling cascade allows for the integration of  
environmental signals into the regulation of  Spo0A dependent processes, including 
sporulation. The two functional domains, the N-terminal phosphorylation and 
dimerization domain (receiver domain), and the C-terminal DNA binding (effector) 
domain are separated by a hinge region that is relatively poorly conserved (7). 
Phosphorylation is believed to result in a structural rearrangement that facilitates 
dimerization (8,9), resulting in the disruption of  transcription-inhibitory contacts 
between the receiver and effector domains. The isolated DNA binding domain can 
bind legitimate targets of  the Spo0A protein due to the absence of  the transcription 
inhibitory contacts, thereby bypassing the need for phosphorylation (10). Extensive 
characterization of  Spo0A targets has revealed a motif  that represents a high 
affinity Spo0A binding site, the 0A box (10,11). The crystal structure of  the DNA 
binding domain confirms specific and non-specific contacts between the protein 
and the consensus sequence (12,13). It is noteworthy that Spo0A regulates many 
other processes than sporulation, such as competence for genetic transformation, 
DNA replication, and biofilm formation in B. subtilis (14–16), virulence factors and 
stress responses in for instance B. anthracis and B. thuringiensis (17–21), and solvent 
production in Clostridium acetobutylicum (22,23).
C. difficile is a Gram positive, anaerobic bacterium that is the causative agent of  
C. difficile infection (CDI) (for recent reviews see (24,25)). Though many people are 
asymptomatically colonized by C. difficile, the bacterium can cause serious health 
problems, such as pseudomembranous colitis and toxic megacolon, under the 
influence of  risk factors such as age and antibiotic use. As a result, CDI was long 
regarded a nosocomial infection. Recently, however, an increase in the cases of  
community acquired CDI can be observed (26). Outbreaks of  CDI have been 
linked to so called hypervirulent strains, such as PCR ribotypes (RT) 027 (BI/
NAP1) and 078 (27,28). Its main virulence factors are the major clostridial Toxins 
A and B (29,30). In addition, certain strains of  C. difficile, including RTs 027 and 




fecal-oral route. It is believed that spores are crucial to successfully infect new 
hosts, as they are able to withstand the harsh environment of  the stomach, and 
survive antibiotic treatments that alter the endogenous flora, after which C. difficile 
can overgrow (24,25).
There is limited knowledge about the regulation of  sporulation in C. difficile. It 
has been reported that spo0A, as expected, is required for the formation of  spores 
(33) and the gene is required for persistence and transmission in mice (34). Though 
the pathways downstream of  Spo0A seem to a large extent conserved between B. 
subtilis and Clostridia, this is less so for the pathways leading to activation of  Spo0A 
(2). It has been suggested that the orphan histidine kinase CD2492 is involved 
in the activation of  Spo0A (35). Similarly, it was reported that multiple orphan 
histidine kinases can phosphorylate Spo0A in C. acetobutylicum (36). Recently, it was 
reported that spo0A can be transcribed from a SigH-dependent promoter (37). It is 
unknown which genes are regulated by direct binding of  Spo0A to their upstream 
regions.
Here, we establish an in vitro binding assay for C. difficile Spo0A and demonstrate 
for the first time direct binding of  this transcription factor to DNA upstream of  
several putative target genes.
Material and Methods
Bacterial strains and media
Escherichia coli strains were routinely grown in Luria-Bertani broth or plates, 
supplemented with appropriate antibiotics. Chloramphenicol was used at a final 
concentration of  20 μg/mL for agar plates and 10 μg/mL for liquid cultures. 
Ampicillin was used at a final concentration of  100 μg/mL. Kanamycin was used 
at a final concentration of  20 μg/mL. Cloning was carried out using E. coli DH5α, 
overexpression was performed in E. coli Rosetta(DE3) pLysS (Novagen). C. 
difficile strains were grown in a glucose-free trypton-yeast based medium (TTY; 
3% w/v bacto-trypton (BD), 2% yeast extract (Fluka), 0.1% w/v thioglycollate 
(Sigma) pH7.4), supplemented with 20 μg/mL of  lincomycin when appropriate, or 
on CLO or TSS plates (Biomerieux).
Plasmid construction
All plasmids are listed in Table 1. Primers (obtained from Sigma Aldrich) are listed 
in Table 2 and specific cycling conditions are available on request. Unless noted 
otherwise, PCR reactions were carried out using Pfu polymerase (Fermentas) 
according to the instructions of  the manufacturer.
Clostridium difficile 630∆erm Spo0A regulates sporulation
97
5
Plasmid pWKS1251, for the overproduction of  Spo0A-DNA Binding Somain 
(DBD) carrying a C-terminal 6xHis-tag, was constructed as follows. A sequence 
corresponding to the DBD of  Spo0A was amplified using primers oWKS-1123a 
and oWKS-1124 using chromosomal DNA from C. difficile strain 630Δerm as a 
template. The resulting fragment was cloned into pCR2.1-TOPO (Invitrogen), 
yielding pWKS1247. This plasmid was digested with NdeI and XhoI, separated on 
a 1% agarose/0.5x TAE (20 mM Tris Acetate, 0.5 mM EDTA) gel, the fragment 
corresponding to the DNA binding domain was recovered by gel-isolation (using a 
GeneJET Gel Extraction kit, Fermentas) and cloned into similarly digested pMF14 
(10) that had been gel-isolated in the same manner. The construct was verified 
by PCR, restriction analyses and DNA sequencing using primers oWKS-135 and 
oWKS-136.
Plasmid pWKS1245, for the production of  full length Spo0A carrying a 
C-terminal 6xHis-tag, was constructed in a similar manner using chromosomal 
DNA from C. difficile 630Δerm as a template, but using the PCR product of  primers 
oWKS-1122 and oWKS-1123a. Plasmids used as PCR templates for generating 
EMSA probes were constructed by cloning the PCR products into pCR2.1-TOPO. 
The inserts, and in the case of  the mutated PabrB promoters the presence of  the 
desired point mutations in the consensus 0A box, were verified by DNA sequencing 
using primers oWKS-24 and oWKS-25.
DNA sequencing
Sequence grade plasmids were isolated using a Nucleospin Plasmid QuickPure 
kit (Macherey Nagel) according to the manufacturer’s instructions, except that 
two lysis reactions were combined onto a single filter and eluted with 65°C 
prewarmed AE buffer. All constructs were sequenced using BigDye Terminator 
chemistry (Invitrogen) on an ABI3130 sequencer (Perkin Elmer), according to the 
instructions of  the manufacturers. In short, ~200 ng of  plasmid was mixed with 
3.2 pmol of  primer, 1 μL Terminator Ready Reaction Mix (Invitrogen) in a final 
volume of  20 μL. After thermocycling, DNA was precipitated and washed with 
65% isopropanol, and dissolved in 12 μL HiDi formamid (Invitrogen) at 96°C for 
2 mins and stored in the dark at 4°C until the sequencing run. Sequence analyses 
were performed in CloneManager Professional Suite 7 (SciEd) and Geneious 




Table 1: Plasmids used in this study. 
Name Description * Reference
pMF14 pET21b-spo0A-DBD-6xHis (Bsu) (10)
pWKS1245 pET21b-spo0A-DBD-6xHis (Cdi) This study
pWKS1251 pET21b-spo0A-6xHis (Cdi) This study
pWKS1303 pCR2.1TOPO-PabrB (Bsu) This study
pWKS1304 pCR2.1TOPO-PabrB (C4T) This study
pWKS1305 pCR2.1TOPO-PabrB (C4T/G5T) This study
pWKS1306 pCR2.1TOPO-PabrB (G2T) This study
pWKS1307 pCR2.1TOPO-PabrB (G2T/C4T) This study
pWKS1308 pCR2.1TOPO-PabrB (G5T) This study
pWKS1309 pCR2.1TOPO-PcitG (Bsu) This study
pWKS1316 pCR2.1TOPO-Pspo0A (Cdi) This study
pWKS1317 pCR2.1TOPO-PspoIIAA (Cdi) This study
pWKS1318 pCR2.1TOPO-PspoVG (Cdi) This study
pWKS1322 pCR2.1TOPO-PsigH (Cdi) This study
pWKS1323 pCR2.1TOPO-PspoIIGA (Cdi) This study
pWKS1324 pCR2.1TOPO-PspoIIE (Cdi) This study
pWKS1326 pCR2.1TOPO-PtcdB (Cdi) This study
pWKS1329 pCR2.1TOPO-PtcdA (Cdi) This study
pWKS1332 pCR2.1TOPO-PlplA (Cdi) This study
pWKS1340 pCR2.1TOPO-PtcdR (Cdi) This study
pWKS1341 pCR2.1TOPO-PssuA (Cdi) This study
* Bsu = DNA derived from B. subtilis JH642. Cdi = DNA derived from C. difficile 630Δerm.
Protein purification
Plasmids pWKS1245 and pWKS1251 were transformed into E. coli Rosetta(DE3) 
pLysS (Novagen). Transformants were used to inoculate 25 mL of  LB with 
appropriate antibiotics. After overnight incubation, the cells were 1:100 diluted 
in 500 mL fresh medium containing appropriate antibiotics. Protein production 
was induced with 1 mM IPTG at an OD600 of  0.7 and growth was continued for 
another three hours before harvesting. Cells were washed with ice cold PBS and 
stored at -80°C for later use. Purification of  the proteins was essentially done as 
described (10). In short, cells were disrupted in 4 mL lysis buffer (2mM PMSF, 10 
mM imidazole, 5 mM beta-mercaptoethanol, 300 mM NaCl, 50 mM NaH2PO4, 
pH7.9). Cleared cell lysates we incubated with 2 mL pre-equilibrated 50% TALON 
slurry (Clontech) in a final volume of  15 mL lysis buffer for 1hr. The resin was 
allowed to settle on a Poly-Prep column (BioRad) and washed with 2 mL wash 
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Table 2: Oligonucleotides used in this study.
Primer Sequence (5’- 3’) Fragment
oWKS-24 GTGAGCGGATAACAATTTCACACAGG pCR2.1TOPO insert
oWKS-25 GGTTTTCCCAGTCACGACGTTGTAA pCR2.1TOPO insert
oWKS-135 GCGAAATTAATACGACTCACTATAGG pET21b(+) insert
oWKS-136 CAGCCAACTCAGCTTCCTTTC pET21b(+) insert
oWKS-1223a TGCTCGAGTTTAACCATACTATGTTCTAGT C. difficile spo0A-DBD
oWKS-1124 CTCATATGACTAGAAGTGATTTTGTTAAG C. difficile spo0A and spo0A-DBD
oWKS-1122 TTTCATATGGGGGGATTTTTAGTGG C. difficile spo0A
oWKS-1193 AGGATTTTTAGTAGGATAATAGC *B. subtilis PabrB
oWKS-1194 CTCCCAAGAGATACTTATTTG *B. subtilis PabrB
oWKS-1223 CTCCCAAGAGATACTTATTTGTTTAAATTATATTT
TTCTTCGTCATTATTCAACAAAATC
*B. subtilis PabrB -C4A
oWKS-1224 CTCCCAAGAGATACTTATTTGTTTAAATTATATTT
TTCTTCGTCATTATTAAACAAAATC
*B. subtilis PabrB -C4A-G5A
oWKS-1225 CTCCCAAGAGATACTTATTTGTTTAAATTATATTT
TTCTTCGTCATTATTCGAAAAAATC
*B. subtilis PabrB -G2A
oWKS-1226 CTCCCAAGAGATACTTATTTGTTTAAATTATATTT
TTCTTCGTCATTATTCAAAAAAATC
*B. subtilis PabrB -G2A-C4A
oWKS-1230 CTCCCAAGAGATACTTATTTGTTTAAATTATATTT
TTCTTCGTCATTATTAGACAAAATC
*B. subtilis PabrB -G5A
oWKS-1199 TGAAAGCGGAGGATACGAAG *B. subtilis PcitG
oWKS-1200 CAATTCTGTATTCCATTTATGTATC *B. subtilis PcitG
oWKS-1166 ACACAGGAGGTATCGTACAG *C. difficile Pspo0A
oWKS-1167 CCCCCCATTAAAAAACATCTTC *C. difficile Pspo0A
oWKS-1227 GGTGCTACTAGAATGTCTGC *C. difficile PsigH
oWKS-1228 GACAATTGTCCACTAACTCATAAC *C. difficile PsigH
oWKS-1231 GCCTCTACCCTTCTATTCAC *C. difficile PlplA
oWKS-1232 TAACATTAAAGTAGTTCCTCCATAG *C. difficile PlplA
oWKS-1235 GCTGATGGACGAACCATTTG *C. difficile PssuA
oWKS-1236 CAATTAAAACTCCCCCAATTCCC *C. difficile PssuA
oWKS-1166 ACACAGGAGGTATCGTACAG *C. difficile Pspo0A
oWKS-1167 CCCCCCATTAAAAAACATCTTC *C. difficile Pspo0A
oWKS-1277 GGTGCTACTAGAATGTCTGC *C. difficile PsigH
oWKS-1228 GACAATTGTCCACTAACTCATAAC *C. difficile PsigH
oWKS-1231  GCCTCTACCCTTCTATTCAC *C. difficile PlplA
oWKS-1232 TAACATTAAAGTAGTTCCTCCATAG *C. difficile PlplA
oWKS-1235 GCTGATGGACGAACCATTTG *C. difficile PssuA
oWKS-1236 CAATTAAAACTCCCCCAATTCCC *C. difficile PssuA
oWKS-1170 GGTTGGTGGAAGAAACATGG *C. difficile PspoIIAA
oWKS-1171 AATCCCTCCTTCAATAGTTTTG *C. difficile PspoIIAA
oWKS-1172 AAACGTGCGGATATTATAACTG *C. difficile PspoIIE
oWKS-1173 ACAACTGCTACACTTCTTTG *C. difficile PspoIIE
oWKS-1174 ACTTCTACCTAGATATATTGGATTC *C. difficile PspoIIGA
oWKS-1175 ACTCAATATACACCATGTATCC *C. difficile PspoIIGA




buffer (20 mM imidazole, 300 mM NaCl, 50 mM NaH2PO4, pH7.9). The protein 
was stepwise eluted in 1 mL fractions after applying 2 mL elution buffer to the 
column (identical to wash buffer but with 50, 100, 250 or 500 mM imidazole). The 
whole procedure was carried out at 4°C. Fractions were assayed for purity and yield 
and suitable fractions were dialysed against 2x 1L dialysis buffer (50 mM Tris-HCl 
pH8, 1 mM EDTA, 0.5 mM DTT) using Slide-A-Lyzer cassettes with a molecular 
weight cut-off  of  3.5kDa (Pierce). 
Proteins were stored at -80°C in storage buffer (identical to dialysis buffer but 
containing 20% glycerol). Protein concentrations were determined using Bradford 
reagent (BioRad), according to the manufacturer’s instructions.
Electrophoretic mobility shift assays
DNA fragments for use in EMSA experiment were generated by PCR using 
GoTaq polymerase (Promega) and chromosomal DNA from B. subtilis JH642 
(Bacillus Genetic Stock Center 1A96; http://www.bgsc.org), plasmids listed in 
Table 1, or chromosomal DNA from C. difficile 630Δerm (38) as a template. Primers 
for generation of  the EMSA probes are listed in Table 2. DNA fragments of  
the expected size were isolated from a 1xTAE / 8% native polyacrylamide gel 
using diffusion buffer (0.5 M ammonium acetate, 10 mM magnesium acetate, 
1 mM EDTA pH 8, 0.1% SDS) and a QIAExII kit (Qiagen), according to the 
manufacturer’s instructions. Recovered DNA was end-labeled with 32P-γ-ATP 
using FR buffer and T4 kinase (Invitrogen) according to the instructions of  the 
manufacturer. Specific activity was determined on a LS6000 scintillation counter 
(Beckman). 
EMSA conditions were based on previous studies (10). In short, binding 
reactions were carried out in binding buffer (10 mM Tris-HCl pH7.6, 1 mM 
EDTA, 50 mM NaCl, 1 mM DTT, 5% glycerol) in the presence of  200 μg/mL 
bovine serum albumin (NEB) and 200 cpm/μL radiolabeled DNA fragment. 
Reactions were incubated for 20 minutes at 30 °C prior to loading on a 1xTAE / 
8% non-denaturing polyacrylamide gel that was prerun for 20 minutes at 50V in 
1x TAE buffer. Electrophoresis was carried out for 120 min at 85V. After vacuum 
drying the gels onto filter paper, they were imaged after overnight exposure on 
Phosphorimager screens on a Typhoon instrument (GE Healthcare).
Cytotoxicity assay
The toxic effects of  C. difficile culture supernatants on Vero cells (39) were 
determined as follows. Supernatant from a bacterial culture was harvested by 
centrifuging cells for 3 minutes at 14000x g and filtered on a 0.45 μM cellulose 
acetate filter using a syringe. Supernatants were 2-fold serially diluted in cell culture 
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medium (Dulbecco modified Eagle medium (Lonza) supplemented with 100 μg/
mL penicillin, 100 U/mL streptomycin, 10% fetal calf  serum), before applying them 
to a monolayer of  Vero cells, and incubation was continued for another hour. As a 
positive control, 50 μL 1:10 diluted purified toxin (Techlab) was added to the cells. 
To determine if  observed cytotoxic effects were specific for the large clostridial 
toxins, commercially available anti-toxin against TcdA and TcdB (Techlab) was 
added to 10-fold diluted bacterial supernatant for 60 min prior to incubation on 
the Vero cells. Toxin end-point titres were defined as the lowest dilution at which 
no cytopathological effects (cell rounding) were observed. Statistical significance 
was evaluated with an independent sample t-test.
Generation of  antibodies against Spo0A and immunoblot detection
Immunization of  mice with full length C. difficile Spo0A-6xHis was kindly 
performed at the Welcome Trust Sanger Institute (Hinxton, UK). Cells from 1 
mL of  C. difficile culture were collected by centrifugation for 1 min at 14000 rpm 
in a table top centrifuge and resuspended in 200 μL resuspension buffer (10 mM 
Tris HCl pH8, 10 mM EDTA, 0.5 mg/mL lysozyme, 1 mM Pefabloc SC (Roche)). 
After incubation for 30 mins at 37 °C, 50 μL of  5x SDS sample buffer (0.1 M DTT, 
2% SDS, 50 mM Tris HCl pH 6.8, 10% glycerol, 0.0025% BPB) was added, and 
samples were heated to 96°C for 5 mins. Total cell lysates (amounts corrected for 
OD600) were separated on a 12% SDS-PAGE gel prior to semi-dry blotting for 1h 
at 10V to a polyvinylidene fluoride (PVDF) membrane. Membranes were blocked 
in PBST buffer (phosphate buffered saline with 0.1% v/v Tween-20) containing 
5% membrane blocking reagent (Amersham Biosciences). To visualize Spo0A 
protein cleared polyclonal serum from a single mouse at a 1:3000 dilution was 
used, followed by either a goat-anti-mouse HRP-conjugated secondary antibody 
followed by ECL+ detection (Amersham Bioscience), or a goat-anti-mouse-biotin-
conjugated secondary antibody (Dako) followed by a tertiary mouse-anti-biotin 
Cy3-conjugated antibody (Jackson). Detection was done using on a Typhoon 
instrument (GE Healthcare). Background corrected peak volumes were quantified 
using ImageQuant TL (Amersham Biosciences).
Bioinformatics and software
Alignments of  B. subtilis and C. difficile spo0A were made using ClustalW2 (http://
www.ebi.ac.uk/Tools/msa/clustalw2/) on the basis of  the published genome 
sequences, Genbank accession numbers AL009126 and AM180355, respectively, 
and the 630Δerm spo0A sequence as determined in this study. The sequence 
for spo0A of  C. difficile strain 630Δerm was deposited in Genbank (accession no 




command in Genome2D (40), allowing 0 mismatches. The box positions were 
linked to up- and downstream genes using the “Add nearest gene to List of  DNA 
Motifs” feature and Microsoft Excel. The results were manually inspected for those 
boxes within 500 bp upstream of  a gene on the same strand. Figures for publication 
were prepared using ImageQuant TL (Amersham Biosciences), Adobe Photoshop 
CS3 (Adobe Systems Inc) and Corel Graphics Suite X5 (Corel Corporation).
Results
Purification of  Spo0A and its DNA binding domain
In order to characterize C. difficile Spo0A, the full length protein and its DNA 
binding domain (DBD) were expressed as a C-terminally 6xHis-tagged protein in 
the heterologous host Escherichia coli (Figure 1A) and purified to near homogeneity 
using metal affinity chromatography (Figure 1A; lanes P). Full length protein was 
used to raise antibodies to detect Spo0A in total lysates of  C. difficile strains, and 
the purified DNA binding domain was used in subsequent in vitro binding assays 
(see below).
Spo0A is expressed throughout growth
We determined the expression of  C. difficile Spo0A throughout growth. We found 
that the protein is present in lysates from exponential to stationary growth phase 
cells. We performed immunoblotting using polyclonal antibodies against C. difficile 
Spo0A on total lysates of  wild type and spo0A mutant cells grown in a trypton-
yeast based medium (TTY). We found a clear signal of  the size expected for full 
length Spo0A (~31 kDa) as early as 3 hours post inoculation (exponential growth 
phase), through transition phase (8h) as well as 24 and 48 hours post inoculation 
(stationary growth phase) (Figure 1B; 630Δerm). The signals were specific for C. 
difficile Spo0A as they were absent from lysates from the C. difficile spo0A mutant 
(Figure 1B, CT::spo0A). We obtained similar results in other media, such as the 
commonly used supplemented brain heart infusion broth (BHIS; data not shown).
To determine relative levels of  Spo0A throughout growth, we performed an 
immunoblot experiment using fluorescent antibodies, which gives more quantitative 
information compared to the use of  horseradish peroxidase conjugated antibodies 
in our hands. We found that the levels of  Spo0A increases approximately 20-fold 
from 6 hours post inoculation and remains at similar levels from 8 to 48 hours post 
inoculation (Figure 1C).
Though it should be noted that the Western blots do not provide information 
on the phosphorylation state of  the protein, we conclude that the protein in active 
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Figure 1: Purification and detection of  C. difficile Spo0A. (A) Heterologous overproduction 
of  Spo0A-6xHis and Spo0A-DBD-6xHis in E. coli Rosetta(DE3) pLysS. M = molecular 
weight marker, numbers indicate hours after induction with 1mM IPTG. P = metal affinity 
purified protein. Lysates were separated on a 12% SDS-PAGE. (B) and (C). Immunoblot 
detection of  Spo0A in total cell lysates of  a C. difficile spo0A mutant (CT::spo0A) and a wild 
type strain (630Δerm). Times indicated range from early exponential (3h post inoculation) 
to late stationary growth phase (48h post inoculation). Sample volumes were corrected 
for OD600 to ensure loading of  similar amounts of  total cell lysate in each lane. For 
details see Materials and Methods. M = molecular weight marker. (B) ECL+ detection. 
(C) Fluorescent detection. Y-axes show peak volumes normalized to values at 48 hours 
post inoculation (closed diamonds; left axis) and optical density readings at 600nM (open 
squares; right axis). Inset shows the blot on which the curve is based. Vertical dashed line 




Figure 2: (A) Spo0A box is important for high affinity binding by C. difficile Spo0A. (A) 
Domain organization of  Spo0A. The site of  the duplication in strain 630Δerm identified in 
this study is indicated by an arrow. (B) Sequence alignment of  the C-terminal regions of  the 
Spo0A proteins of  B. subtilis 168 and C. difficile strains 630 and 630Δerm. Residues identified 
in structural studies using Bacillus Spo0A as involved in backbone interactions are indicated 
in yellow, residues forming base-specific contacts are indicated in red (13). The region of  
the 6aa duplication and the helix-turn-helix motifs are boxed in gray and the duplication 
in strain 630Δerm is underlined. (C) PCR showing the presence of  the duplication near 
the DNA binding domain in C difficile 630Δerm compared to 630. (D) Electrophoretic 
mobility shift assay using purified C. difficile Spo0A-DBD-6xHis and a radiolabeled PabrB 
DNA fragment. X = no protein control, the triangle indicates 1.3-fold serial dilutions of  
protein to the indicated concentrations. The arrow indicates a DNA:protein complex. (E) 
Electrophoretic mobility shift assays without (-) or with (+) 150 nM Spo0A-DBD-6xHis 
added to radiolabeled PabrB fragments carrying mutations in the consensus Spo0A box 
(in red). Arrows indicate DNA:protein complexes. The negative control is PcitG from B. 
subtilis.
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or inactive form is present throughout growth and is more abundant in stationary 
growth phase. 
Spo0A of C. difficile strain 630Δerm contains a 6-aminoacid duplication
BLAST homology searches readily identify a homolog of  the well-characterized B. 
subtilis Spo0A protein in C. difficile 630 (CD1214) and previous work demonstrated 
that a spo0A mutant (an insertional inactivation of  cd1214) – as expected – no 
longer forms spores (41). In silico analyses suggest a similar secondary structure 
for both proteins (Figure 2A), with a conserved dimerization and DNA binding 
domain, separated by a poorly conserved hinge region (7,12).We compared the 
sequence of  CD1214 obtained from our lab strain 630Δerm (38) to that of  the 
published C. difficile630 genome (42). Strain 630Δerm is a spontaneous erythromycin 
sensitive strain, which is commonly used in mutagenesis studies and was obtained 
by serial passaging of  strain 630 (33,38). The 630Δerm spo0A sequence (Genbank 
accession no JX050222) was derived from the expression plasmids constructed for 
this study, and confirmed in a whole genome sequence of  strain 630Δerm generated 
in our lab (data not shown). We found that 630Δerm spo0A contains an 18 base pair 
direct repeat,resulting in a 6 amino acid (NVGNIE) duplication compared to the 
published reference sequence. The duplication maps to a region of  the protein with 
relatively low sequence conservation (hinge), flanking the highly conserved DNA 
binding domain (Figure 2A and B). We verified the absence of  this duplication in 
strain 630 by PCR (Figure. 2C) as well as sequencing from the chromosomal DNA 
of  C. difficile 630 (data not shown), to rule out an error in the original genome 
sequence and to demonstrate that the difference in size of  the PCR product was 
specific to the 18bp insertion. In addition, we checked several other strains of  PCR 
ribotypes 12 (to which 630 and 630Δerm belong) by PCR, but the duplication was 
found to be unique to 630Δerm among the isolates tested (data not shown).
C. difficile Spo0A-DBD shows similar specificity as B. subtilis Spo0A-DBD
Next, we examined the conservation of  the Spo0A-DBD between B. subtilis and 
C. difficile. In B. subtilis amino acid residues contacting the backbone of  the DNA 
and interacting with specific residues of  the Spo0A binding sequence have been 
defined (13). We found that all these residues were conserved in the C. difficile 
protein sequence (Figure 2B), indicating that the protein likely recognizes a similar 
motif.
C. difficile Spo0A-DBD shows similar specificity as B. subtilis Spo0A-DBD
Next, we examined the conservation of  the DNA binding domain of  Spo0A 




contacting the backbone of  the DNA and interacting with specific residues of  the 
Spo0A binding sequence have been defined (13). We found that all these residues 
were conserved in the C. difficile protein sequence (Figure 2B), indicating that the 
protein likely recognizes a similar motif.
DNA binding by full length Spo0A in B. subtilis requires phosphorylation 
dependent dimerization (8,9). However, it was shown that the isolated DBD is 
capable of  binding to legitimate targets of  the full length protein (10). Analogously, 
we purified the C. difficile Spo0A-DBD for use in in vitro binding assays. As no 
direct targets for the C. difficile protein have been reported so far, we used the 
upstream region of  the abrB gene (PabrB) of  B. subtilis. PabrB is commonly used 
as a high-affinity control in binding assays with the B. subtilis Spo0A or Spo0A-
DBD protein (43,44). It is noteworthy that we failed to identify a homolog of  
abrB in C. difficile using BLAST, indicating that potential indirect regulation by 
Spo0A cannot occur through abrB in C. difficile as it does in B. subtilis. We found 
that C. difficile Spo0A-DBD bound with high affinity to PabrB (Figure 2D and E). 
We performed electrophoretic mobility shift assays (EMSAs) using radiolabeled 
PabrB and increasing amounts of  purified C. difficile Spo0A-DBD that was purified 
using a C-terminal 6xHis-tag. The addition of  protein leads to a dose-dependent 
retardation of  the DNA fragment with an apparent KD of  <50nM. In the same 
range of  protein concentrations, no binding was observed for a negative control 
(a DNA fragment of  B. subtilis citG (45)) (Figure 2E), suggesting that binding 
was specific for the abrB promoter region. B. subtilis Spo0A recognizes a distinct 
sequence (0A box), that is characterized by a 7bp core motif  (TGTCGAA) (10,11). 
Structural studies have revealed that the protein makes specific contacts with the 
G at position 2 (G2), and the C at position 4 (C4) and 5 (G5) of  this motif  (13). 
We introduced G2A, C4A, G5A, G2A/C4A and C4A/G5A mutations in the 
perfect consensus core 0A-box present in PabrB. We found that the affinity of  
C. difficile Spo0A for these mutated PabrB fragments was highly reduced (Figure 
2E). We performed EMSAs using radiolabeled PabrB containing the mutated core 
sequence. For the single point mutations in the DNA, the affinity decreased ~10-
fold. There did not seem to be an additive effect of  a second point mutation for the 
two combinations tested. None of  the mutations abolished binding of  C. difficile 
Spo0A completely, most likely as the result of  binding of  Spo0A to other (non-
consensus) 0A boxes in the abrB promoter (44).
Taken together, we conclude that the guanine and cytosine residues in the core 
TGTCGAA motif  of  PabrB are important for specific binding of  this fragment by 
C. difficile Spo0A-DBD.
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The presence of  a consensus Spo0A box has predictive value for binding by 
C. difficile Spo0A-DBD
Above, we have established that the Spo0A-DBD of  C. difficile is highly homologous 
to that of  the B. subtilis Spo0A protein, and that the proteins recognize a similar 
consensus sequence (Figure. 2). Based on this information, we identified the several 
genes as putative direct targets of  C. difficile Spo0A. We queried the C. difficile 630 
genome sequence for perfect matches to the core 0A box using Genome2D (40). 
Such an analysis revealed the presence of  102 matching motifs, of  which 45 were 
located within 500bp of  the initiating ATG of  an open reading frame on the same 
strand (data not shown). Our attention was drawn to spo0A and sigH, as these two 
genes were previously found to be regulated by Spo0A in B. subtilis and/or play 
important roles in sporulation (3,46–48). We found that C. difficile Spo0A bound to 
DNA sequences upstream of  spo0A and sigH. 
We performed EMSAs with DNA encompassing 220-281bp upstream of  the 
initiating ATG codon of  the spo0A, sigH and spoVG open reading frames. We 
found that the addition of  Spo0A-DBD to the reactions caused retardation of  
the spo0A and sigH DNA fragments (Figure 3A), but not of  a spoVG fragment 
which did not contain a consensus 0A box (Figure 3B). It should be noted that the 
affinity of  Spo0A-DBD for the region upstream of  spo0A was the highest we have 
Figure 3: C. difficile Spo0A binds to predicted and expected target sequences. Electrophoretic 
mobility shift assay using purified C. difficile Spo0A-DBD-6xHis and a radiolabeled DNA 
fragments. X = no protein control, the triangle indicates 1.3-fold serial dilutions of  protein 
to the indicated concentrations. The arrows indicate DNA:protein complexes. (A) In silico 
predicted target sequences upstream of  the genes encoding Spo0A (spo0A), σH (sigH), 
a lipoate ligase (lplA) and an aliphatic sulphonates ABC transporter (ssuA). (B) Target 
sequences predicted on the basis of  findings in other organisms: spoIIAA, spoIIE and 




Figure 4: Specificity controls 
for binding by Spo0A-DBD-
his6. Arrows indicate the 
position of  shifted species 
(DNA:protein complexes). 
Titrations with PCR fragments 
of  PabrB (containing a high 
affinity binding site) and PtcdA 
(lacking such a site) correspond 
to approximately 0.1nM/μL - 
0.03 nM/μL 
(A) Comparison of  binding 
of  Spo0A-DBD-his6, Spo0A-
his6 and CD2195-his6 binding 
to the upstream region of  
spoIIAA. 
(B) Binding of  Spo0A-DBD-
his6 to the upstream region 
of  spoIIAA is reversed by the 
addition of  PabrB, but not by 
the addition of  PtcdA).
(C) Binding of  Spo0A-DBD-
his6 to the upstream region 
of  spoIIE is reversed by the 
addition of  PabrB, but not by 
the addition of  PtcdA. 
(D) Binding of  Spo0A-DBD-
his6 to the upstream region 
of  spoIIGA is reversed by the 
addition of  PabrB, but not by 
the addition of  PtcdA. 
(E) Binding of  Spo0A-DBD-
his6 to the upstream region of  
tcdB is reversed by the addition 
of  PabrB, but not by the 
addition of  PtcdA. 
(F) Binding of  Spo0A-DBD-
his6 to the upstream region 
of  tcdC is not or moderately 
affected by the addition of  
PabrB and/or PtcdA.
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observed so far for any C. difficile DNA. Moreover, the presence of  multiple shifted 
species could indicate the presence of  more than one strong binding site. These 
results establish that spo0A and sigH are likely legitimate targets of  Spo0A in C. 
difficile, and confirm that spoVG is not, in line with results obtained in B. subtilis (10).
We were interested to see if  Spo0A in C. difficile could potentially regulate genes 
that have no documented function in sporulation. Our in silico analysis identified 
several genes with no obvious link to sporulation that had a consensus 0A box 
within 100bp upstream of  their start codon. This positioning is similar to that 
observed for spo0A (-75) and sigH (-78). We confirmed in vitro binding of  the C. 
difficile Spo0A-DBD to the promoter regions of  lplA and ssuA.
We carried out EMSA experiments using probes that included the perfect 
consensus site and purified Spo0A-DBD protein. We observed binding of  the 
protein to fragments upstream of  the lplA gene (CD1654; box at -67) and the ssuA 
gene (CD1484; box at -82) (Figure 3A). The lplA gene encodes a predicted lipoate-
protein ligase, and ssuA is annotated as an aliphatic sulfonates ABC transporter; 
to our knowledge, neither of  these have been directly implicated in sporulation or 
have found to be targets for Spo0A in other organisms.
Together our results establish the potential for binding of  Spo0A to DNA 
upstream of  spo0A and sigH, two genes that are important for sporulation, 
and indicate that Spo0A may have functions that go beyond the regulation of  
sporulation in C. difficile.
C. difficile Spo0A-DBD binds to early sporulation promoters
It has been established that a spo0A mutant of  C. difficile does not produce any 
spores, consistent with a crucial role in the sporulation pathway (33). However, 
the in silico identification of  upstream regions with a consensus Spo0A binding site 
did not point to any of  the early sporulation genes (downstream of  spo0A itself) as 
direct targets of  Spo0A. This is likely the result of  variations in the 0A-box in these 
promoters that were disregarded in the box search. In support of  this, many well-
characterized legitimate direct targets of  B. subtilis Spo0A (such as spoIIAA and 
spoIIE) do a 100% match to the core motif, but rather one or more near-consensus 
boxes (5,49). We found that Spo0A-DBD of  C. difficile is capable of  binding the 
DNA upstream of  the open reading frames of  spoIIAA, spoIIE and spoIIGA with 
low affinity.
We performed EMSA experiments using increasing amounts of  purified 
Spo0A-DBD from C. difficile 630Δerm and the DNA fragments indicated above 
(Figure 3B). For spoIIAA (encoding an anti-anti sigma-factor) and spoIIE (encoding 
a serine phosphatase), we observed a low intensity shifted species at concentrations 




observed the shifted species only at higher concentrations of  protein (>200nM). 
The negative control (spoVG) did not demonstrate binding of  Spo0A-DBD at these 
concentrations. Moreover, the. shift we observed was reversible using unlabeled 
DNA containing a high affinity binding site, but not using unlabeled DNA that 
lacked such a site not contain (Figure 4 B-D). Therefore, we consider the binding 
to spoIIAA, spoIIE and spoIIGA genes to be specific, despite the fact that increasing 
the amount of  protein did not seem to cause a significant increase in the amount 
of  DNA in the complex. Together, these results suggest that Spo0A in C. difficile 
might regulate the transcription of  at least a subset of  early sporulation genes by 
direct binding to their promoter regions.
C. difficile Spo0A-DBD binds to DNA upstream of  tcdB
It has previously been reported that the deletion of  Spo0A in C. difficile results in 
a significantly lower toxin production and a ~1000-fold reduction in the toxicity 
of  culture supernatant derived from spo0A negative cells towards Vero cells (35). 
Considering the absence of  a homolog of  the abrB repressor, direct binding of  
Spo0A and concomitant activation of  toxin gene transcription is a likely mechanism 
through which this could occur. We found evidence for direct binding of  Spo0A-
DBD to the region upstream of  tcdB, encoding one of  the major clostridial toxin 
genes, and possibly tcdC, but this did not seem to result in lower toxin levels in our 
hands.
We performed EMSAs using DNA upstream of  tcdR (encoding a sigma factor 
responsible for the activation of  toxin gene transcription), tcdB (encoding toxin 
B), tcdA (encoding toxin A). In order to test regions upstream of  all open reading 
frames in the PaLoc, we also tested binding of  Spo0A to DNA upstream of  tcdE 
(encoding a holin-like protein (50,51)) and tcdC (encoding a putative negative 
regulator of  toxin production (52–54)), even though this regulator does not have 
a significant effect on toxin levels under the conditions we used (55,56). Of  the 
regions tested, we only observed a clear shifted species, indicative of  Spo0A 
binding, for tcdB (Figure 5A); the shifted species in our EMSA assay was reversed 
by the addition of  unlabeled DNA containing a high affinity binding site, but not 
by DNA lacking such a site (Figure 4E).
For tcdC, some smearing was observed at all concentrations of  proteins 
tested (Figure 5A), and there did not seem to be a clear effect of  the addition of  
unlabeled DNA fragments (Figure 4F). The probes for tcdA, tcdE and tcdR were 
indistinguishable from those obtained with our negative control, spoVG. 
We wanted to determine if  toxin levels in culture supernatants were directly 
or indirectly affected by Spo0A, as was previously suggested. We found no lower 
toxicity towards Vero cells of  culture supernatants derived from spo0A mutant 
cells compared to wild type.
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Figure 5: C. difficile Spo0A does not contribute to toxin production directly. (A) 
Electrophoretic mobility shift assays using purified C. difficile Spo0A-DBD-his6 and 
radiolabeled DNA fragments corresponding to the upstream regions of  the indicated 
toxin-related genes. X = no protein control, the triangle indicates 1.3-fold serial dilutions of  
protein to the indicated concentrations. Arrows indicate (possible) protein:DNA complexes. 
(B) Toxin end-point titre of  culture supernatant from wild type (630Δerm; white bars) or 
spo0A mutant (CT::spo0A; black bars) C. difficile cells. For details see Materials and Methods. 
Error bars represent standard error of  the mean (n=3). None of  the observed differences 




We grew three independent biological replicates of  a wild type (630Δerm) or 
Clostron-generated spo0A mutant (CT::spo0A - a kind gift of  the Minton lab) in 
glucose-free TTY medium. We harvested culture supernatant at late-exponential 
phase (approximately 7 hours post inoculation), the transition phase between 
exponential and stationary growth phase (approximately 9 hours post inoculation), 
as well as two time points in stationary phase (24 and 48 hours post inoculation) 
and determined the toxin endpoint titres (see Materials and Methods). In contrast 
to previous findings, we observed a small (≤4-fold) increase in the toxicity of  
supernatants derived from spo0A mutant cells compared to wild type, but in all 
cases this difference was not statistically significant (p>0.05, independent sample 
t-test). In other medium (BHIS), we observed no differences at all (data not shown). 
We conclude that Spo0A does not positively affect toxin production in C. difficile 
630Δerm and the in vivo relevance of  the binding to regions upstream of  tcdB and/
or tcdC is therefore limited under our experimental conditions.
Discussion
The Spo0A-box of C. difficile
In B. subtilis, the binding site of  Spo0A on target DNA has been well-characterized, 
through a combination of  in vitro binding assays, determination of  in vivo binding 
profiles and mutagenesis of  regulated promoter sequences. This work has led to the 
identification of  a conserved core motif, TGTCGAA, or Spo0A box (5,10,11,45). 
Depending on the analysis, this motif  is flanked by one or more adenine or thymine 
residues (10,11). Interestingly, many target genes do not harbor a perfect match to 
this consensus sequence, but rather contain one or more degenerate motifs. The 
differences in these motifs may reflect different promoter architectures (e.g. AT 
content), modes of  action (e.g. activation or repression) or levels of  regulation. 
Spo0A genes in B. subtilis can be divided in different classes that respond to 
different levels of  phosphorylated Spo0A (43,57).
For C. difficile, we conclude that the Spo0A protein likely recognizes a motif  that 
is similar to the B. subtilis Spo0A box on the basis of  four lines of  evidence; 1. All 
DNA binding/contacting residues are conserved (Figure 2B), 2. C. difficile Spo0A 
can bind with high affinity to a target of B. subtilis Spo0A (Figure 2D), 3. Mutagenesis 
of  key residues in the B. subtilis Spo0A box reduces affinity of  C. difficile Spo0A for 
DNA (Figure 2E) and 4. A B. subtilis Spo0A box has predictive value for DNA 
binding by C. difficile Spo0A (Figure 3A). It is conceivable that our model system, 
using the purified DNA binding domain, does not accurately reflect binding to 
all target sites, if  target site selectivity is determined in part by other parts by of  
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the full length protein. It is likely that differences do exist between the preferred 
binding sites for both proteins that will be evident when a comprehensive analysis is 
performed of  in vivo DNA binding of  C. difficile Spo0A; based on the limited data 
set of  this study, a MEME analysis (58) already suggests possible differences in the 
extended Spo0A motif  (W.K. Smits, unpublished observations). These differences 
may relate to the much higher AT content of  C. difficile compared to B. subtilis (71 
vs. 56.5 %, respectively), or phosphorylation dependent dimerization, for instance.
Regulation of  sporulation; feedback regulation of  spo0A
The initiation of  sporulation in B. subtilis is subject to complex regulation (for 
review see ref  (1,59)). The activation of  Spo0A is controlled by a multi-component 
phosphorelay that can integrate environmental cues (60) and ensures a gradual 
increase in the level of  phosphorylated Spo0A in the cell (57). In addition, the 
transcription of  the spo0A gene is controlled by multiple feedback loops. For 
instance, Spo0A regulates its own transcription by binding to the spo0A promoter 
(46), as well as by indirectly stimulating the transcription of  sigH, encoding a 
sigma factor that recognizes the spo0A promoter (48). In C. difficile, there are some 
interesting differences and similarities in the regulatory pathways. Most notably, 
there seems to be no phosphorelay (2) and the phosphorylation state of  Spo0A is 
supposedly controlled by orphan histidine kinases (35). The transcription of  spo0A 
in C. difficile is under control of  the transition state sigma factor Sigma H (37), as it 
is in B. subtilis (61). Our data indicate that both spo0A and sigH could be targets for 
direct regulation by Spo0A in C. difficile (Figure 3A), raising the possibility of  auto-
regulation of  spo0A. The putative direct regulation of  sigH by Spo0A may reflect 
that the C. difficile genome does not harbor a homolog of  the pleiotropic regulator 
AbrB, which is responsible for the Spo0A-dependent regulation of  sigH in B. 
subtilis (48). Consistent with a model in which spo0A is positively auto-regulated, 
we noted a sharp increase in the levels of  Spo0A as cells approach the stationary 
growth phase (Figure 1C).
Downstream of  Spo0A, we found binding of  Spo0A to DNA upstream of  
several early sporulation genes, such as spoIIAA, spoIIE, and spoIIGA (Figure 3B). 
All these observations are consistent with direct regulation of  these genes by 
Spo0A in other organisms (5,45,49,62), and the conservation of  the sporulation 
pathway (2).
Regulation of  processes outside sporulation
Though Spo0A is the key regulator for sporulation in Firmicutes, it regulates 
numerous other processes in various bacteria. In the non-pathogenic B. subtilis, for 




production of  and resistance to antimicrobial compounds, chromosome dynamics 
and aspects of  phage biology (10,14–16). Importantly, several of  these processes 
are indirectly regulated, through the Spo0A-dependent repression of  abrB. 
Additionally, transcription of  abrB responds already to low levels of  Spo0A~P 
(43). As a result these effects are detectable in late-exponential and early stationary 
phase, as some Spo0A is present throughout growth in B. subtilis cells.
Though abrB is absent from C. difficile, this does not exclude the possibility 
of  indirect transcriptional regulation through Spo0A-dependent effects on other 
regulators. Alternatively, Spo0A may exert a direct effect. In Clostridium acetobutylicum 
and C. beijerinckii, Spo0A is a direct regulator of  solvent formation, as well as 
sporulation (22,23). It seems therefore conceivable that Spo0A in C. difficile also 
affects aspects of  metabolism. In this respect, it is important to note that also in 
C. difficile Spo0A is detectable from early exponential growth phase on (Figure 1B).
We observed direct binding of  C. difficile Spo0A to the promoter region of  sigH 
(Figure 3A). This gene encodes the key sigma factor for the transition phase, and 
regulates processes outside sporulation as well (37). Moreover, we found significant 
levels of  Spo0A from early stationary phase on (Figure 1B and unpublished 
observations), indicating the regulatory actions of  Spo0A need not be limited to 
stationary phase in C. difficile. In line with this idea, we found a potential regulatory 
link between Spo0A and two genes that to our knowledge are not related to the 
sporulation process, the lipoate ligase lplA and the aliphatic sulfonates transporter 
ssuA (Figure 3A). The presence of  a putative Spo0A binding site upstream of  
these genes, as well as the spacing compared to the start codon, is conserved in the 
problematic Stoke-Mandeville strain (R20291), a member of  RT 027. This could 
indicate that these aspects of  regulation by Spo0A are conserved in multiple strains 
of  C. difficile.
It should be noted that our work so far has been limited to an in vitro 
analysis of  Spo0A binding, and therefore does not indicate whether activation or 
repression of  the putative target genes occurs in vivo. To answer this question, 
detailed transcriptome and/or proteome studies have to be performed. In order to 
distinguish direct from indirect effects, in vivo binding profiles of  Spo0A should 
be performed. The antibodies generated for this study should prove to be useful 
for this type of  experiments.
Regulation of  toxin production
Amongst the pathogenic Firmicutes, Spo0A has been reported to affect toxin 
production in multiple species. In B. anthracis a spo0A mutation results in elevated 
levels of  AbrB, and concomitantly lower levels of  the toxin genes pagA, cya and 
lef  that are under AbrB control (17). Similarly, the production of  the emetic toxin 
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cereulide in B. cereus is greatly repressed in a spo0A mutant, in an AbrB-dependent 
manner (63). In contrast, Spo0A directly represses the expression of  the cry toxin 
genes in B. thuringiensis and a spo0A mutant is therefore a hyper-producer of  the 
insecticidal crystal protein (18,21). In Clostridium perfringens TpeL, a member of  the 
large clostridial toxins just like TcdA and TcdB, is directly dependent on Spo0A (64) 
and also the production of  enterotoxin in this organism seems to be (indirectly) 
dependent on sporulation (65,66).
In C. difficile an insertional spo0A mutant generated using Clostron technology 
was reported to have ~10-fold reduced levels of  Toxin A (TcdA), both intracellularly 
and extracellularly as well as ~1000-fold reduced toxicity towards Vero cells, which 
are primarily sensitive towards Toxin B (TcdB) (35). Our in vitro binding data 
indicate a potential binding site for Spo0A upstream of  tcdB and possibly tcdC 
(Figure 5A). However, the in vivo relevance of  this binding seems limited as in 
our hands an independently derived but otherwise identical mutant (a kind gift of  
the Minton lab; (33)) did not demonstrate a reduced toxicity towards Vero cells. In 
contrast, we found that in TTY medium toxin levels were slightly elevated in spo0A 
mutant cells compared to wild type (≤2-fold in exponential phase cells up to 4-fold 
in late-stationary phase cells). The small, and not significant, differences in toxin 
levels in our experiments might be attributed to differences in the susceptibility 
of  cells for lysis rather than the production of  toxin, but could also indicate a 
negative regulatory effect of  Spo0A on toxin production. In support of  the latter 
hypothesis, it was recently reported that a spo0A mutant of  C. difficile strain R20291 
(a RT 027/BI/NAP1 epidemic strain) demonstrates ~10-fold higher toxin levels 
than its isogenic wild type 30h post inoculation, and is significantly more virulent 
in a mouse model of  disease (34).
The differences between Underwood et al (35) on the one hand and our study as 
well as the study of  Deakin and coworkers (34) on the other hand may be explained 
by differences in experimental conditions, such as the medium used. However, we 
observed no difference in cytotoxicity between supernatant derived from wild type 
or spo0A mutant cells when they were grown in BHIS, a medium nearly identical to 
that used previously (data not shown). Alternatively, the differences could indicate 
integration of  the group II intron at more than one location in the chromosome 
in the strain used in Underwood et al (35). In the absence of  a complementation 
experiment and/or Southern blot data, this remains to be established.
In summary, our data are consistent with a model in which the regulation of  the 
major clostridial toxins in C. difficile is not positively affected by Spo0A, in contrast 
to previous findings and other pathogenic Clostridia. Whether Spo0A is truly a 
negative regulator of  toxin production remains to be confirmed using in vitro and 





In the present study we have for the first time demonstrated direct binding of  
the DNA binding domain of  C. difficile Spo0A to putative target DNA. This 
work has revealed that aspects of  Spo0A binding are conserved between Bacillus 
and C. difficile (0A box, possible auto-regulation and binding to early sporulation 
promoters), whereas others are not (the absence of  abrB as a direct target in C. 
difficile, binding to DNA upstream of  lplA, ssuA). The effects of  Spo0A on toxin 
production may be similar to those observed for B. thuringiensis (18,21). Future 
work will be aimed at determining the effect of  Spo0A on the transcription of  the 
putative target genes, and carry out a comprehensive analysis of  Spo0A binding in 
vivo. The identification of  genes affected by Spo0A in C. difficile may shed light on 
the role of  the protein in virulence and pathogenesis of  this organism.
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In the past decade, Clostridium difficile has emerged as an important gut pathogen. 
Symptoms of  C. difficile infection range from mild diarrhea to pseudomembranous 
colitis, sometimes resulting in colectomy or death. The main virulence factors of  
C. difficile are toxin A and toxin B. Besides the genes encoding these toxins (tcdA 
and tcdB), the pathogenicity locus (PaLoc) also contains genes encoding a sigma 
factor (tcdR) and a putative anti-sigma factor (tcdC). The important role of  TcdR 
as a sigma factor for toxin expression is undisputed, whereas the role of  TcdC as 
an anti-sigma factor, inhibiting toxin expression, is currently the subject of  debate.
To clarify the role of  TcdC in toxin expression, we generated an isogenic 
ClosTron-based mutant of  tcdC in Clostridium difficile strain 630∆erm (CT::tcdC) and 
determined the transcription levels of  the PaLoc genes and the expression levels 
of  the toxins in the wild type strain and the tcdC mutant strain.
We found only minor differences in transcription levels of  the PaLoc genes 
between the wild type and CT::tcdC strains and total toxin levels did not significantly 
differ either. These results suggest that in C. difficile 630Δerm TcdC is not a major 
regulator of  toxin expression under the conditions tested.




Clostridium difficile is an anaerobic, Gram-positive, spore forming rod shaped 
bacterium that can cause disease with a wide variety of  symptoms, ranging from 
mild diarrhea to severe forms of  pseudomembranous colitis (1–3). Since 2004, 
numerous countries have reported outbreaks in health-care facilities caused by 
hypervirulent C. difficile PCR Ribotype (RT) 027 (1–6). Clostridium difficile infection 
(CDI) caused by RT 027 is associated with a more severe course of  the disease and 
a higher mortality rate than other ribotypes (1,3,6). Recently, increasing numbers 
of  the hypervirulent RT 078 are reported (7). C. difficile RT 078 is more frequently 
associated with community acquired CDI and affects a younger population than 
RT 027 (6–9). Furthermore, CDI caused by RT 078 is associated with an increased 
morbidity compared to other ribotypes (8).
The main virulence factors of  the enteropathogenic C. difficile are the two 
large clostridial Toxins, Toxin A (TcdA) and Toxin B (TcdB). These toxins are 
glycosyltransferases that inactivate Rho, Rac and Cdc42, thereby disrupting the 
cytoskeleton and tight junctions of  the cells, resulting in apoptosis (10). This 
induces an inflammatory response and degradation of  the intestinal epithelial cell 
layer. Besides the genes encoding these toxins (tcdA and tcdB), the Pathogenicity 
Locus (PaLoc) also contains genes encoding a sigma factor (tcdR) and a putative 
anti-sigma factor (tcdC) (11–13). In between the toxin genes the tcdE gene is situated, 
which encodes a putative holin protein (14). Interestingly, both hypervirulent RTs 
027 and 078 have been shown to contain mutations in the tcdC gene, encoding 
the proposed negative regulator of  toxin gene transcription, and this has been 
proposed as a possible explanation for their increased virulence (8,15).
The exponential growth phase of  C. difficile has been reported to be associated 
with a high transcription level of  the tcdC gene and low transcription levels of  tcdR 
and the toxin genes, whereas the stationary growth phase is associated with a low 
transcription level of  the tcdC gene and high transcription levels of  tcdR and the 
toxin genes in strain VPI10463 (16). The synthesis and secretion of  the toxins is 
increased upon entry into the stationary growth phase (16–19). The decreasing 
transcription of  tcdC correlates with diminishing TcdC protein levels in stationary 
growth phase (16,20).
TcdR is an alternative sigma factor that positively regulates toxin production 
(11,12). The direct interaction of  TcdR and the RNA polymerase core enzyme 
mediates recognition of  the toxin promoters and the tcdR promoter (11,12,21). 
TcdC has been reported to act like an anti-sigma factor for toxin production by 
destabilizing the TcdR-RNA polymerase core enzyme complex in a way that is not 




The reported inverse correlation between the transcription of  tcdC and the toxin 
genes and the expression patterns of  the corresponding proteins, together with 
the biochemical data, has led to the prevailing model that TcdC is an important 
repressor of  toxin expression (12,16,17,20). This model seems to be supported by 
the finding that the absence of  a functional TcdC caused by a frame shift mutation 
(∆117 bp) in the tcdC gene is linked to a supposed increased toxin production in 
certain (hyper) virulent strains (15,22).
Recently, some doubts were raised about the importance of  TcdC for regulation 
of  toxin expression on the basis of  two findings. First, two studies have found 
increasing levels of  tcdC transcription in time that coincide with increasing 
transcription of  the toxin genes and increasing amounts of  toxin production 
(18,19). Second, there is a great variability in toxin expression levels among (hyper) 
virulent strains, even though these generally carry mutations in tcdC (15,18,19). 
Therefore, a minor (or modulatory) role for TcdC in the regulation of  toxin 
expression was proposed (18,19).
Here, we sought to clarify the role of  TcdC in regulation of  the toxin production 
by generating an isogenic tcdC mutant (CT::tcdC) using the ClosTron technology. 
We find only minor differences in transcription levels of  the PaLoc genes between 
the wild type and CT::tcdC strains and the expressed total toxin levels did not 
significantly differ, suggesting that the role of  TcdC in toxin regulation is not of  
significance under the conditions tested in C. difficile strain 630∆erm.
Material & Methods
Bacterial strains and growth conditions
The Clostridium difficile and Escherichia coli (E. coli) strains and plasmids used in this 
study are described in Table 1. E. coli strains were grown in Luria Bertani (LB, USB 
cooperation) medium supplemented with appropriate antibiotics when required. 
C. difficile strains were grown anaerobically in a microaerobic cabinet (Don Whitley 
DG 250) at 37 ºC in pre-reduced 3% Bacto Tryptose (Difco), 2% Yeast extract 
(Difco) and 0.1% thioglycolate (pH 7.4) medium (TY) or Brain Heart Infusion 
broth (Oxoid) supplemented with 0.5% yeast extract and 0.01% L-cysteine (Sigma) 
(BHIS) (40,41). When required, the broths were supplemented with appropriated 
antibiotics. For RNA extraction and toxin quantification, C. difficile 630∆erm (wild 
type) and two independent isogenic tcdC mutant strains (CT::tcdC) were serially 
diluted and pre-cultured (overnight) in pre-reduced TY broth. Mid-logarithmic 
growth phase pre-cultures (OD600 0.4-0.8) were used to inoculate pre-reduced TY 
broth to a starting OD600 of  0.05 (± 0.01). Optical density readings and samples for 
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total toxin quantification were taken hourly in the exponential growth phase (until 
8 hours post inoculation) and at 12, 24 and 48 hours post inoculation. Samples 
for RNA extraction were taken at 6, 8, 12, and 24 hours post inoculation. Samples 
for Western blot detection of  TcdC were taken at 8 hours post inoculation. We 
routinely monitored the purity of  the C. difficile cultures by culturing on appropriate 
agar plates and performed control PCRs to ensure that the insertional disruption 
of  the tcdC gene had remained intact during our experiments. All experiments were 
performed six times.
Table 1: Strains and plasmids used in this study.
Generation of  tcdC mutant strains
We generated two independent isogenic tcdC mutants by insertional inactivation of  
the tcdC gene in the wild type strain 630∆erm using ClosTron technology (24,25). 
Briefly, the Perutka algorithm on the ClosTron website (http://www.clostron.
com) was used to design primers (Table 2) for retargeting the Group II intron 
(Sigma; Targetron). The retargeted intron was cloned using the restriction enzymes 
BsrGI and HindIII into plasmids pMTL007C-E2 and the constructs were verified 
by sequencing (25). The verified plasmid (pDB001) was transformed to E. coli 
CA434 and transferred to the wild type strain 630∆erm via conjugation (34,41). The 
selection of  C. difficile transconjugants was done by subculturing on pre-reduced 
BHIS agar supplemented with thiamphenicol (Sigma; 10μg/mL) and C. difficile 
selective supplement (Oxoid). This was followed by several rounds of  subculturing 
on pre-reduced BHIS agar supplemented with lincomycin (Sigma; 20 μg/mL) and 
C. difficile selective supplement to promote integration of  the GroupII intron into 
the gene of  interest. Chromosomal DNA isolated from the transconjugants using 
Strains Description Origin
Escheria coli
DH5α ErythromycinS, LincomycinS Laboratory stock
CA434 ErythromycinS, LincomycinS, KanamycinR, plasmid R702 (41)
Clostridium difficile
630∆erm (wt) Erythromycins, LincomycinS (34)
Leeds_035 RT 035, tcdC negative, PaLoc negative (44)
CT::tcdC1 630∆erm∆tcdC623as , ErythromycinR, LincomycinR This study
CT::tcdC2 630∆erm∆tcdC623as , ErythromycinR, LincomycinR This study
Plasmids
pMTL007C-E2 ThiamphenicolR, ErythromycinS (25)




a QIAamp blood kit (Qiagen) was used in conventional PCRs and sequence runs to 
confirm the disruption of  tcdC and the nucleotide position of  the insertion in the 
tcdC gene. Primers used for cloning and sequencing are listed in Table 2.
Complementation can be a valuable control for knockout studies. However, 
as our tcdC mutant strains have no clearly detectable phenotype regarding toxin 
production, complemented mutant strains are expected to be comparable to wild 
type and tcdC mutant strains, as also reported recently in an independent study (38). 
Therefore, a complementation study would not add to the message this manuscript.
Southern blots
Southern blot analysis was performed to verify a specific single integration into the 
genome. Genomic DNA was extracted using a Phenol-chloroform extraction (42). 
Four µg of  genomic DNA was digested with EcoRV enzyme and separated on a 
0.8% agarose/0.5xTris-acetate-EDTA gel by electrophoresis. DNA was transferred 
onto a Hybond N+ filter (Amersham) in 10x saline sodium citrate (SSC) solution. 
The filter was washed in 2X SSC and baked at 80°C for 2 hours. Prehybridization 
of  the filter was done for 2 hrs at 60°C in 5x SCC, 5x Denhart and 100 mg/mL 
of  yeast tRNA. Probes specific for the group II intron (EBS2-tcdC623as/Sal-R1), 
ermB gene (oWKS1131/oWKS1132) and tcdC gene (tcdC5-tcdC6) were generated. 
Primers are listed in Table 2. The generated probes (100 ng) were radiolabeled (32P 
dATP) using Klenow enzyme (Roche) and overnight hybridized in 10 mL fresh 
pre-hybridization buffer at 60°C. The filter was washed for 30 min in 2x SCC, 0.5% 
SDS, 30 min in 1X SSC, 0.5% SDS and 30 min in 0.5X SSC, 0.5% SDS and analyzed 
using phosphorimage screen and a Typhoon 9410 scanner (GE healthcare).
Western blots
Antibodies against TcdC were generated by immunizing rabbits with a synthetic 
peptide (CQLARTPDDYKYKKV) representing a specific TcdC epitope 
(Genscript). Note that this epitope is located before the Clostron insertion site, 
and would therefore also be expected to detect truncated TcdC protein, would 
this be produced. Western blots were performed as follows. C. difficile (2 mL) 
cultures were harvested by centrifugation (2 min, 11.000 xg, 4ºC) and washed 
with Phosphate Buffered Saline (PBS). The bacterial pellets were resuspended 
in PBS containing protease inhibitor cocktail (Complete, Roche) and lysed by 
sonification. The bacterial lysates were centrifuged at low speed (3 min, 1000xg, 
4ºC) to remove unbroken bacterial cells (20). To separate the cytosolic proteins 
from the membrane associated proteins the bacterial supernatant was centrifuged 
at 200.000 xg, 4ºC for 1 hr (20). The pelleted membrane associated proteins were 
resuspended in 10 mM Tris-HCl (pH 7.4), 5 mM EDTA with 2% Triton X-100 
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Table 2. Primers and probes used in this study.















tcdC1 Control PCR/ATGTTTTCTAAAAAAAATGAT This study
tcdC2 Control PCR/TTAATTAATTTTCTCTACAGCT This study
tcdR Forward Multiplex 1/ATAATGATGCCCACAAGATGATTTAG This study
tcdR Reverse Multiplex 1/AAAGAAGTGATCTATATCATCAGT-
TAC
This study
tcdR probe Multiplex 1/TEX-TATGACCTGAACCACCTTCCAT-
TCTCC-BHQ-2
This study
tcdB forward Multiplex 1/ATAATGATGCCCACAAGATGATTTAG This study
tcdB Reverse Multiplex 1/AAAGAAGTGATCTATATCATCAGT-
TAC
This study
tcdB probe Multiplex 1/TEX-TATGACCTGAACCACCTTCCAT-
TCTCC-BHQ-2
This study
tcdE Forward Multiplex 2/ATTTGATACATTATTAGGATGTT-
TAAG
This study
tcdE Reverse Multiplex 2/AAATATACATGCTATCATTGCTAC This study
tcdE probe Multiplex 2/FAM-TGATTCCTCCATCTATTC-
CAAAACTAGAA-BHQ-1
This study
tcdA forward Multiplex 1/AATTCCAATACAAGCCCTGTAG This study
tcdA Reverse Multiplex 1/TATCAGCCCATTGTTTTATGTATTC This study
tcdA probe Multiplex 1/FAM-ATCACTGACTTCTCCACCTATC-
CATACAA-BHQ-1
This study




tcdC probe Multiplex 1/YAK-TGCACCTCATCACCATCTTCAA-
TAACTTG-BHQ1
This study
rspJ Forward GATCACAAGTTTCAGGACCTG This study
rspJ Reverse GTCTTAGGTGTTGGATTAGC This study
tcdC5 CATATCCTTTCTTCTCCTCTTC This study
tcdC6 AATTGTCTGATGCTGAACC This study 
oWKS-1131 AAAGCGATGCCGAGAATCTG This study





for 30 min at room temperature. Equal amounts of  the resuspended membrane 
associated proteins were separated on 15% SDS PAGE gel and transferred onto 
polyvinyl difluoride (PVDF) membranes. Similarly generated membranes with the 
transferred membrane associated proteins of  a RT 035 (PaLoc negative) strain 
were used for pre incubation of  the TcdC antibodies. The membranes were probed 
with the pre incubated TcdC antibody and an antibody against the β subunit of  
the E. coli F0F1 ATPase that cross reacts with the homologous protein in C. difficile 
(20,43). The probed membranes were analyzed using secondary anti-mouse horse 
radish peroxidase conjugated antibodies (Dako), a chemiluminescence detection 
kit (Amersham) and a Typhoon 9410 scanner (GE healthcare).
RNA extraction
Five mL of  the C. difficile cultures were 1:1 diluted with ice cold methanol and stored 
overnight at -80°C. Bacterial pellets, obtained by centrifugation (20 min, 3000 x g, 
4°C), were resuspended into 200 μL lysisbuffer (100 mM EDTA, 200 mM Tris-
HCl pH 7.0, 50 mg/mL lysozyme) and incubated for 1 hr at 37°C. Tri-pure reagent 
(Roche) was used for the extraction of  RNA according to the manufacturer’s 
instruction with minor modifications. Briefly, 1 mL Tri-pure was added to the lysed 
bacterial pellets and incubated for 5 min at room temperature. Per 1 mL Tri-pure, 
200 μL chloroform was added and carefully shaken by hand for 3 min, followed by 
an incubation of  2-5 min at room temperature. The aqueous phase was collected 
after centrifugation (12,000 x g for 15 min at 4°C) and transferred to a fresh tube. 
RNA was precipitated by mixing the aqueous phase with 500 μL isopropanol, 
followed by an incubation of  10 min at room temperature. The precipitated RNA 
was collected by centrifugation (12,000 x g, 10 min, 4°C) and resuspended in 100 
μL DNase/RNase free water. The RNA was re-precipitated overnight at -80°C 
with ammonium acetate (Fluka; 10 mM) and 3 volumes of  absolute ethanol. The 
re-precipitated RNA was washed once with 80% ethanol and dissolved in 50 
μL DNase/RNase free water. The RNA was treated twice with a TurboDNase 
(Ambion) according to the manufacturer’s instruction followed by another Tri-
pure RNA isolation. The quality and purity of  the extracted RNA was assessed 
using a RNA nano chip on an Agilent Bioanalyzer.
Transcriptional analysis of  the PaLoc genes
A RevertAid™ H Minus Reverse Transcriptase kit (Fermentas) was used to 
synthesize cDNA according to the manufacturer’s instruction. Random hexamers 
were used to convert 750 ng RNA into cDNA. The synthesized cDNA was 
treated with RNase (Qiagen) for 1 hour at 37°C and stored at -20°C. The software 
program Molecular Beacon (Premier Biosoft) was used to design primer pairs 
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and probes (Table 2) for the 2 multiplex quantitative PCRs (qPCR), based on the 
available genome of  C. difficile strain 630 (35). All primer pairs were first tested 
by conventional PCR and multiplex PCR to confirm specificity and amplicon 
sizes. The primer pair and the probe for the amplification of  the tcdC gene are 
in front of  the insertion site in the tcdC gene (Figure 1A), allowing detection of  
tcdC transcription levels in wild type and CT::tcdC strains. The real-time multiplex 
qPCR amplification of  the PaLoc genes and the reference gene encoding for a 
ribosomal protein (rpsJ) was performed on a CFX96 real-time PCR detection 
system (Biorad) (31). The amplification efficiencies of  the PaLoc and reference 
genes were determined using serially diluted genomic DNA (standard curve). The 
manually calculated efficiencies and the reference gene rpsJ were used to normalize 
the expression levels of  the PaLoc genes. The amplification was performed in a 25 
μL final volume. The first real-time multiplex qPCR (target genes: tcdA, tcdA and 
tcdC) contained 25 μL Hotstar mastermix (Qiagen), forward and reverse primers 
(80 nm each primer), 2.5 mM MgCl2, 100 nM of  each probe and 2 μL synthesized 
cDNA. The second multiplex real-time multiplex Q-PCR (target genes: tcdR, tcdE) 
contained 25 μL Hotstar mastermix (Qiagen), forward and reverse primers (80 nm 
each primer), 3.5 mM MgCl2, 100 nM of  each probe and 2 μL synthesized cDNA. 
The real-time qPCR to quantify the reference gene rpsJ contained 25 μL Hotstar 
mastermix (Qiagen), forward and reverse primers (80 nm each primer), 2.5 mM 
MgCl2, 0.06% SYBRgreen (Sigma) and 2 μL synthesized cDNA. The real-time 
qPCR protocol included an enzyme activation step for 15 min at 95°C, followed by 
50 cycles of  amplification; 95°C for 30 sec, 52°C for 30 sec and 72°C for 30 sec.
Relative quantification of  toxin expression
Total toxin amounts were quantified using 2 assays; a toxin end point titer assay 
and a commercial available ELISA (Ridascreen, Biopharma). The supernatants of  
culture samples (1 mL) were collected after centrifugation (30 min, 3000 xg, 4ºC), 
filter sterilized (0.45 μM cellulose acetate membrane) and stored at 4°C.
For the toxin end point titer assay, Vero cells were seeded into a 96 wells plate at 
a density of  1x 104 cells per well and incubated overnight at 37°C and 5% CO2. The 
filter sterilized supernatants of  5, 8, 12, 24 and 48 hours post inoculation (hpi) were 
diluted 2, 101, 102, 103, 104 and 105 fold in cell culture medium (Dulbecco modified 
Eagle medium (Lonza) supplemented with penicillin 100 u/mL, streptomycin 100 
U/mL, fetal calf  serum(10%). Fifty μL of  the dilutions were added onto the Vero 
cell monolayers and incubated for 1 hr at 37ºC and 5% CO2. For the neutralization 
assay a 2-fold dilution of  each tested time point (5, 8, 12, 24 and 48 hpi) was pre-
incubated with a 1/100 diluted anti-toxin (Techlab) for 1 hr at 37°C and 5% CO2. 




incubated bacterial supernatants were aspirated off  after one hour and replaced 
with 100 μL cell culture medium. After 24 hrs of  incubation the end-point titer 
was determined of  each diluted time point (26). The end-point titer was defined 
as the first dilution at which the Vero Cell morphology was indistinguishable 
from the neutralized 2-fold diluted supernatants (26). The enzyme immunoassay 
(Ridascreen, Biopharma) was performed according manufacture’s protocol.
Statistical analysis
Statistical analysis was performed using the software package SPSS 18 (IBM). An 
independent sample t-test was employed to compare the strains at different time 
points. 
Results
The importance of  TcdC for regulation of  toxin expression was recently challenged 
by two studies (18,19). It was proposed, based on the increasing transcription levels 
of  the PaLoc genes in time and the variability in toxin expression levels among 
virulent strains, that TcdC has a minor or modulatory role on toxin expression 
rather than a major role as previously assumed. In this study we sought to clarify 
the role of  TcdC for toxin expression by generating an isogenic tcdC mutant. As 
toxin gene expression is subject to complex regulation influenced by glucose and 
cysteine, we performed our experiments in a trypton-yeast (TY) based broth (17,23). 
TY broth does not contain glucose and no cysteine was added. We verified that in 
TY broth earlier and higher expression of  toxins was achieved in comparison to 
the commonly used Brain Heart Infusion (BHI) broth (data not shown).
Generation and characterization of  a TcdC mutant
TcdC consists of  three domains: a hydrophobic domain, a proposed dimerization 
domain and a proposed C-terminal repressor domain (Figure 1A) (12). We 
successfully disrupted the tcdC gene in the region coding for the repressor domain 
using ClosTron technology. Disruption of  genes using the ClosTron technology 
results in stable mutants and no or non-functional proteins (24–26). The genotype 
of  the disruption was confirmed with conventional PCRs using the tcdC2 primer 
and the EBS universal primer and with primer pairs (tcdC1 and tcdC2) flanking the 
ClosTron insertion site (Figure B). Sequence analysis confirmed that the disruption 
was in the proposed repressor domain of  the tcdC gene at the expected site (data not 
shown). In addition, Southern blot analysis using intron-, ermB and tcdC- specific 
probes clearly confirmed a specific single insertion of  the Group II intron in the 
genome (Figure 1C).
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Figure 1: Characterization of  the C. difficile tcdC mutant. (A) Schematic representation of  
3 different domains of  TcdC and the intron insertion site for the inactivation of  TcdC. 
The arrows in the putative repressor domain represent the locations and orientation 
of  the primers used in the RT-q-PCR and conventional control PCRs. (B and C) PCR 
confirmation of  the wild type strain and the CT::tcdC mutant. The primer EBS universal 
and tcdC2 generated a PCR product of  302 bp for the CT::tcdC strains. Primers tcdC1 and 
tcdC2 generated a 699 bp PCR product for the wild type and for the CT::tcdC strain a PCR 
product of  circa 2800 bp. (D) Southern blot analysis of  EcoRV digested genomic DNA of  
wild type and CT::tcdC strains with a Group II intron, ermB gene and tcdC specific probes. 
Note that probing with the ermB probe results in 2 bands for the CT::tcdC strains, since wild 
type already carries a copy of  the ermB gene in the genome (35). (E) Western blot analysis 
of  TcdC production in wild type and CT::tcdC strain 8 hours post inoculation. The arrow 
indicates the location of  TcdC protein based on MW and absence of  the protein in the 
PaLoc negative Type 035 strain. Note that cross-reaction of  TcdC antibody with a protein 
of  similar MW was also observed in Carter et al. (30). (F) Growth curves of  C. difficile 
630∆erm and C. difficile CT::tcdC mutant strains. The absorbance (OD600) was measured over 
48 hrs of  growth in TY medium. The error bars indicate the standard error of  the mean 




Western blot analysis, using antibodies against TcdC, confirmed that the 
isogenic tcdC mutant no longer expressed TcdC (Figure 1D). A control blot using 
antibodies against F0F1, indicated that the lack of  signal in the TcdC Western blot 
was not a results of  lower amounts of  proteins loaded in the lanes of  RT 035 (a 
PaLoc negative strain) and the tcdC mutant.
The growth kinetics of  the wild type and CT::tcdC strains showed no significant 
differences in various media tested (Figure 1E and data not shown). In TY broth, 
which does not contain glucose or added cysteine, the wild type strain and the 
CT::tcdC strains showed an exponential growth phase in the first 8 hours post 
inoculation and after 12 hours post inoculation both strains entered into the 
stationary growth phase (Figure 1E). Conventional control PCRs confirmed that 
the disruption of  the tcdC gene had remained intact during our growth curves 
experiments (data not shown).
Comparable relative transcription levels of  PaLoc genes in wild type and 
CT::tcdC
In order to determine the influence of  TcdC on the transcription levels of  the 
PaLoc genes we compared the relative transcription levels of  the PaLoc genes of  
wild type and CT::tcdC strains by reverse transcriptase quantitative real-time PCR 
(RT-qPCR). We found comparable transcription levels of  all PaLoc genes in wild 
type and CT::tcdC strains. 
Overall, the logarithmic growth phase was associated with lower transcription 
levels of  the PaLoc genes and by entering into the stationary phase increasing 
transcription levels of  PaLoc genes were found, as previously described for tcdR, 
tcdE, tcdB and tcdA (16,18,19) and tcdC (18,19) (Figure 2). The transcription levels of  
tcdR in wild type and CT::tcdC strains increased approximately 100-fold between 6 
and 24 hours post inoculation (Figure 2A). Though the expression of  tcdR was, on 
average, 3-fold higher at the various time points in the CT::tcdC strains compared 
to the wild type, this difference was not statistically significant (Figure 2A, all p 
values ≥ 0.088). Similarly, we observed a 10- to 100-fold increase in the transcription 
levels of  tcdB (Figure 2B), tcdE (Figure 2C), tcdA (Figure 2D) and tcdC (Figure 2E) 
when comparing values from the logarithmic growth phase with those observed 
in the stationary growth phase. The expression levels of  tcdB, tcdE, tcdA and tcdC 
were, on average, 1.5-fold, 2.5-fold, 1.4-fold and 1.7-fold higher, respectively, in the 
CT::tcdC strains compared to the wild type. With one exception, these differences 
were not found to be significant. The type level at 8 hours post inoculation (Figure 
2D). However, no significant differences are found between the wild type and 
CT::tcdC strains at any of  the other time points. transcription level of  tcdB in the 
CT::tcdC1 strain is significantly (P=0.046) higher compared to wild Therefore, we 
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Figure 2: The relative PaLoc 
gene expression profiles of  
wild type and CT::tcdC in 
time. The error bars indicate 
the standard error of  the 
mean (n=6). The asterisk (*) 
indicate a significant difference 
between wild type and CT::tcdC 
strain. Values are normalized 
to rpsJ expression. Wild type 
corresponds to black bars, 
CT::tcdC1 mutant strains to 
gray bars, CT::tcdC2 to the 
white bars. 
(A) The relative expression of  
tcdR. 
(B) The relative expression of  
tcdB. 
(C) The relative expression of  
tcdE (
D) The relative expression of  
tcdA. 




Figure 2: The relative PaLoc gene expression profiles of wild 
type and CT::tcdC in time. The error bars indicate the standard 
error of the mean (n=6). The asterisk (*) indicate a significant 
difference between wild type and CT::tcdC strain. Values are 
normalized to rpsJ expression. Wild type corresponds to black 
bars, CT::tcdC1 mutant strains to gray bars, CT::tcdC2 to the 
white bars. (A) The relative expr ssion of tcdR. (B) The relative 
expression of tcdB. (C) The relative expression of tcdE (D) The 
relative expression of tcdA. (E) The relative expression of tcdC. 
 
 
titer (Figur  3A) (26). In the exponential growth phase (5 
and 8 hours post inoculation) no cytotoxic effects were 
detectable (data not shown). In the stationary growth 
phase (12, 24 and 48 hours post inoculation) we 
observed increasing cytotoxic effects, indicative of the 
presence of toxin. Importantly, the observed cytotoxic 
effects were specific for C. difficile Toxin A and B, as a 
pre-incubation of the filter sterilized bacterial 
supernatants with anti-toxin, a polyclonal antibody 
against Toxin A and Toxin B (Techlab), resulted in 
complete neutralization of cytotoxic effects on the Vero 
cells at all time points (data not shown). The tcdC mutant 
strains showed no significant differences in toxin levels 
compared to the wild type strain (Figure3A). Next, we 
used an enzyme immunoassay (Ridascreen, Biopharma) 
for the direct detection and relative quantification of the 
secreted toxins. In the exponential growth phase (5 and 
8 hours post inoculation) no toxins were detectable 
(data not shown), consistent with the lack of toxicity 
Towards Vero cells described above. In the stationary 
growth phase (12, 24 and 48 hours post inoculation) increasing toxin levels were detectable. When we 
compared the toxin levels at various time points, there were equal amounts of toxins in the wild type and tcdC 
mutant strains. We conclude that the disruption of the tcdC gene does not result in consistently and 








Figure 3. The toxin production profiles of  wild type and CT::tcdC mutant strains in time. 
Wild type corresponds to black bars, CT::tcdC1 mutant strains to gray bars, CT::tcdC2 to the 
white bars. Total toxin amounts were quantified by using two independent assays. (A) The 
supernatants were incubated in a ten fold dilutions series on Vero cell monolayers. After 24 
hrs the cytotoxic effects were quantified by determing the toxin end point titer. Values are 
given as means (n=6). (B) An enzyme immunoassay was used for direct quantification of  
the secreted toxins according manufacters protocol. The supernatants of  12 and 24 hours 
post inoculation were 10 times diluted. The supernatants of  48 hours post inoculation were 
diluted 10 and 100 times. Values are given as means ± standard error of  the mean (n=6). 
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conclude that the disruption of  the tcdC gene does not result in a consistently and 
significantly increased transcription level of  the PaLoc genes.
Comparable toxin expression in wild type and CT::tcdC
Considering the small increase in PaLoc gene expression in the CT::tcdC 
mutants observed in the RT-qPCR experiments, we were interested to see if  this 
difference translated into higher toxin levels. We determined toxin levels using 
two independent assays, but found no consistent difference between wild type 
and mutant cells. First, filter sterilized bacterial supernatants were incubated on 
a Vero cell (a kind gift of  Dr. E.J. Snijder (27)) monolayer and cytotoxic effects 
were quantified after 24 hours by determining the end-point titer (Figure 3A) (26). 
In the exponential growth phase (5 and 8 hours post inoculation) no cytotoxic 
effects were detectable (data not shown). In the stationary growth phase (12, 24 
and 48 hours post inoculation) we observed increasing cytotoxic effects, indicative 
of  the presence of  toxin. Importantly, the observed cytotoxic effects were specific 
for C. difficile Toxin A and B, as a pre-incubation of  the filter sterilized bacterial 
supernatants with anti-toxin, a polyclonal antibody against Toxin A and Toxin B 
(Techlab), resulted in complete neutralization of  cytotoxic effects on the Vero cells 
at all time points (data not shown). The tcdC mutant strains showed no significant 
differences in toxin levels compared to the wild type strain (Figure3A). Next, we 
used an enzyme immunoassay (Ridascreen, Biopharma) for the direct detection 
and relative quantification of  the secreted toxins. In the exponential growth phase 
(5 and 8 hours post inoculation) no toxins were detectable (data not shown), 
consistent with the lack of  toxicity
Towards Vero cells described above. In the stationary growth phase (12, 24 
and 48 hours post inoculation) increasing toxin levels were detectable. When we 
compared the toxin levels at various time points, there were equal amounts of  
toxins in the wild type and tcdC mutant strains. We conclude that the disruption of  
the tcdC gene does not result in consistently and significantly increased toxin levels.
Discussion
C. difficile infections caused by the (hyper-)virulent RT 027 (NAP1/REA B1) and 
RT 078 (NAP7/REA BK) are associated with an increased morbidity and severity 
of  disease compared to other types (1,3). This increase is suggested to be linked to 
toxin hyper production (3,22,28). A potential mechanism by which this could occur 
is through inactivation of  a negative regulator of  the toxin gene transcription. TcdC 




In the currently prevailing model, a major role for TcdC in the repression of  
toxin genes has been proposed on the basis of  three lines of  evidence. First, in C. 
difficile VPI10463 (a high toxin producing strain that also expresses high levels of  
TcdC (18,29)), an inverse correlation between the transcription of  tcdC and the 
genes encoding the toxins is found (16,18,29). This correlation for TcdC is also 
observed in protein levels (20). Second, elegant in vitro experiments have established 
that heterologously produced and purified TcdC protein can interfere with TcdR-
mediated transcription of  toxin genes in a way that is not yet fully understood (12). 
Finally, a frame shift mutation (∆117 bp) in tcdC, that results in a non-functional 
protein, is associated with increased toxin production in certain (hyper)virulent 
strains (15,22).
Recently, it was reported that the introduction of  a functional tcdC gene from 
a high toxin-producing strain that lacks any of  the hyper virulence associated tcdC 
mutations (VPI10463, RT 087) into an epidemic strain carrying a non-functional 
tcdC (M7404, RT 027/NAP1/REA B1) can reduce toxin expression levels and 
moderately attenuate virulence (30). This data seems consistent with the model 
discussed above. However, it is unclear how the levels of  TcdC in the complemented 
strain relate to the physiological levels of  the protein prior to the inactivation of  
TcdC in this strain background. The introduced tcdC gene, including its transcription 
signals, was derived from a different genetic background (VPI10463, RT 087) and 
was introduced on a multicopy plasmid. In addition, the reintroduction of  TcdC 
in a strain lacking a functional TcdC, may affect processes that are not normally 
affected. Finally, the experiments were not corrected for the additional copies of  
the tcdC promoter that could result in the titration of  regulators binding to those 
sequences.
In an alternative approach that addresses many of  the issues above, the role of  
tcdC in toxin expression could be addressed by removing it from a background in 
which it is normally functional. To this end, we generated an isogenic ClosTron-
based tcdC mutant strain that could be directly compared to its wild type counterpart, 
in which the TcdC protein was expected to be functional. Our data obtained with 
these mutant strains show that TcdC does not exert a major or even significant 
effect on the transcription of  the PaLoc genes or the expression levels of  the 
toxins under the conditions tested.
Our experiments were performed in a glucose free TY broth medium, since 
glucose is a known repressor of  toxin production (17). Indeed, we observed earlier 
and higher levels of  toxin production in TY broth than in the commonly used 
Brain-Heat-Infusion broth (BHIS) based media, that does contain low amounts of  
glucose (0.2%) and to which frequently cysteine is added. However, also in BHIS 
we did not observe a significant effect of  a tcdC deletion on toxin expression (data 
not shown). 
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We controlled critical parameters in our experiments by performing conventional 
PCRs which confirmed that the disruption of  tcdC remained intact throughout the 
growth curve. Western blot analysis with antibodies raised against a TcdC epitope 
confirmed that the disruption of  the tcdC gene resulted in the absence of  TcdC 
protein (Figure 1D). The disruption of  the tcdC gene did not affect the growth 
kinetics compared to the wild type strain (Figure 1E). 
In the RT-qPCR experiments, sample to sample variation was corrected 
by normalizing to the reference gene rpsJ (31). The rpsJ gene was selected for 
normalization, since rpsJ was overall the highest ranked reference gene regarding 
gene expression stability (31).Reverse transcription was carried out using random 
hexamers, to prevent gene specific biases (32). PCR efficiency in the qPCR was 
determined using a standard curve for each gene, enabling post run correction 
(33). To obtain objective data concerning the quantification of  the secreted toxins, 
we used an end point titer assay and an enzyme immunoassay rather than a manual 
(subjective) cell scoring system (26).
The trends observed in the transcription of  the PaLoc genes and the expression 
of  the toxins generally conform to previously reported data (18,19). It should 
be noted that the up-regulation in time of  tcdC transcription was not observed 
in earlier studies on C. difficile VPI10463 (16) but is consistent with more recent 
reports (18,19). We observed an increase in transcription of  the PaLoc genes in 
time, and a concomitant increase in toxicity of  culture supernatant in stationary 
phase that can be attributed to the toxins as it is fully neutralized by anti-toxin 
against Toxin A and B.
The disruption of  the tcdC gene resulted in an on average 1.7 fold higher 
transcription level of tcdC in time compared to the wild type strain, although this 
difference was not found to be statistically significant. It should be noted that 
we detect these differences because the real time PCR probe detects a region of  
the gene upstream of  the ClosTron insertion site (Figure 1A). This finding might 
indicate some kind of  feedback mechanism on TcdC expression. Similar to tcdC 
gene expression, the disruption of  tcdC resulted in a slightly higher transcription 
level of  the other PaLoc genes, although this was generally not significant. 
Moreover, the increased transcription level of  the toxin genes did not result in a 
detectable increase in toxin levels as measured with two independent assays. 
 Based on the paradigm that TcdC is a major suppressor of  toxin production 
we expected precocious and significantly elevated transcription levels of  tcdA, tcdB, 
tcdE and tcdR in the CT::tcdC strains compared to wild type. However, our data 
indicate that TcdC exerts a moderate, if  any, effect on the transcriptional levels 





Clostridium difficile strain 630∆erm is a derivative of  the clinical isolate 630 (34,35), 
a RT 012 strain. RT 012 strains constitute 4% of  the clinically isolated toxinogenic 
isolates in Europe (7). Clostridium difficile 630 (RT 012)-derived strains are commonly 
used to investigate virulence of  mutants (26,36,37). 
An independent study, published during the preparation of  this manuscript, 
reached a similar conclusion with respect to the role of  TcdC in toxin regulation 
in C. difficile 630Δerm using an allelic exchange technique (38). In that paper 
reintroduction of  a single functional copy of  tcdC at its native locus did not affect 
toxin production in strain R20291 either (38). R20291 is a strain from problematic 
RT 027 (NAP1/REA B1) that was isolated following an outbreak in Stoke 
Mandeville, UK.
Our work and that of  Cartman and coworkers (38) seem at odds with the 
previous reports that clearly demonstrate that TcdC can act as a repressor for toxin 
gene expression (12,30). However, we cannot exclude the possibility that TcdC 
exerts a more profound effect under specific conditions, or in other strains of  C. 
difficile than 630Δerm and R20291. It should be clear though that in vivo relevance of  
TcdC for toxin regulation in these two strains is limited.
In conclusion, we suggest that TcdC might have a modulatory role in regulating 
toxin expression, and that TcdC functionality is therefore not a major determinant 
of  the virulence of  C. difficile. This is supported by the lack of  correlation between 
virulence, toxin production and tcdC gene variants that was noted by several other 
studies (18,19,30,39).
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Clostridium difficile infections are increasing worldwide due to emergence of  virulent 
strains. Infections can result in diarrhea and potentially fatal pseudomembranous 
colitis. The main virulence factors of  C.difficile are clostridial toxins TcdA and 
TcdB. Transcription of  the toxins is positively regulated by the sigma factor 
TcdR. Negative regulation is believed to occur through TcdC, a proposed anti-
sigma factor. Here, we describe the biochemical properties of  TcdC in order to 
understand the mechanism of  TcdC action.
Bioinformatic analysis of  the TcdC protein sequence predicted the presence 
of  a hydrophobic stretch (amino-acids 30-50), a potential dimerization domain (aa 
90-130) and a C-terminal OB-fold (oligonucleotide-binding).
Gel filtration chromatography of  two truncated recombinant TcdC proteins 
(TcdCΔ1-89 and TcdCΔ1-130), showed that the domain between aa 90 and 130 is 
involved in dimerization.
Binding of  recombinant TcdC to single-stranded DNA was studied using a single-
stranded SELEX approach. This involved specific binding of  ss-DNA sequences 
from a pool of  random oligonucleotides, as monitored by electrophoretic-mobility 
shift assay. Analysis of  the oligonucleotides bound showed that the OB-fold 
domain of  TcdC can bind specifically to DNA folded into G-quadruplex structures 
containing repetitive guanine nucleotides forming a four-stranded structure.
In summary, we provide evidence for DNA binding of  TcdC, which suggests 
an alternative function for this proposed anti-sigma factor.




Clostridium difficile is a spore forming, anaerobic bacterium that can cause antibiotic 
associated diarrheal disease in humans. In the past decade, the incidence, 
complications and mortality of  Clostridium difficile-associated infection (CDI) have 
increased dramatically due to the emergence of  new hypervirulent PCR Ribotypes 
(RT) (1-4). Virulence of  C.difficile has been linked to the production of  two toxin 
molecules, Toxin A and Toxin B, which are encoded within the Pathogenicity Locus 
(PaLoc). These toxins cause intestinal damage and ultimately clinical disease (5). 
Both toxins have the same enzymatic activity. Upon entering intestinal epithelial 
cells they catalyze the transfer of  glucose onto the Rho family of  GTPases, leading 
to reorganization of  the actin cytoskeleton, complete rounding of  cells and 
destruction of  the intestinal barrier function. This causes diarrhea and in some 
cases may lead to a severe inflammatory response and pseudomembranous colitis.
The mechanisms that regulate the levels of  toxin synthesis are slowly being 
unraveled. Toxin genes, tcdA and tcdB, are located on the PaLoc together with two 
regulatory genes tcdR and tcdC, and tcdE, which encodes a holin like protein that may 
facilitate the release of  the toxins into the extracellular environment (6). TcdR has 
been demonstrated to activate gene expression of  both toxins as a specific RNA 
polymerase sigma factor belonging to the subgroup of  extracytoplasmic function 
(ECF) σ70-family of  RNA polymerase sigma factors (7). Members of  this group 
include several σ-factors involved in positive regulation of  potent toxins such as 
botulinum neurotoxin (BotR of  Clostridium botulinum) and tetanus neurotoxin (TetR 
of  Clostridium tetani) (8). Toxin expression is also influenced by the nutritional status 
of  the bacteria; a rapidly metabolizable carbon source such as glucose inhibits 
toxin expression (9). In addition, general regulatory molecules, such as CodY and 
CcpA are known to influence toxin synthesis (10;11). In C.difficile, TcdR not only 
stimulates toxin gene transcription but also activates its own expression suggesting 
a large overshoot in protein expression once activated (7). A negatively acting 
mechanism therefore is required to put a limit on this system during unrestricted 
growth of  C.difficile.
Activation of  bacterial gene expression by specific σ-factors is often subject 
to control by specific antagonists, called anti-sigma factors (12). Generally they 
sequester their cognate σ factor, preventing it from interacting with the RNA 
polymerase. Encoded within the PaLoc is TcdC, which has been postulated to act 
as an anti-sigma factor and negatively regulate toxin production. TcdC transcription 
pattern was reported to be inverse to TcdR and the toxins as it is highly transcribed 
and expressed during the exponential growth phase, while its expression is strongly 




suggested that TcdC interferes with toxin gene expression. However, more recent 
studies have shown that this inverse correlation cannot be confirmed using 
quantitative RT-PCR (14-16). This suggests that TcdC may not be as important in 
toxin regulation as previously thought.
A direct inhibitory effect on transcription of  tcdC has been shown in vitro. 
The TcdR-RNA-polymerase-DNA complex is destabilized by TcdC, preventing 
initiation of  transcription. However, once a stable open complex is formed with 
the promoter no inhibition by TcdC occurs (17). The target of  TcdC in (prevention 
of) complex formation is unclear; no interaction with the TcdR-RNAP-complex 
was found nor does TcdC bind to dsDNA in the promoter, suggesting a potentially 
unique inhibitory mechanism of  TcdC. 
Recent in vivo studies on the importance of  TcdC on toxin expression show 
contradictory results. TcdC complementation of  strain M7404, a toxinogenic strain 
that lacks a functional tcdC gene, results in a reduced amount of  produced toxin 
and an attenuated phenotype in hamsters (18). In contrast, complementation of  
strain R20291, another strain that lacks a functional tcdC gene, with a functional 
tcdC gene did not alter the toxin titers (19). In addition, knockout of  tcdC in strain 
630Δerm did not result in an increased level of  toxins produced, nor did it result in 
increased toxin mRNA production (14). 
Since the suggested anti sigma function of  TcdC is not undisputed and because 
the mechanism by which TcdC is supposed to inhibit TcdR mediated transcription 
is unknown, we aimed to further characterize the biochemical properties of  TcdC. 
Through in silico analyses we found that TcdC contains a predicted single-stranded 
nucleic acid binding fold (OB-fold). In this paper we show for the first time through 
a combination of  in silico analysis and biochemical experiments that TcdC can bind 
to nucleic acids.
Material and Methods
Construction of  plasmids
To construct his10-tagged TcdC expression plasmids, the sequence was amplified 
by PCR from C.difficile strain 630 genomic DNA, using specific primers, see Table 
1. The PCR products were digested with NdeI and XhoI or NdeI and BamHI and 
ligated into pET16b (Novagen) similarly digested with NdeI and XhoI/BamHI. 
This resulted in the construction of  TcdC expression vectors containing a 10-His-
tag at its N-terminus.
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Reverse primer as for Delta1-50 TcdC
Delta1-130 TcdC 
Forward primer, TATGCATATGGGATATGATACTGGTATTAC
Reverse primer as for as for Delta1-50 TcdC
Delta Delta1-89; Delta208-232 TcdC (90-207)
Forward primer as for Delta1-89 TcdC
Reverse primer, TACTGGATCCTTTAAGCACTTATACCTCTTATAG
DNA binding studies
Probes used for band shift assays were obtained from Eurogentec (Maastricht, 
The Netherlands), end labeled with T4-polynucleotide kinase and 32P-γ-ATP and 
purified using Micro Bio-Spin Colums P-30 Tris RNase Free (Biorad) according 
to manufacturer’s instructions. Binding reactions were carried out for 60 minutes 
on ice in 20 ul binding buffer (20 mM Hepes-KOH pH 7.5, 50 mM NaCl, 40 mM 
KCl, 7% glycerol, 1 mM EDTA, 0.1 mM DTT and 0.25 pmol probe (12.5 nM). 
Free DNA and protein-DNA complexes were separated on a 7% polyacrylamide 
gel (37.5:1) run in 0.5xTBE. Dried gels were exposed to a Biorad phosphoimaging 
screen-K and scanned on a Typhoon 9410 from GE Healthcare. The equilibrium 
dissociation constant (Kd) was calculated at half  saturation Kd=Pt-Db (Db=DNA 
bound, 6 nM). The Pt (total protein concentration) was calculated using a deduced 
molecular mass of  18.8 kD for the His10-TcdCΔ1-89 protein.
Single stranded SELEX
The random site used in the first selection round was 5’ 
A G T G C A G T G G A T C C T G T C G - N N N N N N N N N N N N N N -
AGGCGAATTCAGTCCAAGTG 3’, 32P-labelled at the 5’end. Binding reactions 
were as described above with 10 or 100 ng purified TcdC Δ1-89. In the first selection 
round 10 ul of  50% Cobalt2+-beads (Clontech) in binding buffer was added to 
the binding reaction and incubated for 30 min at 4°C under continuous rotation. 
Subsequently the beads were spun down (30 sec. at 100 g) and washed three times 
in 100 ul binding buffer. Bound random oligo was eluted in 20 ul binding buffer 
with 250 mM Imidazol and subsequent heating heating 10 minutes at 95 °°C. Beads 




using 30 PCR cycles with primers, AGTCAGTGCAGTGGATCCTGTCG 
(forward) and CACTTGGACTGAATTCGCCTC (reverse). The resulting 53 
bp PCR product was digested with N.BtsI nicking endonuclease (New England 
Biolabs) and labeled using 32p-γ-ATP. Digested and labeled probe was separated 
on a 12% polyacrylamide gel (19:1). Following exposure of  the wet gel to X-ray 
film (Fujifilm, super RX), the highest band corresponding to the uncleaved top 
stand was cut out and eluted according to the QIAEX II Gel Extraction Kit for 
polyacrylamide Gels (Qiagen). 5 ul of  the extracted probe was used in a next round 
of  selection using bandshift assay. The Protein-DNA complexes were separated 
on a 7% polyacrylamide gel as described above. After exposure to film the bound 
probe (shift) was cut out and eluted for an additional round of  selection.
Quadruplex staining
Specific staining of  quadruplex forming DNA was performed according to Yang et 
al. (20). Briefly, polyacrylamide gels were incubated in 20 uM ETC (C39H47N3O6S4, 
Organica Feinchemie GmbH Wolfen) in phosphate buffer saline (PBS) for 30 
minutes. Rinsed five times with water and then scanned in a Typhoon 9410 ( GE 
Healthcare ), excitation 532 nm and emission 610 nm.
Bioinformatics analysis
For all bioinformatic analyses protein sequence Q189K7 (C.difficile strain 630) was 
used. Predictions of  coiled-coil helices were carried out using the Multicoil Scoring 
Form ((21); http://groups.csail.mit.edu/cb/multicoil/cgi-bin/multicoil.cgi). All 
predictions were performed using standard settings. All sequence alignments were 
performed by use of  Clustal Omega - Multiple Sequence Alignment, available from 
EMBL-EBI European bioinformatics institute (http://www.ebi.ac.uk/Tools/
msa/clustalo/; Sievers et al., Mol Syst Biol. 2011).
Structural models of  the TcdC conserved C-terminal domain were generated 
by the automated I-TASSER (threading, assembly and refinement) simulation 
method; http://zhanglab.ccmb.med.umich.edu/I-TASSER/ (22;23). Predictions 
were done using the standard parameters. As part of  sequence homology 
detection, the protein alignment was analyzed using HHpred at the Max-Planck 
Institute for Developmental Biology (http://toolkit.tuebingen.mpg.de/hhpred; 
(24)). Predictions were done using the following parameters: Selected, database 
pfamA_v26.0; Max. MSA Generation iterations, 0. Other parameters set at default.
Protein purification
E.coli (BL21) lysates (50 mM sodium phosphate buffer, pH 8.0, 5 mM beta-
mercaptoethanol, 0.1% NP40, 300 mM NaCl) containing histidine tagged proteins 
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Figure 1: Domain organization of  Clostridium difficile TcdC. (A). Schematic presentation 
of  TcdC with three predicted domains; Hyd= hydrophobic membrane anchor, 
Dim:dimerization domain and OB fold = conserved C-terminal domain containing a 
predicted oligonucleotide binding fold. Bottom, spatial structure of  the TcdC- C-terminal 
domain (aa 90-232) predicted by the automated simulation method I-TASSER (Roy et 
al., 2010) and represented with a ribbon diagram. N and C indicate amino-terminus and 
carboxy-terminus. (B) Limited proteolysis of  TcdCΔ1-50 and TcdCΔ1-130. Histidine-
tagged proteins were digested with chymotrypsin for 5, 30, 60, or 120 min, and the fragments 
were resolved by SDS-PAGE. Amino-terminal sequences were identified using an Edman 
degradation. Site of  chymotrypsin cleavage (arrow 1) indicated in the primary amino acids 
sequence and TcdC predicted secondary structure elements. H=helix (red box), C=coil 
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were loaded on a 1 mL Ni-NTA column (Qiagen). The column was washed with 20 
mL wash buffer (50 mM sodium phosphate buffer pH 7.0, 300 mM NaCl, 5 mM 
mercaptoethanol, 5% glycerol, 20 mM Imidazol). The His-tagged proteins eluted 
at ~200 mM imidazole when employing a 25 mL linear gradient ranging from 20 to 
250 mM imidazole. Peak fractions containing the His-tagged proteins were pooled 
and 200ul loaded onto a superdex 75 gelfiltration column equilibrated and run in 
50 mM sodium phosphate buffer pH 7.0, 150 mM NaCl, 5 mM mercaptoethanol, 
5% glycerol. Protein concentrations were measured and peak fractions were used 
for DNA binding studies.
Results
In silico analysis of  TcdC 
In many cases sequence similarity allows the inference of  protein function. At 
the primary amino acid sequence level, the C-terminal domain of  TcdC (residues 
130-232, conserved domain, Figure 1A) has sequence identity (conservation) to 
potential/putative protein homologues from both anaerobic and facultative aerobic 
members of  the Firmicutes phylum (Figure 2). Though several TcdC homologues 
have been identified, none of  them have been characterized biochemically in detail 
and therefore do not provide a clue to the TcdC mechanism of  action.
As the primary sequence gave no indication to its function we used computational 
protein structure prediction for detecting remote homologous templates. Structural 
models of  the TcdC conserved C-terminal domain were generated by the automated 
I-TASSER (threading, assembly and refinement) simulation method (22;23). The 
best model (Figure 1A) was predicted to be composed of  a five-stranded closed 
beta-barrel connected by large loops (C-score = -0.9; C-score is a confidence score 
for the predicted model with a C-score score above cutoff  of  − 1.5 is used to select 
models of  correct topology). Matching the best predicted model with proteins 
from the PDB databasesrevealed a nucleic acid binding OB-fold (oligonucleotide 
binding, IPR016027) containing domain in all the 10 top matches/best scoring 
templates (TM = 0.8 – 0.7; TM-score >0.5 indicates a model of  correct match 
topology). The core of  the OB-fold forms a surface to bind to single-stranded 
DNA (ssDNA) or RNA (25;26). Variations in folds, loops and amino-acids in 
the binding interface determine ligand and sequence specificity. Members of  this 
OB-fold group include proteins critical for DNA replication protein (RPA), DNA 
recombination (RuvA), translation (tRNA synthetase anticodon binding protein) 
and telomere-end-binding proteins (hPot-1)(25;26).
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I-TASSER folding of  the region preceding the conserved domain (aa 90-130) 
predicted a large helix (Figure 1A) containing many positive and negatively charged 
amino-acids. Such a helix clearly can form a charged coiled-coil motif  with another 
molecule thereby forming an intertwined dimer as was predicted by Matamouros 
et. al. (17). The coiled-coil prediction was confirmed using the Multicoil Scoring 
Form (21), which calculated a maximum coiled-coil probability of  0.861 of  this 
region (data not shown).
In addition to the protein structure prediction, we used the TcdC conserved 
domain protein alignment (Figure 2) for a highly sensitive profile-based search 
(24;27). Using the TcdC-conserved domain multiple sequence alignment rather 
than a single sequence as a query increases sensitivity and allows for homology 
detection of  protein families. Pairwise comparison of  the TcdC profile with the 
PFAM database resulted in a hit with PF12869, tRNA_anti-like family containing 
the nucleic acid-binding OB fold (E-value 1.3e-6, probability 98.3). In summary, 
these in silico analyses clearly suggest that TcdC forms a dimeric ssDNA binding 
OB-protein fold.
Figure 2: TcdC conserved domain protein alignment with protein homologues from 
members of  the Firmicutes phylum.Numbering top according to alignment; Numbers 




Limited proteolysis suggests a folded structure of  the TcdC conserved 
domain
In order to confirm the predicted domains and borders of  the nucleic acid binding 
OB-fold of  TcdC, we cloned the tcdC gene including 10-histidine codons at 
the N-terminus into a bacterial expression vector. In order to produce soluble 
protein expression in E.coli, the first 50 amino-acids, which contain the reported 
hydrophobic membrane anchor (13) (Figure 1A) were removed. His-10 tagged 
TcdC was overexpressed in E.coli (BL21) and purified using a nickel affinity column.
To investigate the local conformation of  this TcdC protein, we used limited 
proteolytic digestion. Protease resistance is an indication of  structured protein 
sequences, as folded structure is usually protected from proteolytic degradation. 
TcdCΔ1-50 was digested with chymotrypsin, which cleaves after aromatic amino 
acids. Despite the presence of  11 potential cleavage sites (W, Y, F), chymotrypsin 
digestion of  TcdCΔ1-50 led to only one distinct fragment (Figure 1B). To identify 
this fragment, the proteolytic product was subjected to N-terminal sequencing using 
Edman degradation. The identified N-terminal sequence (KMKD) corresponds to 
residue 88 of  TcdC directly adjacent to the large coiled-coil helix. When we tested 
TcdCΔ1-130 (Figure 1B), corresponding to the OB-fold domain, we observe 
hardly any cleavage.
Taken together, these studies provide strong support for a folded structure 
of  the TcdC conserved domain, including the dimerization domain, resistant to 
proteolytic cleavage. 
TcdC contains a dimerization domain
Consistent with the proteolytic protection assay and prediction of  the coiled-
coil dimerisation helix, we constructed an expression vector containing the TcdC 
conserved domain including this putative dimerisation domain (TcdCaa90-232, 
here named TcdCΔ1-89). In addition a construct without the dimerization domain 
(TcdCΔ1-130) was generated. Both proteins were subsequently purified using 
nickel–affinity chromatography and gel-filtration (Figure 3).
Besides extra purity the latter column allows for separation by size and thus 
molecular weight estimation (Figure 4). Indeed the apparent molecular weight 
of  TcdCΔ1-89 of  35 kDa, with a predicted molecular weight of  18 kDa, fits a 
dimeric protein. In contrast, TcdCΔ1-130, with a predicted molecular weight of  
14 kDa and apparent molecular weight of  14 kDa, fits a monomeric protein. This 
confirms that the region between AA 90 – 130 contains a dimerization domain. 
Dimerization was confirmed using a cross linking with glutaraldehyde which can 
form stable intersubunit covalent bonds (Figure 4C). This experiment shows that 
TcdC Δ1-130 forms no visible dimers after crosslinking, while TcdC Δ1-89 forms 
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Figure 3. Cobalt2+ agarose and gel filtration purified His10-TcdC Δ1-50 , Δ1-89 and Δ1-
130.
Figure 4: Gel filtration separation and cross linking of  TcdC deletion mutants show that the 
TcdC dimerization domain is located between AA90-130. (A) Chromatographic separation 
of  purified TcdC proteins on a  superdex 75 column. Arrows indicate the elution points 
(mL) for the proteins. (B) Predicted molecular weight and observed molecular weight on 
the GF column of  the respective deletion mutants. (C) TcdC dimerization as evidenced by 
glutaraldehyde cross-linking. 25 ng of  TcdC was incubated for 30 minutes in the presence 
or absence of  glutaraldehyde. Glutaraldehyde (G.A.) concentrations were 0.006% , 0.003%, 
0.0006% and 0% (from left to right). After incubation, proteins were analyzed by Western 
blot analysis, using His-tag specific monoclonal antibody (Abcam). * indicates the bands 
corresponding to monomeric protein. ** corresponding to the dimer.
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dimers already at low concentration of  glutaraldehyde, thereby confirming the gel-
filtration experiments.
TcdC does not bind to tcdA promoter elements
Based on existing evidence for the TcdC point of  action i.e. destabilizing open 
complex formation before transcription initiation (17), we tested binding to (ss-)
DNA corresponding to the region of  the tcdA promoter that undergoes melting 
during transcription (opening of  the double helix, resulting in exposed ssDNA) 
(28;29). Using protein TcdC Δ1-89 in a mobility shift assay, we tested binding to the 
tcdA double stranded promoter (-32 to +22 relative to transcription start), single 
stranded promoter top strand (non-template), single stranded promoter bottom 
strand (template), open promoter complex (region -10 to -6 or -13 to +4 open) as 
well as the tcdA mRNA gene transcript (+1 to +22) and the DNA-RNA hybrid 
(see Table 2). Surprisingly, we found no DNA binding for any of  these fragments 
(data not shown). Also partially double stranded/single stranded overhang (5’and 
3’) and forked templates of  the promoter (see Table 2) showed no binding. Finally, 
we tested a synthetic Holliday junction (30;31), which can be found at replication 
origins and recombination junctions, but found no binding.
TcdC binding sites selected through Selex 
Because of  our unsuccessful attempt to find the TcdC DNA binding site directly, 
we adapted a single-stranded SELEX (Systematic Evolution of  Ligands by 
EXponential enrichment, (32), a procedure that allows extraction of  oligomers 
with an optimal binding affinity from an initially random pool of  oligonucleotides 
(Figure 5). After site-selection and PCR amplification, single stranded DNA 
is recreated using (asymmetric -) nicking of  the bottom strand of  the amplified 
selected sites followed by denaturation. These sites are subsequently used in 
an additional selection round thereby increasing the specificity of  the selection 
procedure (Figure 6). Initial selection of  his10-TcdCΔ1-89 bound fragments from 
the pool of  ss-oligonucleotides, containing a stretch of  15 random nucleotides 
was performed through Cobalt2+-agarose beads pull down (round 1, Figure 2). 
Two additional selection rounds were carried out using separation of  bound DNA 
fragments on a polyacrylamide gel (round 2 and 3, Figure 6).
During these selection rounds we observed a higher molecular weight product 
(HMW) arise, which is bound and shifted by TcdCΔ1-89 (Figure 6). Each round 
showed a clear enrichment of  the amount of  higher molecular weight product being 
bound and shifted in the presence of  TcdCΔ1-89. After three rounds of  selection 
the enriched sites were cloned and sequenced. Table 3, shows the individual sites 
selected by the TcdCΔ1-89 ssSELEX. Most of  the sequences selected (17/18) 
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Table 2: Primers used to test TcdC ss/ds DNA binding.
tcdA promoter double strand promoter 795576..795629
                                                          -10                      +1 
5’CAAATTACTATCAGACAATCTCCTTATCTAATAGAAGAGTCAATTAACTAATTG 3’
3’GTTTAATGATAGTCTGTTAGAGGAATAGATTATCTTCTCAGTTAATTGATTAAC 5’  
tcdA promoter template strand
5’CAATTAGTTAATTGACTCTTCTATTAGATAAGGAGATTGTCTGATAGTAATTTG 3’
tcdA promoter non-template strand
5’CAAATTACTATCAGACAATCTCCTTATCTAATAGAAGAGTCAATTAACTAATTG 3’
tcdA promoter large open promoter -13 to +4
                                                    CTCCTTATCTAATAGAA 
5’CAAATTACTATCAGACAAT                                             GAGTCAATTAACTAATTG 3’
3’GTTTAATGATAGTCTGTTA                                            CTCAGTTAATTGATTAAC 5’
                                                   CTCCTTATCTAATAGAA  
tcdA promoter small open promoter -10 to -6
                                                              TTAT 
5’CAAATTACTATCAGACAATCTCC           CTAATAGAAGAGTCAATTAACTAATTG 3’
3’GTTTAATGATAGTCTGTTAGAGG         GATTATCTTCTCAGTTAATTGATTAAC 5’
                                                              TTAT 
tcdA promoter 3’overhang
5’CAAATTACTATCAGACAATCTCCTTATCTAATAGAAGAGTCAATTAACTAATTG 3’
3’GTTTAATGATAGTCTGTTAGAGGAATAGATTA            5’  
tcdA promoter 5’overhang
5’CAAATTACTATCAGACAATCTCCTTATCTAATAGAAGAGTCAATTAACTAATTG 3’
3’                                                                                   TCTTCTCAGTTAATTGATTAAC 5’  
tcdA promoter vorked template
                                                                                       TCTTCTCAGTTAATTGATTAAC 3’
5’   CAAATTACTATCAGACAATCTCCTTATCTAAT            
3’GTTTAATGATAGTCTGTTAGAGGAATAGATTA
                                                                                      TCTTCTCAGTTAATTGATTAAC 5’
 
tcdA RNA transcript +1 to +22
5’AGAAGAGUCAAUUAACUAAUUG 3’
tcdA DNA-RNA hybrid 
                                                                                 5’AGAAGAGUCAAUUAACUAAUUG 3’











contain a stretch of  3 Gs (highlighted bold) and 2/3rd of  the selected clones 
contains an A nucleotide preceding this G-stretch. 6 out of  18 clones contain two 
stretches of  3 Gs. Next, we selected two sites obtainedfrom the ssSELEX. One 
clone with a single aGGG consensus site (clone #2, Table 3) and one with a double 
consensus site (clone #5, Table 3) and tested these individually on a polyacrylamide 
gel. As shown in Figure 7A, both clones form the HMW product also observed in 
the ssSELEX, although in different efficiencies (on average ~90% of  #5 formed 
HMW product compared to ~10% of  clone #2). When we tested TcdC binding the 
HMW band was readily shifted, thereby confirming their efficient binding selection. 
In contrast to the HMW product, none of  the ssDNA product was shifted (Figure 
3A). Assuming a simple binding model, gel retardation experiments allow for a 
quick estimate of  the protein equilibrium binding constants (Kd) at half  saturation 
using the formula Kd=Pt-Db (the total protein and DNA concentrations at 50% 
binding). Quantification of  the binding revealed a protein dissociation constant 
of  ~30 nM (Figure 7B). When we assume that TcdC binds as a dimer, the Kd is 
~15 nM. Typically, affinity of  OB-fold proteins range from 1nM to 100 nM (33). 
Upon titration of  TcdC, at least three complexes can be observed, which suggest 
multiple binding sites on the quadruplex structure (Figure 7B), with the first shifted 
complex representing the highest affinity binding site. Alternatively the dimeric 
protein might bind more than one quadruplex structure (each monomer bindings 
separate quadruplexes) thus forming larger complexes.
Figure 5: In vitro selection of  TcdC binding sites (ssSELEX) starting with a random 
ssDNA oligonucleotide library, including generation of  single stranded DNA after PCR 
amplification using a sequence specific nicking endonuclease (Nb.BtsI) that cleaves only 
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Characterization of  the TcdC bound sequences 
To characterize the structure of  the HMW product and demonstrate that the HMW 
complex is the result of  intra- or intermolecular structures, we heated radiolabeled 
clone #5 in the presence of  formamide thereby denaturing DNA duplexes and 
secondary structures. Upon heating, the HMW product shifts to a lower molecular 
weight (Figure 8A), suggesting that the DNA element is a multiplex forming 
secondary structures. The fact that this unusual HMW structure is likely to be a 
multiplex and contains stretches of  GGGs suggested that it could form a so called 
G- quadruplex, a four-stranded helical structure with four guanine bases from 
each strand forming hydrogen-bonds G-tetrads). Three (or more) guanine tetrads 
can stack on top of  each other to form a G-quadruplex. We therefore tested the 
HMW product with ETC (C39H47N3O6S4), an extended aromatic cyanine dye(that 
specifically recognizes stacked G-quadruplexes (20).
Figure 8B shows that ETC specifically stains the HMW product but not duplex 
and single-strand DNA (compare to Figure 8C), confirming that the selected 
element forms a G-quadruplex. To further support the quadruplex structure (QS) 
proposed for the #5 sequence we analyzed the HMW formation with a number 
of  point mutations. We did not observe changes in the quadruplex HMWs when 
Figure 6. Mobility shift assay of  TcdC Δ1-89 selected binding sites. ssDNA selected at 
each round (see ‘Materials and Methods’) were used as probes in gel mobility analysis. The 
selection rounds are indicated. Shifted probes in round 2 and 3 were cut out and eluted as 
indicated and cloned after the last round.
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Figure 7.Binding characteristic of  TcdC Δ1-89. A. Binding to two selected clones (#2 and 
#5 corresponding to Table 3) was tested using 100 ng of  TcdCΔ1-89 in a bandshift assay. 
ssDNA = single stranded; HMW= higher molecular weight product formed; shift indicated 
protein-DNA complex). B. Determination of  the dissociation constant of  TcdCΔ1-89 
for #5 HMW binding. Lanes 1 to 7 of  the inset gel shows increasing concentrations of  
TcdCΔ1-89 3 ng, 6 ng, 12 ng, 25ng, 50 ng and 100 ng. Band shift assays were performed as 
described under material and methods.
Figure 8: Characterization of  a TcdC bound sequence element. (A) Higher molecular 
weight product (HMW) is formed by inter molecular interactions which are lost at 5 min 
95°C in formamide. DNA was 5’end labeled with 32Pγ-phosphate for visualization using 
storage phosphor screen autoradiography (AR). (B) Recognition of  HMW product by 
ETC: a quadruplex specific stain (see ‘Materials and Methods’). (C) Loading control of  gel-
samples loaded in panel B. Each DNA was 5’end labeled with 32P-γ-phosphate see ‘Materials 
and Methods’). (D) Point mutations affecting G-quadruplex formation. G-stretches and 
mutated positions are in bold underlined. Probes were 32P-labelled and separated on a 10% 
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the T9 preceding the G-stretches was replaced with a C (Figure 8D). However 
mutations at positions 12, 15, 18 and 21 of  the #5 sequence resulted in significant 
alteration of  migration on the gel, presumably due to a loss of  QS. Especially when 
guanines involved in a G-tetrad formation, G12 and G15, were substituted with a 
C, the mutations completely abrogated the capacity of  the sequence to fold into a 
G-quadruplex.
Table 3: Selected binding sites for the TcdCΔ1-89 protein in a single stranded SELEX. 
#1                                    TCGGTGTGTTGGGTGAGGGAC
#2                                    TCGGCCTGGATACATAGGGAC 
#3                                    TCGGAATGACTGGCGTGGGAC
#4                                    TCGCGGGTGGCTGGAAGGGAC
#5                                    TCGTTCGATAGGGATAGGGAC 
#6                                        TCGTTGTCTGGTCAGGGGGAC
#7                                          TCGAGCTATAGGTGGGTAGAC
#8                                            TCGGTAGGGGGAGGGAGGGAC
#9                                              TCGACAAAGCATGGGTCCGAC
#10                                              TCGGTCTTTTGGGGTAAGGAC
#11                                                TCGTTTAGGAGGGTCTAGAC
#12                                                  TCGAATATGGGGAAGTAGGAC
#13                                                    TCGATTTGGGGACTGCTGGAC
#14                                                      TCGCGTCAGGAGGTGTTAGAC
#15                                                        TCGCGGAGGGAACGGGTGGAC
#16                                                          TCGTAAAGGGTGATTCTGGAC
#17                                                            TCGGAGGGCCAGGTCGTGAC
#18                                                              TCGAGGGTTACCGTAGGGGAC 
consensus                                                              aGGG                                 
Oligonucleotides sequences obtained are aligned. Stretches of  3G or longer and 
corresponding to the consensus are highlighted in bold. Underlined are the constant 
sequences flanking the randomized 15 nucleotides.
TcdC binds as a dimer
Above we have shown that the dimerization coiled-coil helix forms a proteolytically 
protected structure together with the OB-fold. We were interested to determine if  
dimerization is required for efficient recognition and binding of  the G-quadruplex. 
Therefore electrophoretic mobility shift assay was carried out with TcdCΔ1-130, 
which behaves as a monomer. Figure 9 shows that no binding occurred with purified 
TcdCΔ1-130 indicating requirement of  the TcdC dimerization domain for efficient 
binding. To exclude the possibility that the loss of  binding by TcdCΔ1-130, is 
caused by direct of  binding of  the coiled-coil domain to the quadruplex we tested 
a TcdC protein, which does contain the dimerization helix (aa90-130) but misses 




ssDNA-binding channel (aa208-232). Binding of  this protein, TcdC Δ1-89_Δ208-
232 (Figure 9), to the quadruplex structure was tested and showed no binding 
confirming that the coiled-coil domain is not directly involved in quadruplex 
binding.
Discussion
TcdC has been described to act as a factor responsible for inhibition of  transcription 
of  the toxin genes. Here we describe that the conserved carboxy terminal domain of  
TcdC is predicted to form a coiled five-stranded beta-sheet capped by an alpha helix 
(Figure 1A). This common fold has been described in different proteins which bind 
oligonucleotides or oligosaccharides and thus named OB-fold (oligonucleotide /
oligosaccharide binding) (34). Using ssSELEX, a method to determine the binding 
site of  TcdC, we found that the optimal binding site forms a G-quadruplex.
G-quadruplexes are nucleic acid sequences rich in guanine and capable of  
constituting a four-stranded structure. These four stranded structures are stabilized 
through hydrogen bonds between four guanine bases forming a square planar 
structure called a guanine tetrad (35). Typically three guanine tetrads can stack 
on top of  each other to form a G-quadruplex. Quadruplexes can be formed in 
DNA as well as RNA and can be very diverse as GGG interactions can form 
intramolecularly as well as intermolecular. Intermolecular quadruplexes can be 
arranged from two strands (each containing two GGG stretches) or four strands 
(one GGG stretch each). The spacing (loops) between the GGG-stretches can vary 
between 1-7 nucleotides (36). In silico studies have shown that putative Quadruplex 
structures (pQS) are abundant in prokaryotic as well as eukaryotic gene promoters 
and G-rich telomeres found at the end of  chromosomes (37-40). The presence 
of  QS in human gene promoters has been shown to result in transcriptional 
repression (38). When QS are present in the 5’ untranslated region of  the mRNA 
it can interfere with ribosome binding and translation initiation (41;42).When we 
analyzed the whole C.difficile (strain 630) genome in Quadfinder, an online server 
for prediction of  quadruplex-forming motifs in nucleotide sequences (36), we 
found 5 pQS. Unfortunately none of  these were located in the PaLoc, where TcdC 
is speculated to act. Three pQS are present within open reading frames (CD1092A, 
CD1115 and CD1849) and two in the 3’UTR of  genes (CD0938 and CD2929) in the 
strand that is complementary to mRNA (producing CCC stretches in the mRNA). 
It should be noted that prediction programs can only identify intramolecular QS (4 
GGG stretches on the same strand) not the bimolecular or tetramolecular forms.
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Figure 9: TcdC dimerization domain 
is required for DNA binding. TcdC 
dimer (Δ1-89) or monomer (Δ1-130) 
was incubated with oligo #5. Only the 
TcdC dimer was able to bind to the 
quadruplex DNA, as evidenced by the 
shifted DNA. 
Figure 10: Pairwise comparison between TcdC homologues containing Firmicutes. Two 
examples are shown.Top; comparison between Bacillus cereus ATCC 14579 and Bacillus 
cereus 172560W showing a single insertion of  the TcdC homologue BC0954. Bottom; 
comparison between Oenococcus oeni PSU-1 and Oenococcus oeni ATCC BAA-1163 
showing an insertion of  five genes including the TcdC homologue OEOE_068.
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Telomers contain single stranded repeats of  TAGGG found at the end of  
chromosomes protecting them from exonuclease degradation. Intramolecular QS 
of  these TAGGG repeats play a role in telomere maintenance (43). However, in 
order to efficiently replicate the lagging strand of  these telomeres these QS must be 
disrupted, thereby permitting processive telomere elongation. At least two proteins 
have been reported to bind and unfold these quadruplex structures, human POT1 
and RPA, both characterized by the presence of  an OB-fold (44-47). Despite the 
similarity in protein fold and DNA recognition site between TcdC (aGGG) and 
these OB-fold proteins (TAGGG), we could not find identical DNA contacting 
amino-acids when the TcdC structure was superimposed on the hPOT-1-DNA 
co-crystal (43). Although the circular genomes of  Firmicutes do not contain single-
stranded ends, a role for the OB-fold containing TcdC homologues in destabilizing 
alternative DNA secondary structures could be envisaged.
An alternative mechanism of  TcdC action might be exemplified by the eukaryotic 
RNA polymerase II complex, which includes a subunit (rpb7) with an OB-fold. 
It was speculated that this OB-fold domain, which is located at the RNA exit 
path, binds RNA as it exits the enzyme thereby stabilizing the early transcribing 
complex (48). An opposite effect i.e. destabilizing the initiation complex by an 
OB-fold protein, such as TcdC, could be pictured. An unexpected G-quadruplex 
structure is described in the crystal structure of  a bacterial -10 promoter element, 
5’TGTACAATGGG 3’ (-14 to -4), complexed with sigma factor TaqσA (49). In this 
structure the downstream G-6G-5G-4 do not interact with the protein but twist away 
from the protein-DNA complex and form G-quadruplexes with other (symmetry-
related) GGG motifs. The relevance in this complex was not clear and such a 
GGG-motif  is absent next to the tcdA -10 promoter element.
TcdC is part of  the pathogenicity locus, a well defined genetic element that is 
present at identical locations in the chromosome of  pathogenic C.difficile strains. 
In non-toxinogenic strains, however, it is completely absent. These observations 
have led to the suggestion that the PaLoc may be associated with a (bacteriophage) 
transposable genetic element (50). Examining the genomic location of  TcdC 
homologues of  other Firmicutes showed that several of  these family members 
are located on insertional-elements. For example the TcdC homologue (E-value 
1e-23) of  Oenococussoeni strain PSU-1 (Figure 10) is part of  an insertion containing 
4 additional genes encoding three putative cell-wall proteins and one site specific 
recombinase. In contrast, a TcdC homologue of  Bacillus cereus strain 172560 
(E-value 1e-41) is inserted without any additional genes.
It is interesting to mention that the TcdC variants present in LactoBacillus and 
Leuconostoc are also found in their homologous phages (i.e. LactoBacillus phages A2 
and Lrm1 and Leuconostoc phage phiMH1).In these phages the TcdC homologues 
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are present in the lysis/lysogeny genetic switch operon, located between the CI 
repressor and Int, integrase, suggesting that TcdC is part of  the regulatory decision 
circuit.
Our overall data suggests that C.difficile TcdC forms an OB-fold that binds 
quadruplex structures. However, the in vivo relevance remains unreported. 
Extensive investigations showed no binding to tcdA promoter elements. Clearly, 
quadruplex structures play a role in gene regulation and expression. Unfortunately, 
no multiple G-stretches are found within the PaLoc where TcdC is thought to 
exert its function. It may well be that the single stranded regions of  the quadruplex 
mimics another structure bound by TcdC and the quadruplex is an approximation 
of  the optimal structural binding determinant. It remains to be established in which 
way the capability of  dimeric TcdC to bind G-quadruplexes demonstrated in this 
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In the past decade, Clostridium difficile has emerged as an important gut pathogen. 
Symptoms of  C. difficile infection range from mild diarrhea to pseudomembranous 
colitis. Besides the two main virulence factors Toxin A and B, other virulence factors 
are likely to play a role in the pathogenesis of  the disease. In other Gram positive 
and Gram negative pathogenic bacteria conserved High temperature requirement 
A (HtrA)-like proteases have been shown to have a role in protein homeostasis and 
quality control. This affects the functionality of  virulence factors and the resistance 
of  bacteria to (host-induced) environmental stresses.
We found that the C. difficile 630 genome encodes a single HtrA-like protease 
(CD3284; htrA) and have analyzed its role in vivo and in vitro through the creation of  
an isogenic ClosTron-based mutant of  htrA in C. difficile strain 630Δerm (wild-type). 
In contrast to the attenuated phenotype seen with htrA deletion in other pathogens, 
this mutant showed enhanced virulence in the Golden Syrian hamster model of  
acute C. difficile infection. Micro-array data analysis showed a pleiotropic effect of  
htrA on the transcriptome of  C. difficile, including up-regulation of  the toxin A 
gene. In addition, the htrA mutant showed reduced spore formation and adherence 
to colonic cells. Together, our data show that htrA can modulate virulence in C. 
difficile.




The bacterial pathogen Clostridium difficile is the leading cause of  infectious nosocomial 
diarrhoea (1-3). Clostridium difficile infection (CDI) can cause disease with a wide 
variety of  symptoms, ranging from mild diarrhea to severe pseudomembranous 
colitis (1,4,5). Since 2003, the global prevalence of  reported CDI cases has escalated 
(5-8). In addition, the severity of  the disease and the mortality has increased (1,4,9).
The main virulence factors of  C. difficile are the two large clostridial toxins, 
Toxin A (TcdA) and Toxin B (TcdB) (10-12). These toxins are glycosyltransferases 
that inactivate Rho, Rac and Cdc42, thereby disrupting the cytoskeleton and tight 
junctions of  the colon epithelial cells, resulting in activation of  the inflammasome 
and cellular apoptosis (10,12). A third toxin, binary toxin, is produced by certain 
strains (e.g. PCR ribotype (RT) 027 and 078) that have been associated with 
increased levels of  mortality and morbidity (1,9). It has been suggested that binary 
toxin may contribute to disease in hamsters (13). In vitro assays have demonstrated 
that the binary toxin affects adhesion of  C. difficile to cells through protrusion 
formation of  the target cells (14).
Besides the three toxins, little is known about other virulence factors and their 
role in colonization and establishment of  an infection in the host. Presently, several 
surface proteins have been identified or hypothesized to play a role in colonic 
adhesion. These include the fibronectin-binding protein A (15), S-layer proteins 
(16), Cwp84 (17), flagellar proteins (18) and CD1581 (19).
Alongside colonization factors, adaptation to stresses in the host (including the 
antibacterial response, elevated temperatures, extreme pH and osmotic stress) are 
likely to play a vital role in the establishment of  an infection. These stresses can 
result in the accumulation of  (partially) unfolded proteins that are non-functional 
or form poisonous aggregates (20). The well-conserved family of  bacterial High 
temperature requirement A (HtrA) proteases plays an important role in the protein 
quality control and homoeostasis by combining proteolytic and chaperone activities 
in a variety of  microorganisms (21-23).
HtrA-like proteases are generally composed of  three structurally distinct 
domains: a trypsin-like serine protease domain, one or two PDZ domains and 
a trans-membrane domain or a signal peptide (22-24). The PDZ domain(s) are 
highly flexible domains and are involved in oligomerization, substrate recognition 
and/or the regulation of  protease activity (21,24). Membrane anchored HtrA-like 
proteases are active as trimers and soluble HtrA-like proteases form larger active 
oligomers (21,22).
In this study we describe the identification and characterization of  a C. difficile 




has enhanced virulence in the Golden Syrian hamster model of  acute C. difficile 
infection. This contrasts data reported for other pathogens, in which mutation of  
htrA results in attenuation (25-27). Furthermore, the htrA null mutant displayed a 
pleiotropic effect in a transcriptomic analysis. Several differentially expressed genes 
were validated and are discussed in the context of  C. difficile virulence.
Material & Methods
Bacterial strains and growth conditions
The C. difficile and E. coli strains and plasmids used in this study are listed in Table 
1. E. coli strains were grown in Luria Bertani medium (LB, USB cooperation) 
supplemented with appropriate antibiotics when required. C. difficile strains were 
grown anaerobically in a microaerobic cabinet (Don Whitley DG 250) at 37 ºC 
in pre-reduced TTY medium (30 g/L Bacto Trypton (BD), 20 g/L Yeast extract 
(Difco) and 0.1% thioglycolate pH 7.4) or Brain Heart Infusion broth (Oxoid) 
supplemented with 5 g/L yeast extract and 0.01% L-cysteine (Sigma) (BHIS) (28). 
Logarithmic growth phase bacteria (OD600 0.4 ± 0.08) from overnight pre-cultures 
were used to inoculate pre-reduced TTY broth at a starting OD600 of  0.05 (±0.01). 
Optical density readings were taken hourly until the stationary growth phase (8 
hour post inoculation) and at 24 and 48 hour post inoculation. Cultures of  C. difficile 
strains harboring an expression plasmid were induced with anhydrotetracycline 
(100 ng/mL) at one hour post inoculation. We routinely monitored the purity of  
cultures by performing control PCRs to confirm identity of  mutant strains and 
stability of  conjugated expression plasmids.
Protein purification of  His10-∆(1-30)-HtrA and His10-∆(1-30)-HtrA-S217A
To facilitate purification from Escherichia coli, CD3284 was cloned without the 
N-terminal 30 amino acids into pET-16B, resulting in a fusion protein with an 
N-terminal 10xhis-tag but lacking the predicted transmembrane helix. To generate 
this clone, the CD3284 open reading frame was amplified using primers CD3284F2 
and CD3284R2 using Pfu polymerase (Fermentas) and chromosomal DNA from 
strain 630∆erm (29) as a template. The resulting product was digested with NdeI and 
XhoI and ligated into similarly digested pET-16B (Novagen), yielding pVW001. 
After sequence verification using conventional Sanger sequencing, the plasmid was 
transformed into E. coli C43(DE3), in which expression of  toxic proteins/proteases 
is feasible (30). To induce expression of  His10-∆(1-30)-HtrA, an overnight culture 
grown in LB with 100 µg/mL ampicillin was diluted 1/100 in 500 mL fresh medium 
to an optical density at 600 nm of  0.6 after which 1mM of  IPTG was added for 
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3 hour. Hereafter, cells were harvested by centrifugation (10 minutes 10 rpm 4 
°C) and the protein was purified essentially as described for Spo0A (31), with the 
following modifications: an 0.5 mL TALON Superflow column was used, and the 
stepwise washing/elution was carried out with 8, 4, 4, 4, and 4 column volumes 
(20mM, 50mM, 100mM, 250mM, 500mM, respectively). After the addition of  
glycerol to a final concentration of  8%, protein was quantified by measuring the 
absorption at 280nm on a Nanodrop ND-200 machine (ThermoScientific), using 
an extinction coefficient (ε) of  14440 M-1 cm-1 and a molecular weight of  36.77 
kDa, based on analysis of  the protein sequence using the ProtParam tool (http://
web.expasy.org/protparam/). Protein not used immediately was stored at -80°C. 
To generate a catalytic mutant of  HtrA, we mutated the conserved Ser217 to an 
alanine on the basis of  published mutants of  the E. coli DegS protease. To do 
so, oligo-directed mutagenesis was performed using primers CD3284S217AF 
and CD3284S217AR on plasmid pVW001, yielding plasmid pJV001. The mutant 
protein (His10-∆(1-30)-HtrA-S217A) was purified and quantified as described for 
His10-∆(1-30)-HtrA.








DB0051 630∆erm, pRPF185 This study
DB0002 630∆erm, cd3284::(ClosTron, ermB) This study
DB0052 630∆erm, cd3284::(ClosTron, ermB) pRPF185 (catP) This study
DB0047 630∆erm, cd3284::(ClosTron, ermB) ,pDB0031 (catP) This study
WKS1237 630∆erm, spo0A::(ClosTron, ermB) (32)
WKS1710 630∆erm, tcdA::(ClosTron, ermB) tcdB::(ClosTron, catP) (40)
Plasmids
pMTL007 catP, ClosTron GroupII Intron (32)
pDB0001 pMTL007::cd3284-162s, catP This study
pRPF185 tetR, Ptet-gusA, catP, (35)
pDB0031 tetR, Ptet-cd3284, catP This study
pVW001 PT7-His10-∆(1-30)-htrA, bla This study





























































































































































































































































































































































































































































































































































































































































































































































































































Protease activity of  the purified proteins was assayed as follows. In a 100 µL 
reaction, 2.5 µM of  His10-∆(1-30)-HtrA or His10-∆(1-30)-HtrA-S217A was 
incubated with 20 µM of  casein or beta-casein (molecular weight ~24kDa) in 
1xHNE buffer (150mM NaCl, 0.1mM, 5mM HEPES, pH7.4, 0.1 mM EDTA), 
with the pH adjusted to pH5.5 by the addition of  0.1x MES/A buffer (0.01M 
MES, 0.01M acetic acid, pH5.0). Reactions were incubated on ice (0°C) or at 37°C 
for 18h with a no-protein control included. After incubation, the reaction was 
terminated by the addition of  25 µL 5xSDS sample buffer (10% SDS, 10% beta-
mercaptoethanol, 50% glycerol, 0.1% bromophenolblue, 250mM Tris-HCl pH6.8, 
50mM EDTA) and heating to 96°C for 2 minutes. 20 µL volumes of  the samples 
were loaded on a 12% SDS-PAGE gel and separated by electrophoresis at 80mA. 
Gels were stained with Coomassie solution (0.1 % Coomassie Brilliant Blue R-250, 
20 % (v/v) methanol, 10% (v/v) acetic acid) and destained with 50% methanol 
-10% (v/v) acetic acid.
Generation of  an htrA (cd3284) mutant strain
An htrA mutant was generated by insertional inactivation of  the cd3284 gene in 
630∆erm (which will be referred to as wild type in the rest of  this paper) using 
ClosTron technology (32,33). Briefly, the Perutka algorithm on the ClosTron website 
(http://www.clostron.com) was used to design primers (supplemental Table 2) 
for retargeting the Group II intron (Sigma; Targetron). The retargeted intron was 
cloned using the restriction enzymes BsrGI and HindIII into plasmid pMTL007 
and the constructs were verified by sequencing (33). The sequenced verified plasmid 
(pDB001) was transformed to E. coli CA434 and transferred via conjugation to C. 
difficile (29,34). The selection of  C. difficile transconjugants was achieved by sub-
culturing on pre-reduced BHIS agar supplemented with thiamphenicol (Sigma; 10 
μg/mL) and C. difficile selective supplement (Oxoid). After this, several rounds of  
sub-culturing on pre-reduced BHIS agar supplemented with lincomycin (Sigma; 20 
μg/mL) and C. difficile selective supplement were used to promote integration of  
the GroupII intron into the gene of  interest. Chromosomal DNA isolated from 
the transconjugants (QIAamp blood kit, Qiagen) was analyzed by conventional 
PCR and sequencing of  the PCR product to confirm the insertional inactivation 
of  the cd3284 gene. Primers used for cloning and sequencing are listed (Table 2). 
In addition, Southern blot analysis with an ermB probe was performed to verify a 





Generation of  strains carrying a plasmid based inducible htrA
Chromosomal DNA from the wild type strain (WKS1241) was used to PCR 
amplify the open reading frame of  cd3284 with primers oDB0067 and oDB0068. 
The resulting amplicon was digested with BamHI and SacI and cloned into 
pRPF185 thereby replacing the gusA gene (35). The sequence of  the resulting 
inducible plasmid (pDB0031) was verified with primers NF_794, NF_1323 (35), 
oDB0067 and oDB0068. Plasmid pDB0031 was transferred into E. coli CA434 
and conjugated into the htrA null mutant, resulting in a htrA mutant that can be 
complemented by inducible expression of  a plasmid located copy of  htrA. To 
address potential effects of  the conjugated plasmid (pDB0031) in the phenotypic 
assays we generated control strains by conjugating the pRPF185 plasmid into wild 
type (DB0051) and htrA mutant (DB0052) strains (35). These strains served as 
controls in the in-vitro assays. There was no significant difference between strains 
with and without pRPF185 (data not shown).
Animal experiments
All procedures were conducted in strict accordance to the Animals (Scientific 
Procedures) Act 1986 approved by the Home Office, U.K. (project license number 
PPL60/4218). Female Golden Syrian hamsters that weighed approximately 100g 
(bred in-house) were housed individually and given water and food ad libitum. 
Telemetry chips (VitalView Emitter) were inserted by laparotomy into the body 
cavities of  the animals at least 3 weeks before infection with C. difficile. Once 
the wounds healed, the animals were placed on receiver pads, and the body 
temperature and activity were monitored (Vital View software). Each animal 
received orogastrically 30 mg/kg of  clindamycin phosphate in a single dose five 
days before infection. Six animals per group were inoculated by oral gavage with 
104 spores of  C. difficile. Animals were carefully monitored and culled when core 
body temperature dropped below 35 °C (28).
Statistical analyses were performed using the GraphPad Prism 5.03 (GraphPad 
Prism Software). A Mantel-Cox Log-rank statistical test was used to determine 
significant differences in hamster survival times between C. difficile strains. P values 
≤0.05 were considered significant.
Minimum Inhibitory concentration (MIC) determination
The MIC of  C. difficile wild type and htrA null mutant to erythromycin and 
clindamycin was determined by the doubling dilution method described previously 
(26). Briefly, rows of  pre-conditioned BHI broth (90 µl) were supplemented with a 
concentration range of  1024-0.06 µg/mL of  either antibiotic. Wells were inoculated 
with ~5x103 spores/100 µl and incubated at 37 °C for 48 hour anaerobically. 
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Wells to allow positive and negative evaluation of  growth were included in which 
either no antibiotic or no spores were added. After incubation, plates were visually 
inspected and compared to the controls; the MIC value was determined as the 
lowest concentration of  antibiotic at which growth was no longer visible. Results 
are given as the median MIC from three biological repeats.
RNA extraction
Five mL of  the C. difficile cultures were diluted with ice cold methanol (1:1) and 
stored overnight at -80°C. Bacterial pellets, obtained by centrifugation (20 min, 
3000 x g, 4°C), were resuspended in 200 μL lysis buffer (100 mM EDTA, 200 mM 
Tris-HCl pH 7.0, 50 mg/mL lysozyme) and incubated for 1 hour at 37°C. RNA 
was isolated using Tri-pure reagent (Roche) as previously described (28). The RNA 
was treated twice with a TurboDNase (Ambion) according to the manufacturer’s 
instruction, followed by another Tri-pure RNA isolation. The Agilent Bioanalyzer 
(Agilent Technologies Netherlands BV) and a ND-1000 spectrophotometer 
(NanoDrop Technologies) were used to analyze the quality and purity of  the 
extracted RNA.
DNA Microarray Analysis
Random nonamers were used to convert total RNA into amino allyl-modified cDNA 
using a Superscript III reverse transcriptase kit (Life Technologies) and purified with 
Nucleospin Gel and PCR clean-up kit (Machery-Nagel). The synthesized cDNA 
was labeled with DyLight 550 and DyLight 650 Amine/Reactive Dyess (Pierce 
Biotech USA) and purified again with the Nucleospin Gel and PCR clean up kit. 
The Agilent DNA micro-arrays (G2509F Custom Microarray GE 8x15K 60mer) 
were designed based on the available genome sequence of  C. difficile 630 (36,37). 
The custom made micro-array slides consist of  8 sub-arrays each with 15.208 60-
mer probes (37). The Agilent microarray slides were competitively hybridized with 
300 ng labeled cDNA made from RNA isolated from both wild type and htrA 
mutant (DB0002) during logarithmic phase (OD600 0.5 ±0.1) and stationary phase 
growth (12 hour post inoculation) . The microarray slides were scanned with a 
GenePix scanner and the fluorescent intensities were quantified using GenePix 
6.1. The raw data files were analyzed with a LimmaR package via the Genome2D 
pipeline (http://genome 2d.molgenrug.nl) (38) using the following settings; i) 
the microarray data was normalized using LOESS normalization, followed by 
quantile normalization between the slides ii) a weight factor was determined based 
on the quality of  each DNA microarray slide. For each time-point (logarithmic 
or stationary phase) 3 biological replicates were used. The complete data set, 





Reverse Transcriptase Quantitative PCR
For Reverse Transcriptase quantitative PCR (RT-qPCR) the RevertAid™ H Minus 
Reverse Transcriptase kit (Fermentas) was used to synthesize cDNA according 
to the manufacturer’s instruction. Random hexamers were used to convert 750 
ng RNA into cDNA. The synthesized cDNA was treated with RNase (Qiagen) 
for 1 hour at 37°C and stored at -20°C. The software program Molecular Beacon 
(Premier Biosoft) was used to design primer pairs (Table 2) for the quantitative 
PCRs (qPCR), based on the available genome sequence of  C. difficile strain 630 (36).
All primer pairs were first tested by conventional PCR to confirm specificity and 
amplicon sizes. The RT-qPCR reactions were then performed using a CFX96 real-
time PCR detection system (Biorad). The amplification efficiencies of  the genes 
were determined using serially diluted genomic DNA. Expression levels of  the 
tcdA and spo0A genes were normalized using the amplification efficiencies and the 
expression level of  the reference gene rpsJ (39). The qPCR for tcdA and rpsJ was 
performed as previously described (28). The qPCR for the spo0A gene contained 
25 μL Hotstar mastermix (Qiagen), forward (oDB0117) and reverse primers 
(oDB0118) (80 nm each primer), 2.5 mM MgCl2, 0.06 % SYBRgreen (Sigma) and 
2 μL synthesized cDNA. The qPCR protocol included an enzyme activation step 
for 15 min at 95 °C, followed by 50 cycles of  amplification; 95 °C for 30 sec, 52 °C 
for 30 sec and 72 °C for 30 sec.
To determine the specificity of  the fluorescence, the fluorescent data was 
converted into melt curve peaks. For each biologic replicate (n=3) four technical 
replicates were tested. An independent student t-test was employed to compare the 
strains at different time points.
Western blot analysis of  TcdA and Spo0A
Quantitative western blots for TcdA and Spo0A were performed as follows. 
For TcdA, filtered (0.45 µm) bacterial supernatants from 48 hour cultures were 
analyzed by SDS-PAGE (6% polyacrylamide) and transferred onto nitrocellulose 
membranes. For Spo0A protein, bacterial pellets from cultures in the logarithmic 
phase (OD600 nm 0.5 ±0.1), and at 8, 12 and 24 hour post inoculation were 
collected by centrifugation (10 min, 11,000 g, 4 °C). Pellets were resuspended in 
PBS containing protease inhibitor cocktail (Sigma) and lyzed with a TissueLyser 
LT bead beater (50 Hz, 10 min, Qiagen) using acid wash glass beads (≤ 106 µm, 
Sigma). Equal amounts (OD600 nm corrected) of  the lyzed bacterial pellets were 
separated on 15 % SDS-PAGE gels and transferred onto nitrocellulose membrane. 
For TcdA quantification the membranes were probed with a mouse monoclonal 
anti-TcdA antibody (TCC8, tgcBiomics, Bingen, Germany) and for Spo0A 
quantification the membranes were probed with a mouse polyclonal Spo0A serum 
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(31). The probed membranes were analyzed by using a secondary anti-mouse 
biotin-labeled antibody (Dako) and a tertiary anti-biotin antibody labeled with Cy3. 
A Typhoon 9410 scanner (GE Healthcare) was used to measure the fluorescence 
intensity. C. difficile strains WKS1237 (spo0A null mutant) and WKS1710 (tcdA 
and tcdB null mutant) were used as control strains (32,40). The software package 
ImageQuant TL (Amersham Biosciences) was used to quantify fluorescence 
intensity.
Relative quantification of  toxin expression
Quantification of  the total toxin production was performed on filtered (0.45 µM) 
24 and 48 hour post-inoculation supernatants, using a Vero cell based cytotoxicity 
assay (28). The end-point titer was defined as the first dilution at which Vero cell 
morphology was indistinguishable from the neutralized 200 fold diluted supernatant 
and untreated cells (28). C. difficile strain WKS1710 (tcdA and tcdB null mutant) was 
used as a negative control (40). Each experiment was performed in duplicate on 
three separate occasions. An independent student t-test was employed to compare 
the strains at different time points. 
Relative quantification of  sporulation efficiency
Sporulation efficiency was determined by analyzing culture samples of  24 and 48 
hour post inoculation. Serially diluted non-heat shocked and heat shocked (20 min 
, 65 °C) culture samples were plated onto BHI plates supplemented with 0.1 % 
taurocholate to stimulate germination and enhance spore recovery (41). Plates were 
incubated for 48 hour before colony forming units (CFU) were enumerated. The 
C. difficile strain WKS1237 was included as a negative control for sporulation (32). 
Sporulation efficiency was normalized using the CFU count of  the non-treated 
sample. Three biological replicates were analyzed in duplicate. An independent 
student t-test was employed to compare the strains at different time points.
Relative quantification of  adhesion to Caco-2 Cells
Adhesion of  C. difficile to Caco-2 cells was performed essentially as described 
previously with minor modifications (42). Briefly, Caco-2 cells were grown in RPMI 
(GE healthcare), 10 % fetal calf  serum, Penicillin (100 µg/mL) and Streptomycin 
(100 U/mL) in a humidified 5 % CO2 atmosphere at 37 °C. Caco-2 cells were 
seeded into a 24 wells plate at a density of  1x 105 cells per well and incubated 
overnight at 37 °C and 5 % CO2. Confluent Caco-2 monolayers were washed once 
with PBS before transfer into the anaerobic cabinet.
Mid-logarithmic phase bacterial cultures (OD600 0.5 ± 0.08) were collected by 
centrifugation (1 min, 4000 x g, 4 °C) and washed once with pre-reduced PBS. To 
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8  Figure 1: HtrA is a protease. (A) Schematic representation of  the predicted structural 
domains of  HtrA. The box on the top line indicates the position (nucleotide 163) at which 
the group II intron has inserted to create the htrA null mutant (not on scale). The predicted 
N-terminal transmembrane helix is shown in blue, the serine protease domain in red and 
the PDZ domain in yellow. The inset shows the conserved catalytic triad (in green) of  
the serine protease domain. The predicted structure of  C. difficile HtrA is overlaid with 
the structure of  E.coli DegS (1TE0A) in grey. (B) HtrA shows protease activity towards 
β-casein. 2.5μM of  the indicated protein was incubated for 18 hour with 20 μM of  beta-
casein at 0°C or 37°C. wt = His10-∆(1-30)-HtrA, S217A is the catalytic mutant His10-∆(1-
30)-HtrA- S217A. The asterisk indicates a proteolytic product of  β-casein.
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each well of  Caco-2 approximately 1x 108 bacteria were added. Exact numbers 
of  viable bacteria within the inoculums for each well were calculated by serial 
dilution and plating of  cultures on BHIS plates. After 3 hour of  incubation under 
anaerobic conditions, the Caco-2 cell monolayers with the adhered bacteria were 
washed 5 times with pre-reduced PBS. Adherent bacteria were released using 100 
μL 1x trypsin solution (PAA laboratories, Coelbe, Germany) and serially diluted 
and plated on pre-reduced BHIS plates. After 48 hour colony forming units were 
enumerated to determine the percentage of  adherent C. difficile relative to the initial 
inoculum. Each experiment was carried out in duplicate and repeated three times. 
An independent sample t-test was employed to compare the strains at different 
time points.
Results
Bioinformatics analysis of  CD3284
In this study we identify a single HtrA-like protease in C. difficile 630∆erm. 
CD3284 was identified using the BlastP (http://blast.ncbi.nlm.nih.gov/Blast.cgi), 
Smart (http://smart.embl-heidelberg.de/) and Merops (http://merops.sanger.
ac.uk/) databases (36,43-45). Further bioinformatics analyses were performed 
with a conserved domain prediction webserver (http://www.ncbi.nlm.nih.gov/
Structure/cdd/cdd.shtml), the trans-membrane prediction webserver TMHMM2.0 
(http://www.cbs.dtu.dk/services/TMHMM/) and the signal peptide cleavage site 
webserver SignalP4.1 (http://www.cbs.dtu.dk/services/SignalP/). These analyses 
revealed the presence of  a trans-membrane domain (Amino Acid (AA) 7-29), a 
trypsin-like serine protease domain (AA 92-231, E-value 3.96x10-29) and a PDZ 
domain (AA 269-357, E-value 2.17x10-19) (Figure 1A). The N-terminus of  CD3284 
was predicted by TMHMM to be highly hydrophobic, most likely transmembrane, 
whereas SignalP analysis revealed no signal sequence, suggesting that the protease 
and PDZ domains are located extracellularly, but membrane associated (46). 
Comparison of  the CD3284 protein sequence of  our wild type strain with the 
NCBI non-redundant protein sequences database using BlastP, resulted in identical 
protein sequence hits (Query coverage 100%, E-value 0.0) in other epidemic (e.g. 
RT027) and non-epidemic (e.g. RT001) C. difficile strains.
As protein 3D-structure is more conserved in evolution than its equivalent amino 
acid sequence, we validated the homology of  CD3284 using the I-TASSER (http://
zhanglab.ccmb.med.umich.edu/I-TASSER/) and Phyre2 three-dimensional 
structure prediction server (http://www.sbg.bio.ic.ac.uk/phyre2/) (47,48). These 




Figure 2: (A) PCR screening of  the strains used in this study. HtrA PCR: The primers 
oDB0123 and oDB0124 generated a PCR product of  approximately 2200 bp in the htrA 
mutant (ΔhtrA, DB0002) and a PCR product of  150 bp in the wild type (WKS1241), wild 
type/pRPF185 (DB0051), complemented htrA mutant (ΔhtrA/htrA+, DB0047) and ΔhtrA/
pRPF185 (DB0052). pRPF185 PCR: The primers oWKS-1177 and NF794 generated a 
PCR product of  approximately 1800 bp in the DB0051 and DB0052 strains. htrA-ClosTron 
PCR: The primers oDB0123 and EBSuni generated a PCR product of  approximately 280 
bp in DB0002, DB0047 and DB0052 strains. Ptet-htrA PCR: The primers oDB0123 and 
NF794 generated a PCR product of  approximately 1200 bp in DB0047. (B) Southern blot 
analysis of  C. difficile wild type and ΔhtrA. Chromosomal DNA digested of  wild type 
(WKS1241) and ΔhtrA (DB0002) with HindIII was hybridized with an ermB specific probe. 
Note that wild type shows a single band, indicative of  the ermB element that is still present 
in this strain (29), ΔhtrA contains an additional element, pMTL007 is shown as a positive 
control.
A B
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amino-acid identity, the structural homology of  this protein to the HtrA-like 
protease DegQ (49,50), and the predicted structure of  C. difficile HtrA overlaid 
with the structure of  E.coli DegS demonstrated a high level of  structure homology 
(Figure 1A). Homologs of  DegQ and DegS are generally referred to as HtrA-
like proteases in Gram-positive prokaryotes. Considering the above, we will refer 
hereafter to the CD3284 encoding gene as htrA, and the CD3284 protein as HtrA.
C. difficile HtrA (CD3284) shows protease activity towards β-casein
To investigate if  C. difficile HtrA possesses proteolytic activity similar to that of  
other HtrA-like proteases (51) we performed a protease assay. Wild type HtrA 
(His10-∆(1-30)-HtrA) and a catalytic HtrA mutant (His10-∆(1-30)-HtrA-S217A) 
protein were incubated with β-casein, a highly unfolded protein substrate (Figure 
1B). After 18 hour of  incubation at 37 °C casein was only degraded by wild 
type HtrA and not by the catalytic HtrA mutant. These results demonstrate the 
proteolytic activity of  C. difficile HtrA.
Construction of  an htrA mutant
To determine the contribution of  HtrA to C. difficile virulence we constructed an 
htrA mutant using ClosTron technology in the 630Δerm (wild type) (29) strain by 
insertion of  a Group II intron upstream of  the sequence encoding the predicted 
trypsin-like serine protease domain (Figure 1A). Insertional inactivation of  genes 
using the ClosTron technology results in stable mutants and non- functional 
proteins (32,40). The genotype of  the insertional inactivation was confirmed by 
PCR (Figure 2A), sequence analysis and Southern blot (Figure 2B), which verified 
that the ClosTron group II intron was inserted at a single site. Initially, the impact of  
the mutation on growth in vitro was considered. This revealed that post inoculation 
Figure 3: Growth curves of  the wild type and the htrA mutant strain. The absorbance 
(OD600) was measured over 48 hours of  growth in TTY medium. The error bars indicated 




both mutant and wild type strains showed logarithmic growth for the first 8 hour 
and by 12 hour post inoculation both strains had entered stationary growth phase 
(Figure 3). Though growth kinetics were not significantly different from wild type 
cells, we noted that the htrA mutant strain generally showed a slight growth delay in 
logarithmic phase and reached lower optical density in stationary phase (Figure 3).
The htrA null mutant is more virulent in hamsters
HtrA like proteases have been shown to be important for the virulence of  
pathogenic bacteria (25,52,53). To determine the contribution of  HtrA in C. difficile 
virulence we performed in vivo experiments with the htrA mutant and wild type in 
the commonly used Golden Syrian hamster model (54,55). Six clindamycin pre-
treated hamsters were orally infected either with wild type or the htrA mutant. The 
mean time to death for hamsters challenged with wild-type was 53 h and 39 min (± 
5 h and 3 min; n=6). Hamsters infected with the htrA mutant revealed a significant 
decreased survival time (31 h 20 min ± 44 min, n=6, p=0.0005) compared to wild 
type (Figure 4), suggesting that disruption of  htrA causes enhanced virulence in 
this strain. Our experience evaluating a number of  mutants in the hamster model 
suggests that animals challenged with other mutants created using ClosTron 
Figure 4: The htrA null mutant has increased virulence in a hamster model of  infection. 
Survival curve of  hamsters challenged with either 104 spores of  C. difficile 630∆erm (solid black 
line), htrA null mutant (red line), ClosTron mutant 1 & 2 (blue & green lines, respectively) 
or 630 wild-type (dashed black line). Hamsters challenged with htrA mutant (31 h 20 min, 
n=6) showed a significantly decreased survival time compared to those challenged with 
630∆erm (53 h 39 min, n=6, p=0.0005), ClosTron mutant 1 (36 h 41 min, n=7, p=0.049), 
ClosTron mutant 2 (36 h 47 min, n=9, p<0.0001) or 630 (43 h 43 min, n=11, p<0.0001). 
Hamsters were culled when body temperature declined below 35°C (clinical end point) and 
data analysed by Mantel-Cox Log-rank statistical tests.
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technology have a shorter survival time compared to wild type (unpublished data). 
We hypothesize that this observation is due to the greater resistance to clindamycin 
(as a consequence of  ClosTron insertion) and hence greater survival rates in vivo 
following pretreatment of  animals with clindamycin to induce disease. Indeed, we 
find that the htrA mutant (and other ClosTron mutants) in vitro is more resistant to 
clindamycin (MIC >256 µg/mL) than the wild type (630Δerm; MIC = 16 µg/mL).
Nevertheless, if  we compared the htrA mutant to the original parental 630 isolate 
(Wust et al., 1982) (43 h 43 min, n=11, p<0.0001) or to other mutants (ClosTron 
1, 36 h 41 min, n=7, p=0.0049; ClosTron 2, 36 h 47 min, n=9, p<0.0001) infected 
in the same way, the enhanced mortality rate remains significant. We therefore 
conclude that in the Golden Syrian hamster model the htrA null mutant of  C. 
difficile demonstrates an enhanced virulence phenotype.
Comparative transcriptional micro-array data analysis of htrA mutant and 
wild type strains
To understand the enhanced virulence of  the htrA mutant in the Golden Syrian 
hamster model, we performed comparative transcriptome analysis of  the wild 
type and the htrA mutant. The htrA mutant displayed a pleiotropic effect in the 
transcriptomic analysis. The most interesting genes that were differentially regulated 
in the htrA mutant were tcdA, spo0A, and several genes encoding surface associated 
proteins. 
The transcriptional profiles of  the htrA mutant strain and wild type strain were 
studied at two different time points, the logarithmic and stationary growth phase 
respectively. The DNA micro-array raw data sets and the normalized ratio data 
are available from the NCBI GEO database (http://www.ncbi.nlm.nih.gov/geo/, 
accession number GSE55926) (56). In the logarithmic growth phase and in the 
stationary growth phase 551 genes and 567 genes were significantly differentially 
expressed, respectively (fold change ≥1.5, p ≤0.05). In total 248 genes in the 
logarithmic growth phase and 263 genes in the stationary growth phase were up-
regulated. Two-hundred and eight genes were up-regulated both in logarithmic 
and stationary growth phase. Among these, several genes were involved in stress 
adaptation response, like the ctsR and hrcA genes (57). The tcdA gene encoding the 
well-characterized virulence factor Toxin A was 3.3-fold and 3.0-fold up-regulated 
in the logarithmic and stationary growth phase, respectively.
A total of  303 genes in the logarithmic growth phase and 304 genes in the 
stationary growth phase were down-regulated in the htrA mutant. Two-hundred 
and sixty five genes were down-regulated both in logarithmic and stationary 
growth phase. Among these are genes involved in cell metabolism, like ribosomal 




Figure 5: Increased TcdA production of  htrA null mutant compared to wild type. (A) The 
relative tcdA gene expression profiles of  C. difficile strains in logarithmic and stationary 
phase. The asterisks (*) indicate a significant difference between wild type and htrA mutant 
(p<0.000001) and complemented htrA mutant (p<0.000001). (B) Quantitative Western blot 
analysis of  TcdA in culture supernatant of  wild type, htrA null mutant and complemented 
htrA mutant at 48 hour post inoculation. (C) The toxin end point titers of  the various 
C. difficile strains. The asterisk (*) indicate a significant difference between wild type and 
htrA null mutant (p=0.001) at the same time point. The error bars indicate the standard 
error of  the mean of  three experiments. Wild type is WKS1241, htrA mutant is DB0002, 
complemented htrA mutant is DB0047 and tcdA/B mutant is WKS1710.
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indistinguishable from wild type lev ls (Figur  5A). These data s ggest that reduction in transcription of tcdA in 
the htrA mutant is a consequence of the htrA mutation. Second, we determined if the increased level of tcdA 
transcription was reflected in elevated levels of TcdA protein. Quantitative Western blot analysis with a TcdA 
specific monoclonal antibody on filtered supernatants of 48 hour post inoculation cultures showed a 7-fold 
increase of TcdA in the htrA mutant compared to wild type (Figure 5B). Similar to tcdA transcription, 
complementation of the htrA mutant resulted in TcdA levels that were partially restored towards the wild type 
(2-fold, Figure 5B). The signals detected were specific for TcdA as they were absent in the supernatant of the 
control strain WKS1710 (40). 
We also determined the effect of the htrA mutant in a cytotoxicity assay on Vero cells, which detects 
the cumulative effects of both Toxin A and B (28,40) (Figure 5C). We observed a 5-fold increase in toxin end 
point titer for the htrA mutant (p=0.001) compared to the wild type (Figure 5C). Complementing the htrA 
mutant with an inducible copy of htrA on a plasmid (DB0047) restored the toxin end point titer to near-wild 
type levels. To determine these effects as toxin specific, Vero cells were exposed to filter sterilized supernatant 
of strain WKS1710 (630 ΔtcdAΔtcdB) (40), which as expected did not result in cytotoxic effect. Moreover, pre-
incubation of the filter sterilized bacterial supernatants with an anti-toxin (Techlab, Blacksburg, VA, USA) 
resulted in complete neutralization of the observed cytotoxic effects on the Vero cell monolayers (data not 
shown). Thus, the effects of the supernatants on Vero cells were Toxin A and/or Toxin B specific. 
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master regulator of  sporulation (58,59), was 2.4-fold and 2.3-fold down-regulated 
in the logarithmic and stationary growth phase, respectively, and many other 
sporulation genes showed a similar effect. Furthermore, several genes encoding 
surface-associated proteins (like slpA and 5 other paralogues of  slpA) (16), flagella 
associated genes (18,60), and CD1581 (a gene with a potential effect on adhesion 
and intestinal colonization) (19) were significantly down regulated.
Overall, transcriptional profiling of  the htrA null mutant showed a plethora of  
differences compared to wild type. The most prominent differentially regulated 
genes were tcdA, spo0A and several genes encoding surface associated proteins that 
were further investigated phenotypically.
Increased TcdA production of  htrA mutant compared to wild type
Golden Syrian hamsters are exquisitely sensitive to C. difficile toxins and increased 
levels of  tcdA transcription might explain the observed enhanced virulence. 
To validate the increased level of  tcdA transcription in the comparative DNA 
microarray analysis we determined the tcdA transcription by RT-qPCR, quantitative 
Western blot analysis of  TcdA and a cytotoxicity assay. 
First, we confirmed the effect on transcription of  the tcdA gene in the htrA 
mutant. We also complemented the htrA mutant (DB0047) to confirm that the 
observed effect on tcdA transcription in the htrA mutant was specific. RT-qPCR 
was used to compare the normalized tcdA transcription profiles in wild type, 
htrA mutant and the complemented htrA mutant strains in the logarithmic and 
stationary growth phase. In the logarithmic phase and the stationary phase the 
normalized tcdA transcription of  the htrA mutant was significantly increased, 2.1-
fold (p<0.000001) and 8.1-fold (p<0.000001), respectively (Figure 5A). Expressing 
HtrA from a plasmid in the mutant strain (DB0047) partially restored tcdA 
transcript levels in logarithmic phase (1.4-fold, p=0.0022) towards wild type level, 
whilst in stationary phase the tcdA transcript level was indistinguishable from wild 
type levels (Figure 5A). These data suggest that reduction in transcription of  tcdA 
in the htrA mutant is a consequence of  the htrA mutation. Second, we determined 
if  the increased level of  tcdA transcription was reflected in elevated levels of  
TcdA protein. Quantitative Western blot analysis with a TcdA specific monoclonal 
antibody on filtered supernatants of  48 hour post inoculation cultures showed a 
7-fold increase of  TcdA in the htrA mutant compared to wild type (Figure 5B). 
Similar to tcdA transcription, complementation of  the htrA mutant resulted in 
TcdA levels that were partially restored towards the wild type (2-fold, Figure 5B). 
The signals detected were specific for TcdA as they were absent in the supernatant 
of  the control strain WKS1710 (40).
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8 Figure 6: Decreased sporulation of  htrA mutant compared to wild type. (A) The relative 
spo0A gene expression profiles of  C. difficile strains in logarithmic and stationary phase. 
The asterisks (*) indicate a significant difference between wild type and htrA mutant 
(p<0.000001) and the complemented htrA mutant (p<0.000001) at the same time point. 
(B) The quantitative Western blot analysis of  Spo0A in wild type and htrA mutant and 
the complemented htrAmutant in time. (C) Normalized sporulation efficiencies (heat 
resistant CFU compared to wild type) of  the different strains at 24h post inoculation. The 
asterisk (*) indicates a significant difference between wild type and htrA mutant (P=0.0006). 
The error bars indicate the standard error of  the mean of  three experiments. Wild type is 
WKS1241, htrA mutant is DB0002, complemented htrA mutant is DB0047 and the spo0A 
mutant is WKS1237.
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We also determined the effect of  the htrA mutant in a cytotoxicity assay on Vero 
cells, which detects the cumulative effects of  both Toxin A and B (28,40) (Figure 
5C). We observed a 5-fold increase in toxin end point titer for the htrA mutant 
(p=0.001) compared to the wild type (Figure 5C). Complementing the htrA mutant 
with an inducible copy of  htrA on a plasmid (DB0047) restored the toxin end point 
titer to near-wild type levels. To determine these effects as toxin specific, Vero cells 
were exposed to filter sterilized supernatant of  strain WKS1710 (630 ΔtcdAΔtcdB) 
(40), which as expected did not result in cytotoxic effect. Moreover, pre-incubation 
of  the filter sterilized bacterial supernatants with an anti-toxin (Techlab, Blacksburg, 
VA, USA) resulted in complete neutralization of  the observed cytotoxic effects on 
the Vero cell monolayers (data not shown). Thus, the effects of  the supernatants 
on Vero cells were Toxin A and/or Toxin B specific.
In summary, we found increased tcdA transcription levels, increased TcdA 
expression levels and elevated toxin end point titers of  supernatants derived from 
htrA mutant cells compared to wild type. Taken together, these data contribute to 
an explanation for the enhanced virulence of  the htrA mutant strain in vivo.
The htrA mutant displays decreased sporulation compared to wild type
Our transcriptome analysis revealed pleiotropic effects that included a decreased 
transcription of  spo0A, the master regulator of  sporulation, in the htrA null mutant 
compared to wild type (58,59). Sporulation is highly relevant for transmission, 
persistence and biofilm formation of  C. difficile (61,62). To validate the microarray 
results, we performed RT-qPCR, quantitative Western blot analysis of  Spo0A and 
a sporulation assay. 
We used a RT-qPCR to determine the normalized spo0A transcript levels in wild 
type, htrA mutant and the complemented htrA mutant strains in the logarithmic 
and stationary growth phase. The spo0A transcript level in the htrA mutant 
was significantly decreased in the logarithmic phase (4.3-fold, p<0.000001) and 
stationary phase (4.1-fold, p<0.000001) compared to wild type (Figure 6A). The 
complemented htrA mutant failed to reach wild type levels of  spo0A transcript 
in the log phase (5.2 fold difference, p<0.000001), but in the stationary phase the 
complemented strain reached wild type levels of  spo0A transcript (Figure 6A). 
Therefore, we believe that the reduced spo0A transcript level in the htrA mutant is 
partially, if  not completely, due to the htrA mutation.
Next, we quantified the decreased Spo0A levels by quantitative Western blot 
analysis (31). In wild type cells the Spo0A levels increased during growth and 
signals were absent from the spo0A mutant strain as previously reported (Figure 
6B) (31). In the htrA mutant, Spo0A levels were on average 3-fold lower compared 
to wild type (Figure 6B). Complementation of  the htrA mutant restored Spo0A 




We also investigated the sporulation efficiency of  the various strains by 
determining heat resistant colony forming units (CFU). The efficiency of  heat 
treatment on spore recovery was initially tested using cultures of  mutant (32). No 
colonies could be recovered using this strain, indicating that this is a good way to 
measure actual spore formation. At 24 hour post inoculation we observed (12-
fold) decreased sporulation efficiency for the htrA mutant compared to wild type 
(significant, p=0.0006) (Figure 6C). Expressing htrA from a plasmid in the htrA 
mutant strain (DB0047) partly restored sporulation efficiency to wild type levels 
(Figure 6C). In contrast, sporulation efficiency at 48 hour post inoculation appeared 
comparable in all strains tested, including the htrA mutant (data not shown). 
In summary, we show that the htrA mutant has a decreased spo0A transcript 
level, a delayed expression of  Spo0A protein and a significant reduction in the 
number of  spores formed at 24h post inoculation.
Decreased adherence of  htrA mutant to Caco2 cell monolayer compared to 
wild type
In addition to spores, it has been suggested that surface proteins on vegetative 
cells are important factors for adherence of  C. difficile to the colonic epithelium 
and colonization of  the intestine (16,19,63). Prompted by the down-regulation of  
several important cell surface proteins in our transcriptome analyses, we determined 
the capability of  the htrA mutant strains to adhere to colon epithelial cells. 
We incubated the various strains on a monolayer of  Caco-2 cells and determined 
the fraction of  bacterial cells that remained attached after rigorous washing. We 
observed only 10% adherence of  the htrA mutant to the Caco-2 cell monolayer 
(p=0.000001) compared to wild type (Figure 78). Inducing DB0047 resulted in a 
Figure 7: Decreased adhesion of  htrA null mutant to Caco2 cells. The asterisk (*) indicates 
a significant difference between wild type and htrA mutant (p=0.000001). The error bars 
indicate the standard error of  the mean of  three experiments. Wild type is WKS1241, 
ΔhtrA mutant is DB0002, ΔhtrA/htrA+ is the complemented mutant (DB0047).
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slightly increased, but not significant (p=0.17), capability to adhere to a monolayer 
of  Caco-2 cells compared to wild type levels, indicating that the adherence defect 
of  the htrA mutant is specific.
Discussion
Role for HtrA in virulence of  C. difficile
In addition to the prevalence, the severity and mortality of  disease caused by C. 
difficile infections has increased significantly in the last decade (1,6,9). It is unclear 
whether this is a consequence of  more diligent screening or a consequence of  
acquisition of  additional virulence traits by the bacteria. The retractable nature 
of  the organism to genetic manipulation has limited opportunities to investigate 
the role of  many genes in the control of  virulence traits including the two large 
clostridial toxins, the binary toxin and other factors that contribute to the virulence 
of  C. difficile, such as those affecting colonization and survival of  the bacteria in 
the host (15,16,18,19). In multiple organisms HtrA-like foldase/proteases play a 
considerable role in virulence by controlling protein homeostasis (21,22,26,52,64). 
Here, we find that C. difficile encodes a single HtrA-like protease. In contrast to 
observations in other organisms, we have found that a C. difficile htrA mutant 
shows enhanced virulence in the Golden Syrian hamster model of  acute C. difficile 
infection (Figure 4).
The observed increase in virulence is likely to be a consequence of  elevated 
toxin levels. Toxin measurements from the hamsters showed no differences in 
measurement of  toxin production in filtered gut samples, however these samples 
were taken at the endpoint of  infection when toxin levels reflect significant 
symptoms. In vitro, we find increased transcription of  tcdA, increased levels of  TcdA 
protein in the htrA mutant, and increased cytotoxicity of  the filtered supernatant 
derived from htrA mutant cells, all of  which could be substantially reversed by 
prolonged induction of  a plasmid-located copy of  htrA (Figure 5). Shorter 
induction did not result in full complementation, most likely because expression 
levels or the temporal pattern of  expression does not match that of  wild type.
Our transcriptome analysis did not reveal a significant change in tcdB levels 
in the htrA mutant. This has been observed before, and is probably due to lower 
transcription levels of  tcdB compared to tcdA in general though our data cannot 
exclude differential regulation of  the two toxin genes (28,65,66).
We did notice changes in transcription of  several other virulence-associated 
genes. We validated a number of  phenotypes that could be related to these genes 




colon epithelial cell adherence. In agreement with the observation for TcdA, these 
effects could be reversed by complementation (Figures 6 and 7). Whilst the most 
significant impact of  this mutation in the hamster model appears to be the change 
of  toxin expression, this does not reflect the potential role of  HtrA more globally 
on gene expression.
The delay in sporulation, as measured by enumeration of  colonies on 
taurocholate containing plates after heat shock, does not necessarily reflect a block 
in sporulation, but could also be the result of  a defect in germination. However, 
the complementary observation of  decrease in spo0A transcript level in the mutant 
strain would suggest the impact to be on sporulation. In addition, this delay in 
sporulation could result in extending the time spentin the vegetative state during 
which more toxin than wild type cells could be produced.
Structure of  C. difficile HtrA
The HtrA family of  proteases can be distinguished from other serine proteases by 
the presence of  at least one PDZ domain (21,23). PDZ domains are involved in 
the regulation of  the activity of  the protein through protein-protein interactions or 
binding of  specific substrates (22,50). HtrA proteins in other organisms can either 
be membrane associated or secreted (49,50). A detailed bioinformatics analysis of  
C. difficile HtrA suggests that the protein is a membrane-associated protein with a 
single PDZ domain (Figure 1A).
HtrA-like proteases of  E. coli are among the best-characterized members of  the 
family. DegP and DegQ consist of  single protease domains with two associated 
PDZ domains (22,49). Both proteins are foldase/proteases that have relatively 
broad substrate specificity. DegS is a protease with a single PDZ domain, that acts 
specifically as a site-1 protease in a regulatory pathway for the extracytoplasmic 
stress response (49). Considering the domain structure, one might expect HtrA 
of  C. difficile to be a site-1 protease. However, we would argue against this based 
on three findings; first, our protease assay with a non C. difficile related unfolded 
protein suggests a non-specific proteolytic activity. Second, our transcriptome 
analyses suggest a pleiotropic effect, rather than a specific pathway to be affected. 
Third, homology modeling of  the predicted structure of  C. difficile HtrA using 
I-TASSER and Phyre2 suggests that the overall fold of  the catalytic domain and 
PDZ domain is more similar to the DegQ/P subfamily of  HtrA-like proteases 
(22,24,49,50). Finally, site-1 proteases in Gram-positive bacteria generally belong 
to the PrsW family (67-69). Indeed, in C. difficile PrsW (CD0552) is involved in the 
activation of  the extracytoplasmic function sigma factor CsfT (70).




In the majority of  pathogenic bacteria, HtrA is directly or indirectly implicated in 
virulence. In many bacteria htrA null mutants show a complete loss of  virulence, 
or at least a significant level of  attenuation (21,22,25,26,52). To our knowledge, our 
study is the first example of  increased virulence for an htrA null mutant.
Only a few studies have found little or no effect of  htrA on virulence in animal 
models. In Staphylococcus aureus COL, the deletion of  htrA led to minimal changes 
in surface protein expression and virulence (71). In Brucella abortis the htrA mutant 
was not found to be attenuated in a BALB/c mouse model (72). For Porphyromonas 
gingivalis only late effects were observed in a competition assay in mice (73). For 
Streptococcus pyogenes no effects were seen in a murine model of  subcutaneous 
infection (74). In these cases, htrA mutant strains did display an increased sensitivity 
to stresses, or an altered expression of  virulence factors. However, this may reflect 
the choice of  model and environmental niche tested.
It should be noted that the effects of  HtrA can be strain dependent (26,71), and 
may be masked by additional htrA like genes that can compensate in site specific 
deletion mutants (75). In the case of  C. difficile, we have not identified any additional 
HtrA-like genes (data not shown), but we cannot exclude the possibility that other 
(serine) protease(s) might be able to substitute for certain functions of  HtrA. The 
contribution of  the sporulation and adhesion phenotypes of  the htrA mutant of  
C. difficile to virulence therefore awaits validation in a model other than the hamster, 
in which toxin production is so dominant that observation of  changes to other 
traits can be limited. For example, analysis of  this mutant in mice, which can be 
colonized but are less susceptible to toxin production, may be a good alternative 
to study the effects of  htrA on colonization, transmission and persistence (15,35).
Mode of  action of  HtrA
In most pathogens, attenuation as a consequence of  mutation in htrA appears to 
be the result of  a reduced capacity of  the cells to deal with environmental or host-
dependent stresses (e.g. heat or oxidative stress), a reduced level of  virulence factors 
that depend on HtrA for processing or activation, and/or a reduced invasiveness 
of  the bacterium (21,24,50). In some cases, the effects of  HtrA have not been 
traced to a specific protein or pathway (76,77).
Our study revealed broad effects of  the mutation of  htrA on multiple pathways. 
Interestingly, several of  these pathways have been linked to each other in previous 
work. For instance, it was noted that the asporogenic mutant of  spo0A, showed 
elevated levels of  toxin production in PCR ribotype 027, but not in 630Δerm 
(61,78). Similarly, there is a clear link between motility and toxin production as 




in the flagellar operon showed changes in both toxin levels (80) and their capacity 
to adhere to Caco-2 cells (60). Finally, more general effects of  stress (nutrient 
depletion, temperature) on toxin levels were noted (81,82).
Our study shows that htrA of  C. difficile can modulate toxin levels, the formation 
of  spores and the adhesion to colonic cells, all of  which are highly relevant for 
virulence. However, the high connectivity of  the networks regulating these 
processes does not allow us to draw any conclusions as to the direct targets of  
HtrA in C. difficile. Future research will be aimed at identifying which proteins are 
direct targets of  the foldase/protease activity of  C. difficile HtrA.
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Clostridium difficile can colonize the intestines of  humans and animals. Up to 3% 
of  healthy individuals and almost 40% of  hospitalized patients are colonized by 
toxinogenic C. difficile strains (13,76). Antibiotic treatment can result in overgrowth 
of  the commensal flora by C. difficile, thereby causing disease (13,64,72). Clinical 
symptoms of  Clostridium difficile infection (CDI) can range from mild diarrhoea to 
life-threating pseudomembranous colitis (3,4). CDI is currently the leading cause 
of  infectious nosocomial diarrhoea (3,62). C. difficile is also found in the community, 
in animals and in meat, which expands the possibilities for acquiring CDI outside 
healthcare facilities (23,33,35,36,77).
The increase in the incidence, morbidity and mortality of  CDI in the last decade 
is mainly associated with two virulent PCR Ribotypes (RT), i.e. RT 027 and RT 078 
(35,51,58,59,73) and is related to more debilitating and excessive diarrhoea, higher 
relapse rates and a higher chance of  complications such as pseudomembranous 
colitis and colectomy (7,24,35,51,59). Based on incidence rates and management of  
CDI the financial burden is estimated at approximately $8000 million for the USA 
and €3000 million in Europe (7,24). As especially the elderly (≥65 years of  age) are 
at risk for getting CDI and the proportion of  elderly is expected to increase (75.3 
million in 2004 to 134.5 million in 2050 in the European population), it is expected 
that the costs related to CDI will rise even further (http://epp.eurostat.ec.europa.
eu).
To reduce the medical and financial burden of  CDI it is of  utmost importance 
to find better options to curtail the spread and treat the disease. This objective can 
be attained by intervening at multiple levels. First, rapid and accurate diagnosis 
of  CDI patients and molecular typing are essential tools to prevent, monitor 
and control infections and outbreaks. Secondly, studying and understanding the 
mechanisms of  C. difficile fitness and colonization may lead to insights to new 
therapeutic options aimed at preventing colonization. Finally, understanding the 
mechanisms of  toxin regulation may result in the development of  effective medical 
counter measures to reduce the levels of  produced toxin and the clinical symptoms.
Molecular methods for diagnosis and typing C. difficile
Measurements to reduce the medical and financial burden on the healthcare 
system include awareness of  CDI by the hospital staff, hygiene precautions, early 
diagnosis and surveillance of  CDI (74). The pillars for diagnosis of  CDI are still 
the typical clinical features in combination with laboratory assays, such as enzyme 
immuno assays (EIAs) (17). However, the currently used laboratory assays are 




diagnosis of  CDI (17,78). The lack of  accurate (stand-alone) assays has persuaded 
clinicians to introduce two-or three step diagnostic algorithms, which results in 
increasing costs and time for diagnosis of  CDI.
Molecular assays are potentially rapid (26,65) and have been shown to perform 
better than the traditionally used assays (17,20,26,51,60,65). In Chapter 2 we 
describe the evaluation of  three in-house developed molecular assays for the 
diagnosis of  CDI, in comparison with the labour-intensive gold standards, i.e. the 
cytotoxicity assay and the toxigenic culture. Due to the high prevalence of  CDI 
(20%) in the sample collection, the evaluated molecular assays nearly fulfilled the 
criteria defined for sensitivity (≥ 96.0%) but not for the specificity (≤ 90.7%) to 
be applicable as a stand-alone test (60). The calculated positive predicted values 
decreased substantially during a more realistic prevalence of  CDI in a clinical 
setting (10%) and in a community setting (2%). Therefore, we concluded that the 
evaluated molecular assays are not applicable as a stand-alone test for diagnosis 
of  CDI. However, the reported high negative predicted values are valuable in 
the detection of  CDI cases both in an endemic and outbreak situation. Thus, we 
concluded that the molecular based assays are applicable as a first screening assay 
in a two-step screening algorithm for diagnosis of  CDI.
A major drawback of  the gold standards is the long turn-around time (≥ 48 
hrs). Moreover, improper transport and storage conditions for long-time storage of  
faecal samples could lead to degradation of  the toxins and to decreased culturability 
of  Clostridium difficile (2,34). Together, these drawbacks could lead to false negative 
results that could blur the performance of  the highly sensitive molecular based 
assays when comparing to the gold standards. The major advantages of  molecular 
based assays compared to the gold standard are the short turnaround time and 
independence of  phenotypic detection of  toxins and culturability of  C. difficile. 
Therefore, with the development of  the molecular tests the gold standard for CDI 
diagnosis may be reconsidered.
A recently published study demonstrated that only toxin detection using a 
cytotoxicity assay positively correlates with clinical outcome of  the disease and 
not the presence of  C. difficile per se (61). Therefore, the molecular tests cannot be 
applied in a stand-alone test. Nevertheless, asymptomatic carriership could be an 
important source of  transmission within hospitals (28,30,61). These observations 
underline the necessity and the importance to distinguish both C. difficile carriers 
and CDI patients. In order to make this distinction, we will still need to use a two-
step algorithm for diagnosis of  CDI.
In a two-step algorithm, the first assay should be a rapid and accurate assay 
capable of  detecting both asymptomatic carriers and CDI patients. Ideally, this 




and detect both toxin genes directly in faecal samples. This should be followed by 
an assay which detects produced toxins, to distinguish between CDI patients and 
asymptomatic carriers of  C. difficile. To date, several assays are described which are 
able to detect toxins, such as the cytotoxicity assay and EIAs (17). At present, the 
cytotoxicity assay has the overall best performance. Preferably the second assay 
should also have a short turnaround time. Therefore, the applicability of  new 
promising highly sensitive techniques (such as mass spectrometry in combination 
with micro-extraction methods (66) to detect the presence of  C. difficile toxins should 
be further explored. Until that time, it is recommended to use a two-step algorithm 
to distinguish between CDI patients and asymptomatic carriers of  C. difficile. The 
first screening assay should be a molecular based (multiplex) assay, followed by an 
EIA. The great benefit of  this two-step algorithm over the commonly used two-
step algorithms is the more rapid diagnosis of  CDI with comparable accuracy.
Another essential tool for the control of  CDI is to monitor outbreaks within 
healthcare facilities with molecular (sub-)typing methods (47). Multi Locus 
Variable number of  tandem repeat Analysis (MLVA) is currently one of  the most 
discriminatory and reproducible typing methods to study outbreaks and identify 
transmission routes of  C. difficile (29,46). In Chapter 3 we describe the application 
of  an optimized MLVA for the virulent RT 078 on a collection of C. difficile strains 
from human and porcine origin. Despite the lack of  a direct epidemiological link, 
we conclude that there is a high relatedness between human and porcine strains. 
This high relatedness could be an indication of  a common source or transmission. 
Additional evidence for this suggested common source or transmission is the 
shared tetracycline resistance determinant, encoded on Tn916 between the high 
related human and porcine strains. Tetracycline is frequently used in the veterinary 
industry but not in the (Dutch) healthcare system (Nethmap 2013, 240 http://www.
swab.nl (56)). This suggests that tetracycline resistant C. difficile potentially arises in 
the veterinary industry and is being passed on into the human population. Although 
we can not exclude horizontal transfer of  Tn916 due to its wide distribution in 
Gram-positive bacteria (63), frequent use of  tetracycline in the veterinary industry 
has also been implicated in the wide dissemination of  Staphylococcus aureus Sequence 
Type 398 and enterococci in humans and pigs (1,19,79,80). For C. difficile, our 
observations on tetracyclin resistance in combination with a 5 times higher carriage 
rate of  farmers compared to the community (45) and the rise of  RT 078 in the 
(Dutch) community (42) indicate that farm animals may represent an important 
reservoir for CDI. Further research combining human and veterinary medicine is 
needed to prove interspecies transmission of  CDI.
Automated analysis, high reproducibility, discriminatory power and the ability 




sub-typing methods, such as REA and PFGE (46,47). However, in Chapter 3 we 
also expose some shortcomings of  MLVA as sub-typing method. We found that 
the PCRs for the loci B7Cd, C6Cd and G8Cd had to be optimized due to the lack of  
specific PCR products and that locus A6Cd was absent in RT 078. This, together 
with the observation of  invariability of  loci H9Cd and F3Cd in RT 027 (9,71) and 
the low variability of  loci H9Cd and F3Cd in RT 078, demonstrates the potential loss 
of  discriminative power of  the MLVA to distinguish between strains of  certain 
RTs. Epidemiological links may be additionally obscured by the potential presence 
of  multiple MLVA types within one faecal sample (67). This stresses that better 
and more accurate typing methods must be explored to prevent the spread and 
transmission of  CDI.
Whole genome sequencing (WGS) as typing method can address all the above 
mentioned weaknesses of  MLVA as a (sub)typing method. The introduction of  
automated analysis pipelines has opened the way for WGS as a high throughput 
typing method in the future (47). It has also been shown that in a single sequence 
run WGS can reliably detect mixed infections (27), which are estimated to occur in 
7-13% of  the CDI cases (31,70). In contrast, most current typing methods rely on 
a single colony for typing and thereby potentially miss or misclassify transmission 
routes. We expect that WGS will become the preferred typing method in the 
future, as high quality WGS data can also be used to extract additional genomic 
information, such as Single Nucleotide Polymorphisms (SNPs), Multi Locus 
Sequence Type (MLST), and sequence variants of  virulence genes (37,47), and with 
third generation sequencing (Pacific Biosystems) potentially even PCR Ribotypes.
Non-toxin virulence factors of  C. difficile
Preventing colonization is one of  the best ways to intervene in the spread and 
transmission of  C. difficile. Spores are the infectious vehicle of  CDI (72) and 
the ingestion of  spores is the first step in colonization of  a host by C. difficile. 
Subsequently, spores can germinate, and the newly formed vegetative cells can 
outgrow and adhere to colon epithelial cells. During this process successful 
colonization depends on the ability of  C. difficile to cope with environmental and 
host-induced stresses, such as antibiotics and reactive oxygen species. Importantly, 
this is frequently influenced by the presence of  mobile elements that contain 
resistance genes or make novel metabolic pathways possible.
The endospores formed by Clostridium spp and Bacillus spp are produced to survive 
hostile or unfavourable environments and sporulation of  C. difficile is recognized as 
a persistence and transmission factor for CDI (21,64). The sporulation pathway is 
largely conserved between Clostridium spp and Bacillus subtilis (57). Both in Clostridia 




of  sporulation (32,40,57). Phosphorylation of  Spo0A, at least in Bacilli, induces 
binding of  Spo0A to target DNA (32,57), which leads to activation or repression 
of  downstream genes. In Chapter 7 we describe that C. difficile Spo0A binds to 
similar conserved DNA sequences as B. subtilis Spo0A. Although we demonstrate 
that Spo0A binds to the promoter region of  the Toxin B gene, we do not find 
reduced toxin levels in an isogenic Spo0A mutant as previously published (69). 
Our data, however, are in agreement with another report where no positive effect 
of  Spo0A on toxin production was found (21). The apparent discrepancy between 
the data may in part be explained by differences in experimental conditions such 
as medium and the methods used for toxin quantification (21,69). Recently, 
another layer of  complexity has been added to the function of  Spo0A. In vivo 
toxin production may be regulated differently by Spo0A in phylogenetically distinct 
strain types (52). These differences clearly demonstrate that in vitro properties need 
to be corroborated in an in vivo situation and should be interpreted with the strain 
background in mind. To address the differences between the various studies on 
Spo0A in C. difficile, future work should include a comprehensive in vivo analysis of  
Spo0A binding (Chromatin immunoprecipitation-sequencing) combined with an 
extensive transcriptome (RNA-Sequencing) analysis, to determine the effect on the 
transcription of  genes in various strains. These analyses may shed light on the role 
of  Spo0A in pathogenesis and virulence in the various phylogenetically distinct C. 
difficile strains.
Adhesion to the mucosal surfaces is an essential step in the successful colonization 
of  the host by C. difficile (72). Relatively little is known about adhesion of  C. difficile 
to the mucosal surfaces in the host, compared to the overwhelming information 
on toxins and sporulation and their role in pathogenesis. To date, a few cell surface 
proteins have been described to play a role in adhesion and colonization, such 
as SlpA (11) and flagellar proteins (68). Denève and colleagues hypothesized that 
gene expression of  adhesion and colonization factors is enhanced under stress 
conditions (22).
In Chapter 8 we knocked-out the gene encoding an HtrA-like protease which 
we expected to be involved in adaptation and response to stress. The micro-array 
analysis of  the htrA mutant showed decreased gene expression of  well-known 
characterized adhesion and colonization factors, such as SlpA and flagellar proteins 
(11,68). Knocking-out another hypothesized stress-related protease also resulted in 
a reduced expression of  some adhesion and colonization factors, but not of  the 
slpA and flagellar proteins (our unpublished results). In vitro characterization of  
the two protease mutants showed decreased adhesion to Caco-2 cells compared to 
the wild-type strain (Chapter 8 and our unpublished results). These observations 




colonization factors. The difference between the two protease mutant strains in the 
gene expression patterns is suggestive for the existence of  various specific stress 
related pathways in C. difficile. Further research is needed to unravel the various 
stress-related pathways and their role in colonization and development of  infection 
in the host.
Besides the decreased in vitro sporulation and adhesion properties, expected to 
result in decreased virulence, the C. difficile htrA mutant also showed increased toxin 
production (Chapter 8), which could result in enhanced virulence. Indeed, we 
demonstrate enhanced virulence of  the htrA mutant in a hamster model, likely as a 
result of  the increased TcdA levels in combination with exquisite sensitivity of  the 
hamsters for toxin production. This raises the question which of  the phenotypes 
(i.e. decreased sporulation, decreased adhesion or increased toxin A production) is 
more relevant in case of  a human infection. Our study on the in vivo effects of  HtrA 
is limited by the choice of  animal model for the following reasons. First, to get 
reproducible infections in hamsters, the use of  relatively large inocula is necessary 
(10). This may mask subtle effects as a result of  differences in stress resistance. 
Second, the hamster model is not suitable to study persistence and transmission of  
C. difficile, due to the acute nature of  the disease in hamsters. To overcome these 
limitations, several strategies can be employed.
HtrA is involved in different stress responses in various organisms (5,16,53). To 
determine if  the C. difficile htrA mutant strains are more sensitive for environmental 
stresses, stress factors (such as heat, hydrogen peroxide, salt) can be added to 
bacterial cultures of  wild type and the htrA mutant strains, while growth kinetics 
and/or the number of  viable cells are compared. These experiments can also be 
performed in a mixed culture of  htrA mutant and wild type strains to determine 
the relative fitness of  the mutant under stress conditions. An in vivo competition 
experiment, even in the hamster model, may reveal subtle differences between wild 
type and htrA mutant strains that go undetected during a single strain infection. To 
determine if  the in vitro decreased sporulation and adhesion properties observed in 
vitro play an important role in persistence and transmission, these properties should 
be investigated in an in vivo animal model which is less sensitive to the produced 
toxins, such as the mouse (21). We expect that an htrA knockout in such a model 
will show a decrease in virulence similar to other pathogenic bacteria (15,16,64).
HtrA-like proteases of  E. coli are the best-characterized members of  the HtrA 
protease family and they have been shown to possess a dual function as a re-foldase 
and protease (53,55). Our studies do not address whether the re-folding and/or 
degradation function of  HtrA is required for the observed effect (53,55). It would 
be interesting to test the importance of  both functions by complementing the htrA 




by a transcriptome analysis. Variances in gene expression profiles between both 
mutants could give insight in which function of  HtrA is of  importance in which 
response.
In many micro-organisms, antibiotic resistance can be acquired via incorporation 
of  mobile elements (8). Incorporation of  antibiotic resistance genes could result in a 
growth advantage during colonization and the ability to outcompete the commensal 
flora after antibiotic treatment. Besides antibiotic resistance determinants, mobile 
elements also frequently carry other virulence determinants. Therefore, the spread 
of  mobile elements greatly impacts the fitness of  C. difficile. Moreover, analysis 
of  the presence of  mobile elements could also provide valuable information for 
identification of  possible transmission routes. In Chapter 3 and 4 we describe the 
presence of  conjugative transposons, encoding antibiotic resistance markers, in the 
emerging RT 078 strains. In Chapter 3 we describe that the high relatedness of  the 
RT078 strains and the shared tetracycline resistance, encoded by Tn916, indicates a 
possible common source or transmission, as discussed above. The second mobile 
element, Tn6164, encodes besides several antibiotic resistance genes also other 
(putative) virulence genes of  various origins (Chapter 4). The increased mortality 
rates of  patients infected with C. difficile::Tn6164 (29% vs 3%) suggests that the 
presence of  this element may render RT 078 strain more virulent. The observed 
trend could be further explored by comparing isogenic RT 078 and RT 078::Tn6164 
strains in an in vivo model. Additional epidemiological research is also needed to 
confirm the possible link between the presence of  Tn6164 and increased virulence. 
Our work shows that mobile elements can be used as an indication of  a possible 
common source (Chapter 3 and C. W. Knetsch personal communication) and 
may be linked to virulence of  C. difficile (Chapter 4). Together, these observations 
underline the importance to detect the presence of  mobile elements. However, 
the presence of  mobile elements is not recognized by PCR Ribotyping, which 
is currently the most frequently used method (47). Due to their unstable nature 
and variable location, mobile elements are also not recognized by the WGS SNP 
typing method which focuses on the core, rather than the accessory, genome. 
However, WGS can be a powerful tool for recognition of  antibiotic resistance 
and potential virulence genes encoded on mobile elements (Chapter 4 and C. W. 
Knetsch personal communication). Therefore, we argue that WGS should not only 
focus on the core genome, but also should take the accessory genome into account. 
Applying WGS as the typing method in a good surveillance system will result in an 
increased understanding of  the role mobile elements could play in the spread of  C. 





Toxin A and Toxin B are the two major virulence factors of  C. difficile and primarily 
responsible for causing the symptoms of  CDI (48,49,75). Understanding the 
mechanisms behind regulation of  toxin production is necessary for the development 
of  effective medical countermeasures to moderate the clinical course and outcome 
of  disease. Besides both toxin genes, the PaLoc also contains the gene encoding 
the proposed negative regulator (tcdC) of  toxin gene transcription (44,75). Both 
hypervirulent RTs 027 and 078 contain point-mutations in tcdC, which has been 
proposed as a possible explanation for their increased virulence (18,35,76). In 
Chapters 5 and 6, we investigated toxin regulatory capacities and biochemical 
properties of  TcdC.
In Chapter 5 we evaluated the role of  TcdC in toxin production by comparing 
the transcription levels of  the toxin genes and toxin expression levels of  an isogenic 
tcdC mutant and the parental strain (wild type). We concluded that TcdC is not a 
major negative regulator of  toxin expression. Our work and that of  an independent 
study by Cartman et al (14) contradicts previous reports that demonstrate that TcdC 
is a major repressor for toxin production (12,54). We cannot exclude that TcdC has a 
more profound effect in another strain on toxin production under other conditions 
than ours. Preliminary data have shown that overexpression of  TcdC in C. difficile 
can result in decreased toxin production (our unpublished observations). This 
is in line with a report of  decreased toxin production upon expression of  TcdC 
from a multi-copy plasmid (12). As of  yet unidentified conditions leading to the 
overexpression of  TcdC could therefore also reconcile our findings with the in vitro 
property of  TcdC as a repressor of  toxin production (54).
In Chapter 6 we demonstrate a so far uncharacterized function for TcdC. 
Bioinformatic analysis of  the TcdC sequence predicted that the C-terminal domain 
of  TcdC is an Oligonucleotide Binding (OB)-fold which is able to bind to DNA. 
Biochemical analyses showed that TcdC binds to G3-quadruplex structures (QS). 
It has been shown that QS can influence several in vivo processes, like transcription 
(6). Though the C-terminal domain was identified as important for toxin repression 
(25,54), the role of  TcdC binding to QS in toxin regulation is unclear since no QS 
are predicted to be formed in the PaLoc region. Two interesting experiments could 
shed more light on the function of  TcdC and the relevance of  QS structure binding 
by this protein. First, TcdC in vitro binding to DNA-QS in vitro might mimic binding 
to other (unknown) secondary structures in vivo. Chromatin immunoprecipitation 
experiments could reveal the DNA sequences that are bound by TcdC in vivo, 
thereby providing a better understanding of  the in vivo function of  TcdC. Secondly, 
to clarify the role of  the DNA binding domain, knowledge about the topology 




domain are ambiguous. Topology experiments should reveal the subcellular 
location of  the DNA binding domain. If  the DNA binding domain is localized 
extracellularly, it is not likely that TcdC plays a role in the in vivo transcriptional 
regulation of  toxin production. Together these experiments may provide a better 
understanding of  the function of  TcdC. 
Genetic tools
Over the last years major advances have been made in the genetics and molecular 
biology of  C. difficile. The introduction of  (replicative) plasmids by conjugation 
and the Group II intron based mutagenesis system (ClosTron) has spurred the 
genetic characterization and initial understanding of  the virulence of  C. difficile 
(12,39,41,43). However, the use of  these 1st generation genetic tools has several 
limitations. First of  all, phenotypic complementation of  knocked-out genes using 
multi-copy (replicative) plasmids is not ideal. It is unclear how the protein expression 
level in the complemented strain relates to the physiological level in the wild type 
strain. This may result in over-expression of  the introduced gene and thereby over-
interpretation of  the effect (12). Secondly, the use of  ClosTron to generate mutants 
may lead to polar effects on downstream genes (50). Another disadvantage of  the 
ClosTron system is the impossibility to introduce (point) mutations and reporter 
genes into the C. difficile genome.
The development of  the 2nd generation genetic manipulation tools, the Allelic-
Coupled Exchange (ACE) systems, is a major advance in studying C. difficile 
virulence genes (14,38). First of  all, the use of  ACE does not necessarily result in 
polar effects on non-inactivated genes and because of  the fact that genes can be 
introduced in single copy on the chromosome, protein levels in the complemented 
strain are more likely to occur at physiologically relevant levels. Furthermore, the 
ACE system is capable of  introducing and/or restoring possibly important (point) 
mutations in genes which are linked to increased virulence (14,18). Finally, the ACE 
systems do not rely on the introduction of  antibiotic selection markers, allowing a 
fair comparison of  mutant versus wild type in in vivo studies.
The use of  different strains has introduced another layer of  complexity in studying 
the influences of  genes on virulence. Mackin and colleagues demonstrated that in 
vivo toxin production may be regulated differently by Spo0A in phylogenetically 
distinct strain types (52). Ideally, there should be a wide agreement which strain(s) 
and genetic tools should be used to study C. difficile virulence factors. As this is 
unlikely to happen due to the important differences between phylogenetically 
distinct C. difficile strains, each manuscript should mention that the presented data 





Over the last years major advances have been made in the field of  C. difficile 
research. Despite the continuous progress of  research in C. difficile epidemiology 
and molecular biology, the medical and financial burden on the healthcare system 
is still a serious problem. This thesis shows that the development of  molecular-
based techniques in the detection and typing of  C. difficile could be very valuable 
in combating CDI. This also applies for the genetics and molecular biology of  
C. difficile in understanding the virulence of  C. difficile. However, the continuing 
development of  new techniques, both typing and genetic manipulation tools, has 
also led to the recognition of  the potential weaknesses of  the currently frequent 
used techniques. Therefore, it is of  utmost importance to keep up with the technical 
progress in the field of  C. difficile research to enable further elucidation of  the 
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Dit proefschrift beslaat vele facetten van onderzoek aan Clostridium difficile, van 
toegepast tot fundamenteel. Deze Gram-positieve, sporevormende bacterie 
kan een darminfectie veroorzaken, ook wel Clostridium difficile infectie (CDI) 
genoemd. De symptomen van CDI worden veroorzaakt door toxinen die de 
darm beschadigen. CDI wordt tegenwoordig erkend als de belangrijkste oorzaak 
van infectieuze nosocomiale diarree. In het laatste decennium is de incidentie en 
ernst van CDI toegenomen. Deze toename heeft wereldwijd belangrijke financiële 
en medische gevolgen voor de gezondheidszorg en patiënten. Dit proefschrift 
kan onderverdeeld worden in 4 onderdelen: i) een algemene inleiding over het 
toegepaste en fundamentele onderzoek naar CDI; ii) een beschrijving van de 
ontwikkeling van diagnostische en typering methoden voor Clostridium difficile; iii) 
een deel over onderzoek naar de regulatie van (mogelijke) virulentie factoren; en iv) 
een discussie over de bevindingen van dit proefschrift.
Inleiding
Clostridium difficile werd bijna tachtig jaar geleden voor het eerst beschreven door Hall 
en O’Toole. De bacterie werd voor het eerst geïsoleerd uit faeces van pasgeborenen 
en beschreven als een zeer beweeglijke, Gram-positieve staaf  met sub-terminale 
sporen. Gezonde individuen zijn meestal beschermd door de commensale flora in 
het colon. Echter, een antibiotica behandeling kan leiden tot de overgroei van de 
commensale flora door C. difficile, wat uiteindelijk kan leiden tot CDI. De klinische 
symptomen van CDI kunnen variëren van diarree tot aan ernstige colitis. Naast het 
gebruik van antibiotica zijn gevorderde leeftijd (>60 jaar), onderliggende ziekten 
en infectiedruk andere risicofactoren voor CDI.
In het laatste decennium is de epidemiologie van CDI radicaal veranderd. Sinds 
2002 worden grote uitbraken in Noord-Amerika en Europa van CDI gerapporteerd 
die gekarakteriseerd worden door een ernstiger verloop van de ziekte en verhoogde 
sterftecijfers. Deze toename heeft grote implicaties voor de patiënten en de 
gezondheidszorg, en heeft daarnaast ook financiële gevolgen voor het zorgstelsel. 
Op basis van de huidige incidentie cijfers en de verwachte vergrijzing zal deze 
financiële last in de toekomst alleen maar verder toenemen.
Om de bovenstaande gevolgen van CDI te verminderen is het van het grootste 
belang de verspreiding van CDI te beperken en nieuwe behandelopties voor de 
ziekte te onderzoeken. Deze doelen kunnen bereikt worden door in te grijpen 
op meerdere niveaus. Ten eerste zijn een snelle en accurate diagnose van CDI 
patiënten en moleculaire typering essentiële instrumenten om infecties en uitbraken 
te herkennen en onder controle te krijgen. Ten tweede kan het bestuderen en 
begrijpen van de mechanismen die belangrijk zijn voor kolonisatie leiden tot 
nieuwe therapeutische opties, die gericht zijn op het voorkomen van kolonisatie. 
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Tot slot kan het begrijpen van mechanismen van toxine-regulatie leiden tot de 
ontwikkeling van effectieve behandelmethodes om de klinische symptomen van 
CDI te verminderen.
Moleculaire methoden voor de diagnose en typering van C. difficile
Om de verspreiding van C. difficile te beperken is het van belang dat het 
ziekenhuispersoneel op de hoogte is van het voorkomen van CDI. Verder zijn 
(goede) hygiëne voorzorgsmaatregelen, vroegtijdige diagnose en het monitoren 
van CDI essentieel. De diagnose van CDI is nog steeds gebaseerd op de typische 
klinische kenmerken, in combinatie met laboratoriumtesten. Echter, de testen die 
momenteel het meest gebruikt worden zijn tijdrovend of  hebben een gebrek aan 
sensitiviteit en specificiteit voor nauwkeurige en snelle diagnose van CDI. Deze 
beperkingen hebben ertoe geleid dat meerdere monsters per patiënt getest worden 
en dat voor de diagnose van CDI twee-stap algoritmes gebruikt worden. Echter, 
voor preventie van de verspreiding van CDI zijn snellere en meer accurate testen 
essentieel.
In hoofdstuk 2 beschrijven we de evaluatie van drie snelle, binnen het instituut 
ontwikkelde, moleculaire testen voor de diagnose van CDI. Alle drie geëvalueerde 
moleculaire testen voldeden door de hoge prevalentie van CDI in de gebruikte 
monster collectie (20 %) bijna aan de criteria die gedefinieerd zijn voor het gebruik 
als zelfstandige test. Echter, de berekende positieve voorspellende waarde daalde 
aanzienlijk bij een meer realistische prevalentie van CDI in een klinische omgeving 
(10 %) en in de gemeenschap (2 %). Daarom hebben wij geconcludeerd dat de 
moleculaire testen niet gebruikt kunnen worden als een snelle zelfstandige test voor 
de diagnose van CDI.
Een nadeel van een moleculaire test is het onvermogen om onderscheid 
te kunnen maken tussen asymptomatisch dragerschap en CDI. Een onlangs 
gepubliceerde studie heeft aangetoond dat alleen de detectie van toxinen positief  
correleert met klinisch verloop van de ziekte en niet de aanwezigheid van C. 
difficile per se. Niettemin kan asymptomatisch dragerschap een belangrijke bron 
van verspreiding binnen ziekenhuizen zijn. Door de hoge negatieve voorspellende 
waarden van de geëvalueerde moleculaire testen (hoofdstuk 2), zullen deze zeer 
waardevol zijn als een eerste screening test in een twee-stap algoritme, gevolgd 
door een snelle fenotypische toxine-detectie methode (bijvoorbeeld een Enzyme 
Immuno-Assay) voor de diagnose van CDI. Het grootste voordeel van dit tweestaps 
algoritme boven de tot nu toe gebruikte tweestaps algoritmes is de snelle diagnose 
van CDI met bijbehorende gevoeligheid en specificiteit.
Een andere belangrijke methode in de bestrijding van CDI is om uitbraken binnen 
zorginstellingen in kaart te brengen met moleculaire (sub-) typeringsmethoden. De 
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Multi Locus Variable number of  tandem repeat Analysis (MLVA) is momenteel 
een van de meest onderscheidende en reproduceerbare typeringsmethoden. De 
MLVA kan onderscheid maken tussen stammen van hetzelfde PCR-Ribotype (RT) 
en hierdoor is het mogelijk om transmissie routes te identificeren. In hoofdstuk 
3 beschrijven we de toepassing van een geoptimaliseerde MLVA op een collectie 
van RT 078 C. difficile stammen, geïsoleerd van mensen en varkens. Ondanks het 
ontbreken van een rechtstreeks epidemiologisch verband, concludeerden we dat 
er een grote verwantschap bestaat tussen de menselijke en varkensstammen. Deze 
hoge verwantschap kan een indicatie zijn van een gemeenschappelijke bron of  
transmissie. In hoofdstuk 3 beschrijven we ook dat de MLVA enkele zwakke punten 
heeft. Vooral de lage variabiliteit van enkele loci in sommige RTs, de afwezigheid 
van een locus in RT 078 en de benodigde optimalisatie voor de PCRs voor drie 
loci in RT 078 zijn de tekortkomingen van de MLVA als (sub-)typerings methode. 
Samen met de mogelijke aanwezigheid van meerdere MLVA types binnen een fecaal 
monster zou dit kunnen leiden tot het missen van epidemiologische verbanden. 
Het gebruik van Whole Genome Sequencing (WGS) als typerings methode zou op 
termijn wellicht een alternatief  kunnen zijn dat veel van deze nadelen ondervangt.
Non-toxinogene virulentiefactoren van C. difficile
De transmissie van CDI verloopt via de fecaal-orale route. Het voorkomen van 
kolonisatie is een van de beste manieren om in te grijpen in de verspreiding en 
overdracht van C. difficile. Sporen spelen een belangrijke rol in de transmissie en 
kolonisatie van een gastheer. Na inname ontkiemen de sporen en groeien uit tot 
vegetatieve cellen die zich kunnen hechten aan de epitheelcellen in de dikke darm. 
Succesvolle kolonisatie is naast sporulatie afhankelijk van het vermogen van C. 
difficile om te kunnen omgaan met het veranderende milieu en gastheer-geïnduceerde 
stressfactoren, zoals antibiotica en zuurstofradicalen. De aanwezigheid van mobiele 
elementen die resistentiegenen bevatten of  nieuwe metabole routes mogelijk 
maken is hierop van grote invloed.
De sporen van Clostridium spp en Bacillus spp worden geproduceerd om ongunstige 
omstandigheden te overleven. Het sporulatie proces is in grote lijnen hetzelfde in 
Clostridium spp en Bacillus subtilis. Sporulatie van C. difficile wordt erkend als een 
persistentie- en transmissie-factor voor CDI. In hoofdstuk 7 beschrijven we dat C. 
difficile Spo0A bindt aan DNA sequenties die lijken op de herkenningssequentie van 
Bacillus subtilis Spo0A. Daarnaast hebben we ook aangetoond dat Spo0A bindt aan 
de promoter van het toxine B gen. We vonden echter geen verlaagd toxineniveau in 
de Spo0A mutant, in tegenstelling tot een eerdere publicatie.
Naast sporulatie is hechting aan de epitheelcellen van de darm mogelijk een 
belangrijke stap in de succesvolle kolonisatie van de gastheer. Er is echter relatief  
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weinig bekend over de hechting van C. difficile aan de epitheelcellen en de rol van 
hechting in de pathogenese van CDI. Tot op heden zijn er slechts een aantal 
oppervlakte-eiwitten beschreven die een rol spelen in de hechting en kolonisatie. 
Van de expressie van hechting- en kolonisatie-factoren word verondersteld dat 
deze verhoogd is onder stressomstandigheden.
In hoofdstuk 8 hebben we het gen dat codeert voor het HtrA protease, dat 
mogelijk betrokken is bij de reactie op stress, gemuteerd. De micro-array analyse 
van deze htrA mutant toonde verlaagde genexpressie aan van een aantal bekende 
hechting- en kolonisatie-factoren, zoals SlpA en flagellaire eiwitten. Verdere 
experimenten gaven aan dat de mutant minder sporuleerde en minder goed hechtte 
aan epitheelcellen in vergelijking met wild-type. Daarnaast vertoonde de htrA 
mutant ook een verhoogde toxine A productie. Dit, in combinatie met de hoge 
gevoeligheid van hamsters voor toxinen, verklaart mogelijk de verhoogde virulentie 
van de htrA mutant in het hamstermodel van CDI. Om te onderzoeken welke 
van de aangetoonde fenotypen (verminderde sporulatie, verminderde hechting of  
verhoogde toxine A productie) meer relevant is voor de ontwikkeling van de ziekte 
in mensen zullen in vivo experimenten gedaan moeten worden in een diermodel dat 
minder gevoelig is voor toxinen.
In veel micro-organismen kan resistentie tegen antibiotica verworven worden 
via incorporatie van mobiele elementen. Antibiotica resistentie kan resulteren in een 
groeivoordeel tijdens de kolonisatie en geeft de mogelijkheid om de commensale 
flora te overgroeien na een antibiotica behandeling. Naast resistentiegenen dragen 
mobiele elementen ook vaak virulentie factoren met zich mee. Daarom kan de 
verspreiding van mobiele elementen grote invloed hebben op de fitness van C. 
difficile. Daarnaast kan de aanwezigheid van mobiele elementen aanvullende 
informatie geven over mogelijke transmissie routes.
In hoofdstuk 3 en 4 beschrijven we de aanwezigheid van twee mobiele 
elementen, die coderen voor antibiotica resistentie. In hoofdstuk 3 laten we zien 
dat stammen geïsoleerd uit varkens en mensen in hoge mate verwant zijn, en een 
gemeenschappelijke resistentie tegen tetracycline hebben die afkomstig is van een 
Tn916-achtig element. Interessant is dat tetracycline veelvuldig gebruikt wordt 
in de veterinaire sector, maar niet in de (Nederlandse) gezondheidszorg. Dit zou 
kunnen betekenen dat tetracycline resistentie wordt doorgegeven aan de bevolking 
vanuit de veterinaire industrie. De aanwezigheid van een Tn916-achtig element 
en tetracycline resistentie zou dus mogelijk extra informatie kunnen geven over 
transmissie routes tussen de veterinaire industrie en mensen. 
In hoofdstuk 4 beschrijven we het mobiele element Tn6164 dat naast diverse 
resistentie genen ook codeert voor (potentiële) virulentie factoren. De verhoogde 
mortaliteit van patiënten geïnfecteerd met RT 078 met Tn6164 suggereert 
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dat de aanwezigheid van dit element ervoor zorgt dat deze stammen virulenter 
worden. Echter, verder onderzoek is nodig om het mogelijke verband tussen 
de aanwezigheid van Tn6164 en verhoogde virulentie te bevestigen. Bij elkaar 
genomen onderstrepen onze resultaten het belang om resistentie tegen antibiotica 
te monitoren in C. difficile stammen, afkomstig van zowel mensen als dieren.
De aanwezigheid van mobiele elementen wordt op dit moment niet herkend 
door de vaak gebruikte “PCR ribotypering”-methode en wordt daarom niet 
meegenomen in de (moleculaire) epidemiologie van CDI. Bovendien worden 
mobiele elementen vanwege hun instabiele aard en locatie in het “aanvullende” 
genoom, niet herkend door de WGS Single Nucleotide Polymorphisme (SNP) 
typeringsmethode. Toch heeft WGS bewezen dat het een krachtig instrument 
kan zijn om antibioticaresistentie en mogelijke virulentie genen, gecodeerd op 
mobiele elementen, te herkennen (hoofdstuk 4 en C.W. Knetsch, persoonlijke 
communicatie). Daarom zou WGS niet alleen gericht moeten zijn op de verschillen 
in het “kern” genoom, maar ook op de aanwezigheid van de mobiele elementen 
in het “aanvullende” genoom. Toepassing van WGS als typeringsmethode, in 
combinatie met een goed monitoring systeem, zou kunnen resulteren in een beter 
begrip van de rol die mobiele elementen spelen bij de verspreiding en virulentie 
van C. difficile.
Regulatie van toxine productie
Toxine A en toxine B zijn de twee belangrijkste virulentiefactoren van C. difficile 
en primair verantwoordelijk voor de symptomen van CDI. Het bestuderen van de 
regulatiemechanismen van toxineproductie zou kunnen leiden tot de ontwikkeling 
van effectieve maatregelen om het klinische verloop en de uitkomst van de ziekte 
te kunnen verbeteren. Beide toxinen genen zijn gelegen op het Pathogenicity Locus 
(PaLoc), wat daarnaast ook een gen (tcdC) bevat dat codeert voor een veronderstelde 
negatieve regulator (TcdC) van toxineproductie. In de hoofdstukken 5 en 6 hebben 
we verschillende aspecten van TcdC onderzocht.
In hoofdstuk 5 onderzochten we de transcriptie niveaus van de toxine genen 
en de daadwerkelijke productie van toxines in een tcdC mutant en een wild type 
stam. We concludeerden dat TcdC geen belangrijke negatieve regulator van toxine 
productie is. Dit is in tegenspraak met eerdere rapporten die aantonen dat TcdC 
een belangrijke negatieve regulator is van toxinen productie. We kunnen echter 
niet uitsluiten dat TcdC onder andere omstandigheden en/of  in fylogenetisch 
verschillende stammen toch een effect heeft op de productie van toxinen.
In hoofdstuk 6 beschrijven we een tot nu toe onbekende functie voor 
TcdC. Bioinformatische analyse voorspelt dat de C-terminus van TcdC een 
Oligonucleotide Binding vouwing (OB-fold) heeft en mogelijk kan binden aan 
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DNA. Een biochemische analyse laat zien dat TcdC kan binden aan zogenaamde 
quadruplex structuren (QS) waarvan is aangetoond dat ze verscheidende in vivo 
processen (zoals transcriptie) kunnen beïnvloeden. Omdat er echter geen QS 
voorspeld worden in de PaLoc-regio, is het verband tussen QS-binding en toxine-
regulatie vooralsnog onduidelijk. Verder onderzoek is nodig om meer inzicht te 
kunnen krijgen in de functie van TcdC.
Conclusie
In de afgelopen jaren is er grote voortuitgang geboekt op het gebied van moleculair 
en epidemiologisch onderzoek naar C. difficile. Ondanks deze vooruitgang, zijn de 
medische en financiële gevolgen voor patiënten en voor de gezondheidszorg nog 
niet afgenomen. Dit proefschrift toont aan dat de ontwikkeling van moleculaire 
technieken, gebaseerd op de detectie en typering van C. difficile, waardevol kunnen 
zijn in de signalering en preventie van CDI. Hetzelfde geldt ook voor de rol van 
de moleculaire biologie met betrekking tot het begrijpen van de virulentie van C. 
difficile. Echter, de voortdurende ontwikkeling van nieuwe technieken, voor zowel 
typeringen als genetische manipulatie, heeft ook geleid tot inzicht in de potentiële 
zwakheden van de momenteel veel gebruikte technieken. Daarom is het erg 
belangrijk om op de hoogte te blijven van de technische vooruitgang op het gebied 
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Stellingen behorende bij het proefschrift
Molecular characterization of  pathogenic Clostridium difficile strains
1. De hoge negatieve voorspellende waarde en de snelheid van real-time PCR maakt deze 
detectietechniek zeer geschikt als eerste screeningstest in een twee-staps algoritme voor de 
diagnose van Clostridium difficile infecties (dit proefschrift).
2. Het frequente gebruik van antibiotica in de veterinaire industrie kan leiden tot de 
verspreiding van Clostridium difficile bij consumptiedieren en vormt een potentiële bron voor 
humane infecties met (multi)resistente en virulentere C. difficile stammen (dit proefschrift).
3. Het ontkrachten van een paradigma op grond van in vivo experimenten kunnen de basis 
vormen voor nieuwe inzichten in de functie van TcdC (dit proefschrift).
4. Het uitschakelen van een eiwit (HtrA) in de stressresponse cascade hoeft niet altijd te leiden 
tot een minder virulente stam (dit proefschrift).
5. Het gebruik van verschillende genetische manipulatie technieken en verschillende Clostridium 
difficile stammen leidt tot verschillende uitkomsten (PLoS One. 2013 Nov 13;8(11), Nature. 
2009 Apr 30;458(7242), Nature. 2010 Oct 7;467(7316) en dit proefschrift).
6. Asymptomatisch Clostridium difficile dragerschap is een belangrijke bron van ziekenhuis-
infecties (N.Engl.J.Med. 2013; 369:1195-1205.
7. Een goede samenwerking tussen fundamentele onderzoekers en epidemiologen is een 
uitstekende mogelijkheid om potentiële virulentie genen te identificeren en hiermee de 
verdere verspreiding van virulente Clostridium difficile stammen te beperken (Microbiology. 
2011; 157:3113-23).
8. Fecale transplantatie (“poep transplantatie”) is een veilige en efficiënte behandeling tegen 
hardnekkige en terugkerende Clostridium difficile infecties (N.Engl.J.Med 2013;368:407-15).
9. “Een investering in kennis betaalt zich terug met de hoogste rente.” (Benjamin Franklin, 
1750, Poor Richard’s Almanac).
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